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Kurzfassung 
Hintergrund und Zielsetzung: DMD ist die häufigste Form der Muskeldystrophie im 
Kindesalter und bis heute unheilbar. Sie wird durch das Fehlen des Proteins Dystrophin 
verursacht, welches verschiedene Signaltransduktionswege beeinflusst. Das Anliegen der 
Arbeit ist die Untersuchung und Modulation von Signaltransduktionswegen, die als 
alternative Therapiestrategie den Verlust von Dystrophin kompensieren könnten.  
Experimentelle Strategie: Für die Charakterisierung von Dystrophin nachgeschalteten 
Prozessen wurden mRNA-Expressionsanalysen in Muskelgeweben von DMD-Patienten und 
einem DMD-Brüderpaar mit einem infrafamiliär unterschiedlichen Verlauf der DMD 
durchgeführt. Aus diesen Expressionsdaten wurde erstmalig ein Petri-Netz entwickelt, 
welches Dystrophin mit in diesem Zusammenhang bisher unbekannten 
Signaltransduktionswegen verknüpft. Das Petri-Netz wurde auf Netzwerkintegrität und –
verhalten mittels Invarianten- (INA) und theoretischen Knockout- (Mauritius Maps) Analysen 
untersucht. Durch beide Methoden läßt sich der maßgebliche Teilsignalweg bestimmen. In 
diesem Signalweg wurden die Proteinaktivität und die Genexpression durch siRNA, Vektor-
DNA und chemische Substanzen in humanen SkMCs moduliert. Anschließend wurden die 
Proliferation und die Vitalität der Zellen sowie auch die Expression auf mRNA- und Protein-
Niveau untersucht.  
Ergebnisse: RAP2B und CSNK1A1 waren in dem DMD-Brüderpaar differentiell exprimiert 
und konnten erstmalig in einem neuen, komplexen Signalweg in Zusammenhang mit 
Dystrophin nachgeschalteten Prozessen dargestellt werden. Mittelpunkt dieses Signalweges 
ist die De- und Aktivierung des Transkriptionsfaktors NFATc. Seine Zielgene umfassen 
neben anderen den negativen Proliferationsfaktor p21, das Dystrophin homologe UTRN und 
den Differenzierungsfaktor MYF5. Folglich würde ein Anstieg von UTRN eine unerwünschte  
Reduktion der Proliferationsrate von Myoblasten implizieren. Letzteres konnte bereits 
nachgewiesen werden und stellte das Motiv für weitere Studien dar. Jedoch zeigten siRNA- 
und Vektor-DNA-Experimente, daß NFATc nicht der ausschlaggebende Faktor für diese 
Zielgene ist. Die Substanzen Deflazacort (DFZ) und Cyclosporin A (CsA) wurden dagegen 
beschrieben, die Aktivierung von NFATc zu beeinflussen. Die Ergebnisse zeigten, daß beide 
Substanzen die Proliferation von Myoblasten erhöhen können. Die gleichzeitige Applikation 
von DFZ und CsA führte zu einem Anstieg der UTRN-Expression. 
Schlußfolgerung: Die Modulation der Proliferation und UTRN-Expression ist unabhängig von 
einander möglich. Entsprechend der Grundidee der Arbeit zeichnet sich eine neue 
Therapiestrategie ab, welche Dystrophin nachgeschaltete Prozesse einbezieht.  
 
Schlagwörter:  
Muskeldystrophie Duchenne, DMD, Dystrophin, Utrophin, Signaltransduktionwege, 
NFATc, CSNK1A1, RAP2B, Real-time PCR, Skelettmuskelzellen, Myoblasten, Petri 
Netze, Systembiologie 
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Abstract 
Background and aim: DMD is the most common muscular dystrophy in childhood and 
incurable to date. It is caused by the absence of dystrophin, what influences several signal 
transduction pathways. The thesis is interested in the investigation and modulation of signal 
transduction pathways that may compensate the lack of dystrophin as an alternative therapy 
strategy. 
Experimental strategy: To study Dystrophin downstream pathways the mRNA expression of 
DMD patients and two DMD siblings with an intra-familially different course of DMD were 
analysed in muscle tissue. On the basis of these expression data a Petri net was first developed 
implicating signal transduction pathways and Dystrophin downstream cascades. Invariant 
(INA) and theoretical knockout (Mauritius Maps) analyses were applied for studying network 
integrity and behaviour. Both methods provide information about the most relevant part of the 
network. In this part modulation of protein activity and of gene expression using siRNA, 
vector-DNA, and chemical substances were performed on human SkMCs. Subsequently, the 
cells were studied by proliferation and vitality tests as well as expression analyses at mRNA 
and protein level.  
Results: RAP2B and CSNK1A1 were differently expressed in two DMD siblings, and first are 
part of a signal transduction pathway implicating Dystrophin downstream processes. The 
central point of this pathway is the de- and activation of the transcription factor NFATc. Its 
target genes are, among others, the negative proliferation factor p21, the Dystrophin 
homologue UTRN, and the differentiation factor MYF5. Consequently, an increase in UTRN 
implicates an undesirably reduced myoblast proliferation rate. Latter was found in DMD 
patients and was target for further studies. But, siRNA and vector DNA experiments showed 
that NFATc is not the decisive factor for the target genes. Deflazacort and cyclosporin A are 
known to influence the activation of NFATc. The results first showed that both substances do 
induce myoblast proliferation. The use of deflazacort in combination with cyclosporin A 
resulted in an increase of UTRN expression. 
Conclusion: The modulation of proliferation and UTRN-expression independently of each 
other is possible. According to the basic idea of this study, a new therapeutic strategy 
becomes apparent, which considers Dystrophin downstream processes. 
Keywords:  
Duchenne Muscular dystrophy, DMD, dystrophin, signal transduction pathways, 
NFATc, CSNK1A1, RAP2B, Real-time PCR, skeletal muscle cells, myoblasts, Petri net, 
systems biology 
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Abbreviations 
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BCA bicinchoninic acid 
bDG β-dystrobrevin 
BMD Becker muscular dystrophy 
BrdU  5-bromo-2'-deoxyuridine 
BSA Bovine serum albumin 
CARP cardiac ankyrin repeat protein 
CBFB core binding factor beta 
CDK cyclin-dependent kinase 
CMV cytomegalovirus promoter 
Cryo-SFM cryo-serum free medium 
CsA cyclosporin A 
CSNK1A1 casein kinase 1 alpha 1 
CPN coloured Petri Nets 
CT cycle threshold 
CTI covered by t-invariants 
DCTN3 dynactin 3 light chain 
ddNTPs dideoxynucleotide 
DEPC diethyl dicarbonate (Diethylpyrocarbonate) 
DGC dystrophin-glycoprotein complex 
DIF desmin intermediate filaments 
DMD duchenne muscular dystrophy 
DMEM dulbecco's Modified Eagle's Medium 
DMSO dimethyl sulfoxide 
DRP dystrophin-related proteins 
DTT dithiothreitol 
ECL enhanced chemiluminescence 
EDTA ethylene diamine tetraacetic acid 
eGFP enhanced GFP 
ER endoplasmatic reticulum 
FCS fetal calf serum 
FRET fluorescence resonance energy transfer 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
GFP green fluorescent protein 
Grb2 growth factor receptor-bound protein 2 
IC261 3-[(2,4,6-trimethoxyphenyl)methylidenyl]-indolin-2-one 
IP3 Inositoltrisphosphat 
IRES internal ribosome entry site 
LB lysogeny broth (Luria-Bertani broth) 
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m marking 
MCA metabolic control analysis 
MCT-set maximal common transition set 
MGB minor groove binder 
MLCf1 Myosin light chain 1 
MTCC Muscle Tissue Culture Collection 
NFATc nuclear factor of activated T-cells 
NHDF human dermal fibroblast nucleofector kit 
nNOS neuronal NO synthase 
NO nitric oxide 
ODE Ordinary Differential Equation 
ODN oligodesoxynucleotide -mediated gene correction 
OMIM Online Mendelian Inheritance in Man 
P place 
p21 cyclin-dependent kinase inhibitor 1A 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
p-invariant place invariant 
p/t net place/ transition net 
PIP2 phosphatidylinositol bisphosphate 
POD peroxidase 
RAP2B ras related protein 2 beta 
RIPA radio-immuno-precipitation assay 
S syncoilin 
SCID-Xl X-linked severe combined immune deficiency 
SDS-PAGE sodium dodecyl sulfate poly-acryl-amide gel electrophoresis 
SG sarcogylan complex 
siRNA short interfering RNA 
SkMCs skeletal muscle cells 
Spn sarcospan 
Syn syntrophins 
T transition 
TAE Tris-acetate-EDTA 
TBS Tris-buffered saline 
TBS-T Tris-buffered saline with Tween 20 
TFB transforming buffer 
t-invariant transition invariant 
TNS trypsin neutralisation solution 
UPGMA unweighted pair group method with arithmetic mean 
UTRNA utrophin A 
WST-8 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-
tetrazolium, monosodium salt 
XLDC X-linked dilated cardiomyopathy 
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1 Introduction 
 
Molecular biology 
 
1.1 Duchenne muscular dystrophy – general aspects 
 
Duchenne muscular dystrophy (DMD) is an X-linked recessive disease with a birth 
prevalence of 1 in 3500 live born males and usually affects boys. The first clinical symptoms 
appear at the age of 2 to 4 years.  
DMD patients often show a delay in milestones of the development in early childhood 
including delays in sitting and standing independently followed by developing of gait 
abnormalities such as difficulties in climbing stairs and waddling walking. Some patients also 
show mental retardation. At the age of 9 to 12 years the patients are wheelchair-dependent. In 
their early teens, the patients suffer from cardiomyopathy and/or respiratory complications. At 
the end of the second or at the beginning of the third decade, DMD patients die due to cardiac 
insufficiency or respiratory problems. 
Becker muscular dystrophy (BMD) is characterised by a later onset and a milder progression 
of the disease with a birth prevalence of 1 in 18500 live born males. The patients become 
wheelchair-dependent in their 3rd of 4th decade. The age of death varies from  
40 to 60 years, and heart failure is the common cause of morbidity (Pongratz et al., 1990). 
 
 
1.2 Molecular basis of Duchenne and Becker muscular dystrophy  
 
DMD is a consequence of the loss of the protein dystrophin. BMD patients still posses a 
truncated form of dystrophin. In 1986, the gene dystrophin was identified by positional 
cloning at the location Xp21 (Monaco et al., 1986). It spans 2.4 Mb, consists of 79 exons, and 
results preferentially in a 14kb transcript, which encodes the 427kD dystrophin protein. But, 
the dystrophin gene also causes different mRNA-transcripts encoding various dystrophin 
isoforms. The expression of these isoforms is regulated by 7 tissue-specific promoters as well 
as alternative splicing of the pre-mRNA. The length of the known dystrophin isoforms and 
their tissue-specific expression state are summarised in figure 1. 
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figure 1: Differential expression of the dystrophin gene (Wells et al., 2002) 
a) The position of the different promoters in the dystrophin gene (B, brain; M, muscle; P, Purkinje; R, retina; K, kidney; S, 
Schwann cells; G, general)  
b) The 6 isoforms of dystrophin and their domains. Dp427 include the N-terminal actin-binding domain. The other isoforms 
contain some triple-helical coiled-coil repeats and the C-terminus (repeats = parallel rod; hinges = notch) 
 
 
The most frequent isoform of dystrophin is expressed full length with 3685 amino acids in the 
skeletal and cardiac muscle and located in the sub-sarcolemmal region of the muscle fibre in 
humans (Hoffman et al., 1987). It consists of 4 distinct domains (Koenig et al., 1988) as 
shown in figure 2.  
 
 
 
figure 2: The domain composition of the full-length protein dystrophin. The N-terminal domain mediates binding of γ-actin binding 
filaments. The subsequent central rod domain contains 4 hinge regions followed by a cystein-rich domain responsible for interaction 
with integral membrane proteins. A unique C-terminus completes the protein dystrophin.------------------------------------------- 
[http://www-biology.ucsd.edu/classes/bimm110.SP07/images/dystrophin.jpg] 
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The domain at the N-terminal end presents homology with actin-binding proteins such as  
α-actinin and ß-spectrin. It is responsible for binding the γ-actin filaments and comprises 
between 232 and 240 amino acids. The following central rod domain is the largest domain of 
the protein and consists of 24 triple helical spectrin-like repeats interspersed with 4 putative 
hinge domains. The end of the rod domain is associated with the third domain, a cysteine-rich 
domain with 2 EF-hand motifs. This region interacts with integral membrane proteins, 
including sarcoglycan and dystroglycan, members of a complex known as  
dystrophin-glycoprotein complex (DGC) (see section 1.3.3.1). This domain is thought to 
provide the essential anchor of dystrophin to the cell membrane and consequently to the 
sarcolemma. The carboxy terminus is unique to dystrophin with the exception that 2 other 
proteins show homology to this region: utrophin (UTRN) and dystrobrevin. Dystrophin 
consists of an α-helical structure, which interacts with syntrophin, and dystrobrevin. 
Syntrophin, dystrobrevin, sarcoglycan and dystroglycan form the DGC. The first and the last 
part of the N-terminal and the C-terminal domains are assumed not to be essential for the 
development of the DGC (Ervasti, 2007). 
 
Mutations in dystrophin comprise deletions, insertions, and point mutations. The mutations 
can result in a premature stop of the translation or a modified structure due to a different 
amino acid sequence (Roberts et al., 1994; Legardinier et al., 2009) that lead to a functional 
impairment of the protein. Approximately 30% of the mutations occur spontaneously. The 
most common mutations in dystrophin are deletions of single or multiple exons, which applies 
to 65% of the DMD patients. Point mutations are found in around 30% of the cases, resulting 
in a shift of the open reading frame or directly in an early stop codon. The remaining patients 
are found to have insertions.  
At first, diagnostics include a blood test to measure serum creatine kinase that is increased at 
least 10fold as a consequence of a myogenic degradation. An electromyography is used to test 
the electrical activity of the musculature, which offers the distinction between a myositis, a 
dystrophy and a disturbed neural maintenance. Detection of mutations by PCR is the main 
point in molecular diagnostics. Routinely, up to 85% of the mutations can be detected by 
including deletions and duplications. Point mutations are also identifiable via high-throughput 
denaturing HPLC followed by direct sequencing. In spite of this, diagnostic procedures are 
usually not applied because of the size of dystrophin gene on the one hand and the rareness of 
the cases on the other (Trimarco et al., 2008). In cases of undetected mutations, a muscle 
tissue sample is taken from the patients to verify the absence of dystrophin at protein level 
INTRODUCTION 
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using western blot analysis or immunohistochemical analyses. In BMD patients, the protein 
level of dystrophin is changed but still detectable. Muscle tissue revealed from DMD patients 
also shows abnormal variation in the diameter of the muscle fibres with atrophic, hypertrophic 
and necrotic fibres and an increase of endomysial connective and fat tissue (Speer and Oexle, 
2000). 
 
 
1.3 Therapeutic strategies 
 
Whereas diagnostics can be considered satisfactory, no causal and/or efficient therapy is 
currently available for DMD. The patients are presently treated with corticosteroids such as 
prednison or deflazacort, physical therapy, and orthopaedic equipment as well as orthopaedic 
surgery and respiratory assistance. 
For most of the laboratory investigation of therapeutic strategies, cell culture systems such as 
primary human myoblasts or DMD model organisms such as the mdx mouse or the DMD-dog 
are used. Both, the original mdx mouse and the DMD-dog are species with a naturally 
occurring lack of dystrophin. Additional transgenic mouse models are also designed with 
different introduced mutations in the dystrophin gene. Whereas the DMD-dog, often a golden 
retriever, presents a phenotype like that found in humans, mdx mice are clinically only 
marginally affected, which leads to the assumption that the mdx mouse by-passes the defect 
by means of an elusive signalling pathway (Vainzof et al., 2008). 
There are many approaches being discussed to reduce progression of the disease or to restore 
muscle function. They can be classified into gene-therapeutic, cell-based and pharmacological 
strategies and include the substitution and correction of dystrophin, up-regulation of  
utrophin A (UTRNA) and dystrophin downstream signalling cascades (Manzur et al., 2008b).  
An overview of therapy strategies and medical treatment is given in table 1 (Sakamoto et al., 
2002; Zhou et al., 2006). Selected aspects itemised in table 1 are presented in more detail in 
section 1.3.1 and 1.3.2. 
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table 1:  Therapeutic strategies and current pharmacological treatment (modified after Sakamoto et al. and Zhou et al. (Sakamoto et 
al., 2002; Zhou et al., 2006)). As a rule, publications represent review article. If available, references that discuss or refer to 
appropriate clinical studies are also included. The list does not claim to be complete. 
Molecular 
therapy 
Clinical trials 
Substitution of the 
dystrophin gene 
 
Plasmid DNA (Rando, 2007) 
Adeno-viral vector (Odom et al., 2007)  
Adeno-associated vector (Odom et al., 2007) 
Lenti-viral vector (Odom et al., 2007) 
(Fardeau et al., 2005; 
Duan, 2008) 
 
 
Correction of the 
mutation 
RNA 
level 
Viral-directed exon skipping (Bertoni, 2008)  
Antisense oligonucleotides producing 
skipping of mutated exons (Rando, 2007) 
 
(Bertoni, 2008; Muntoni 
et al., 2008) 
DNA 
level 
Oligodesoxynucleotide-mediated gene 
correction (ODN)  
(Bertoni, 2005) 
 
Up-regulation of 
dystrophin-related 
proteins (DRP) 
Plasmid DNA bearing DRP (Miura and Jasmin, 2006) 
Plasmid DNA containing transcription factors of the 
DRP (Miura and Jasmin, 2006) 
 
Cell-based 
strategies 
Stem cell therapy 
(Grounds and 
Davies, 2007) 
Satellite cells (Zhou et al., 2006)  
Adipose, muscle- or bone-marrow-derived side 
population cells (Vieira et al., 2008) 
Embryoid body-derived cells (Shao et al., 2009) 
 
 
 
Myoblasts 
(Grounds and 
Davies, 2007) 
Myoblast transfer (Skuk et al., 2007) 
Pharmacological 
treatment 
UTRN up-regulation of UTRN (Miura and Jasmin, 2006)  
Bypassing stop 
codons  
(Schmitz and 
Famulok, 2007) 
Gentamicin  
PTC124 
(Politano et al., 2003) 
(Hirawat et al., 2007) 
Muscle repair 
(Zhou et al., 2006)  
IGF-1  
Inhibtion of myostatin 
 
Protease inhibitors 
(Zhou et al., 2006) 
Calpain inhibition  
Serin protease inhibition  
Proteosome inhibition 
 
Anti-inflammatory 
drugs 
 
Cyclosporin A (Sharma et al., 1993) 
 
Prednison/ Deflazacort (St-Pierre et al., 2004) 
 
(Sharma et al., 1993) 
(Korinthenberg, 2008) 
(Houde et al., 2008; 
Manzur et al., 2008a; 
Mavrogeni et al., 2009) 
Anti-oxidant agent Idebenone (Buyse et al., 2009)  
Calcium channel 
blockers 
Diltiazem/Verapamil (Matsumura et al., 2009) (Phillips and Quinlivan, 
2008) 
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1.3.1  Substitution and correction of dystrophin 
 
1.3.1.1 Dystrophin substitution 
 
DMD is a monogenic disease. The first attempt was to correct the defect by substitution of 
dystrophin. In early studies, the dystrophin gene was transferred into the mdx mouse, which 
led to a reverse of the disease symptoms. The simplest way to deliver the dystrophin gene is 
the intravenous or intramuscular injection of plasmid DNA containing the dystrophin gene 
(Fardeau et al., 2005; Duan, 2008). Disadvantages of this method are an activation of 
antibody-mediated immune response because of its neo-antigen character for the cells, the 
short retention time, and the poor distribution of the plasmid DNA with a distance of a couple 
of centimetres to injection site. In France, a phase I clinical trial with DMD-patients involving 
plasmid DNA containing dystrophin confirmed these findings. Despite the disadvantages 
mentioned above, plasmid DNA approaches have the advantage of avoiding additional 
immune response as would be expected if viral vectors were used.  
Gene delivery by using viral vectors is slightly more efficient than plasmid DNA. The 
substituted dystrophin gene may be able to integrate into chromosomal DNA and permanently 
correct the gene defect. Apart from the immune response, the viral vectors may trigger 
oncogenesis in consequence of their integration site, especially by the use of lenti-viral 
vectors. Currently, 3 different viral vectors are applied in studies: adeno-viral,  
adeno-associated-viral and lenti-viral vectors (Odom et al., 2007). 
By nature, adeno-viral vectors possess a cloning capacity of 8kb, which could only include a 
truncated form of dystrophin. The new generation of fully truncated adeno-viral vectors offer 
a cloning capacity of 36kb. This vector can carry the full length cDNA of dystrophin, but also 
presents reduced immune response because of the lack of viral proteins (Ohshima et al., 
2009). It was demonstrated that 52% of muscle fibres were dystrophin-positive after an 
infection with a fully truncated adeno-virus bearing 2 copies of the murine full-length 
dystrophin (Dudley et al., 2004).  
The adeno-associated viruses are advantageous because of the non randomised integration 
into the chromosomal locus 19q13, which reduces enormously the risk of oncogenesis and the 
inability for replication. The latter diminish the immune response. Furthermore, recombinant 
vectors do not include any viral genes, but still the capsid proteins may induce humoral 
immune response. The cloning capacity represents 5kb, which only allows a transfer of a 
micro-dystrophin. Another limitation is that adeno-associated viruses rarely integrate into 
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chromosomes, and may consequently be lost after several cell cycles. A modified  
adeno-associated vector carrying a micro-dystrophin is used in a clinical Phase I/IIa study at 
Columbus Children’s Hospital in Ohio, USA. It is injected into the biceps of DMD patients 
(Muntoni and Wells, 2007).  
Lenti-viruses, in particular the HI-virus, are used for delivering of a 6kb mini-dystrophin in 
proliferating but also in differentiated cells. In contrast to adeno-viral vectors, lenti-viruses do 
not induce a cytotoxic T-cell lymphocyte response. Also, a self-inactivating lenti-viral vector 
was engineered to exclude safety concerns. The main disadvantage is the rather unspecific 
integration of the virus into chromosomal DNA, which might lead to oncogenesis (Romano, 
2005). In France, a clinical trial on patients suffering from X-linked severe combined immune 
deficiency (SCID-Xl) led to the development of leukaemia in 2 of 11 patients after treatment 
with a retro-viral vector (Hacein-Bey-Abina et al., 2003a; Hacein-Bey-Abina et al., 2003b). 
The study of Schroeder et al. demonstrated regional hotspots for integration of the  
HI-virus, and also showed that active genes were preferential integration targets (Schroder et 
al., 2002). Up to now, the integration site of lenti-viral vectors cannot be predicted with 
certainty, but attends to influence the integration target are currently being made. The use of a 
novel system based on integrase-deficient lenti-viral vectors allows efficient gene transfer 
without challenges of lenti-viral vectors integration (Philpott and Thrasher, 2007).  
 
1.3.1.2 Dystrophin correction 
 
The substitution of a correct dystrophin gene is possible, but complex due to the size of the 
gene and the difficulty of safe and efficient delivery of the vector. A correction of the 
dystrophin gene would be feasible at RNA and DNA level.  
At the RNA level, short DNA sequences, called antisense oligonucleotides (AON), are able to 
recognise sequences at the mRNA level specifically resulting in different effects such as gene 
knockdown, gene up-regulation or shifting of the reading frame (Rando, 2007; Bertoni, 2008; 
Mitrpant et al., 2009). Originally, AON are designed to knock down the expression of a target 
gene by binding complementary to the mRNA, which possibly blocks or inhibits protein 
expression. But, exon-specific AON can concurrently block splicing enhancers or sequence 
regulatory elements that control exon recognition induces skipping of the exon(s) that may 
carry an out-of-frame mutation. This restores coding reading frame leading to expression of 
an in-frame mRNA encoding for a shorter protein that may be still functional (Doran et al., 
2009). Thus a DMD phenotype could be transformed in BMD. Aartsma-Rus and van Ommen 
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suggest that multi exon skipping of 20 exons in the central rod domain would theoretically be 
beneficial for at least 63-75% of all DMD patients (artsma-Rus and van Ommen, 2007; 
Beroud et al., 2007; artsma-Rus et al., 2009). However, in a more recent study the authors 
report on a multiexon 45-55 skipping that led to a minimal skip frequency comparable to 
controls (van Vliet et al., 2008). The central rod domain is the largest domain of the protein, 
but does not contain the essential DGC or actin-binding elements. Certain BMD-like patients 
demonstrate the expression of an in-frame transcript encoding for a much shortened but 
extremely functional form of dystrophin. 
In 1995, the pioneering work of the group of Takeshima et al. was able to modulate exon 
skipping of dystrophin exon 19 in an in vitro system. For that purpose, artificial dystrophin 
mRNA precursors were established containing exon 18, a truncated intron 18, and exon 19. 
An antisense 31-mer 2'-O-methyl ribonucleotide, complementary to the splicing recognition 
sequence of exon 19 inhibited splicing of wild type pre-mRNA in a dose- and time-dependent 
manner (Takeshima et al., 1995). Since then, exon skipping is discussed as a new therapeutic 
approach for DMD (Muntoni and Wells, 2007; Bertoni, 2008). One of the main limitations of 
this approach is the half-life of skipped RNA and truncated protein as well as the continuous 
administration of AON to a large area and number of fibres. The most favourable candidates 
for a specific delivery of AON are viral vectors, but they are of course subject to the hurdles 
as described for dystrophin substitution. The safety of the AON itself has been described as 
fairly good from data received from human trials, but toxicities in terms of hybridisation have 
been reported (Muntoni and Wells, 2007). Recently, Neri et al. reported that dystrophin 
protein levels between 29% and 57% were found in families with X-linked dilated 
cardiomyopathy (XLDC) in a completed clinical trial phase I A. XLCD patients carry a 
mutation at the 5' end of the gene and typically suffer from myopathy restricted to the cardiac 
muscle, but possess dystrophin in the skeletal muscle. So it is assumed that a level of 
dystrophin of 30% of normal would be sufficient to avoid muscular dystrophy (Neri et al., 
2007). The efficiency of different chemical variants of AONs are currently being studied 
(Heemskerk et al., 2009). However, since 2006, in the Netherlands a clinical Phase I/II study 
has been conducted on DMD patients using RNA-based therapeutic PRO051, and is still 
ongoing (van Deutekom and van Ommen, 2006; van Deutekom et al., 2007). Current clinical 
trials using AON are summarised by Muntoni et al. (Muntoni et al., 2008).  
At the DNA-level, the oligodesoxynucleotide-mediated gene correction (ODN) is based on a 
designed mismatch between the targeting vector and the genome sequence of interest 
inducing a desired single base pair change through endogenous DNA repair (Bertoni, 2005; 
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Rando, 2007). Thus, DMD patients carrying a point mutation would benefit from this 
therapeutic strategy, which applies to approximately 10-15% of all patients (Muntoni et al., 
2003). In several reports, a correction of the dystrophin gene was published using ODN 
restoring of dystrophin expression. The main disadvantages of this technique are the low 
efficiency of delivering and the effect of ODN. However, the greatest advantage of  
ODN-mediated gene correction is the permanent correction of the gene defect and 
consequently constitutes the most efficient therapeutic strategy for DMD patients. 
 
1.3.1.3 Bypassing of stop-codons  
 
The idea of a read-through strategy is based on the fact that some antibiotics, such as 
aminoglycosides, are able to repress stop codons. The medication of patients suffering from 
DMD due to a stop codon with such an antibiotic may lead to read-through of the stop-codon 
resulting in a functional protein (Schmitz and Famulok, 2007). A study using gentamicin in 
mdx mice was able to demonstrate an increased expression of dystrophin of 20% and a 
reconstitution of the DGC at the sarcolemma. Subsequent clinical trials with DMD and BMD 
patients (each with 2) treated with gentamicin did not result in any appreciable detection of 
full-length dystrophin (Politano et al., 2003). These disappointing results in addition to the 
eventual toxicity of a permanent intake of antibiotics initiated the development of new 
strategies. The biopharmaceutical company PTC Therapeutic discovered an orally 
administered, small-molecule drug called PTC124. PTC124 targets post-transcriptional 
control processes allowing ribosomes to bypass the nonsense mutation in mRNA. In mdx 
mice, its efficiency to initiate the production of full-length dystrophin has been determined to 
be up to 20-25% that of the control mice muscles (Welch et al., 2007). A change concerning a 
read-through of physiological stop codons could not be detected since mRNA typically carries 
multiple stop codons at the 3´ end (Muntoni and Wells, 2007). The Phase I study has 
indicated that PTC124 is well tolerated with little adverse effects at the highest dosage 
(Hirawat et al., 2007). Currently, PCT124 is in Phase II clinical trials with promising 
preliminary results. About 50% demonstrated an increase in the immunostaining expression 
of dystrophin. Analysis of the data is still ongoing. However, the efficiency of PTC124 is 
limited due to its varying ability to enhance read-through of different stop sequences. In vitro 
experiments show suppression of UGA>>UAA~UAG, but most readily if the specific 
sequence is UGAC. Since fewer than 10% of all DMD patients carry a nonsense mutation, 
only a few percent may benefit from PTC124 (Aurino and Nigro, 2006; Wilton, 2007). 
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1.3.2  Elevation of utrophin 
 
1.3.2.1 Utrophin – member of the dystrophin/ dystrobrevin family 
 
The UTRN is a homologue of dystrophin, and was first discovered by Love et al. (Love et al., 
1989). It is similar to dystrophin as shown in figure 3, and consists of an N-terminal  
actin-binding domain, a large rod followed by a cysteine-rich domain and the C-terminal 
region. The gene undergoes promoter-specific expression resulting in 2 known protein 
variants: UTRNA and utrophin B (Miura and Jasmin, 2006). Both of them have a different 
unique 5´-exon that splices at exon 3 into a common RNA. In humans, UTRNA is mainly 
expressed in muscle cells whereas utrophin B is detected in muscle blood vessels. In DMD 
patients as well as in the mdx mouse, UTRN is found to be up-regulated. 
 
 
figure 3: Similarities of dystrophin to dystrobrevin and UTRN. Structures of the dystrophin/dystrobrevin family are compiled from 
the crystal structures of the dystrophin. They also include α-actin-binding domain, 2 spectrin repeats from actinin, and the  
cysteine-rich region of dystrophin. The structure of UTRN is very similar to dystrophin. 
Actin-binding domain: cyan, CH1; green, CH2. ‘Cysteine-rich’ region: green, WW domain; red, orange, cyan, and purple,  
EF hands. Carboxy-terminal region: yellow, syntrophin-binding segment; red, leucine heptads.  (Roberts, 2001) 
 
UTRN is able to link the extra-cellular matrix to intra-cellular structural proteins in similar a 
manner as dystrophin and associates with the DGC (figure 4). Both proteins bind indeed the 
same complement of proteins but differ in their localisation, binding mode and affinity. 
Whereas dystrophin is found throughout the length of muscle fibres, UTRN is primarily 
located at the postsynaptic membrane of the neuromuscular junction. However, in 
regenerating muscle fibres, UTRN is localised throughout the entire sarcolemma as described 
for early foetal development. Biochemical data demonstrate that UTRN differs in its mode of 
contact with actin filaments and ß-dystroglycans due to a lack of cluster of basic,  
actin-binding spectrin repeats. These repeats, which are present in dystrophin, lead to a 
rearranged actin-binding region in UTRN. Thus, the actin-binding domains are located on 
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different positions in UTRN and dystrophin from which it can be assumed that both proteins 
bind actin filaments with different affinities. However, a study using stabilised UTRN and 
dystrophin was able to prove similar affinities for actin filaments. In contrast, binding to  
ß-dystroglycan was reported to be less effective by UTRN compared to dystrophin. Double 
knockout mdx mice lacking UTRN demonstrate a more severe phenotype similar to DMD 
patients and were rescued via adeno-viral delivery of UTRN. In conclusion, elevation of 
UTRN has become very interesting in connection with the search for a way to treat DMD 
(Miura and Jasmin, 2006; Ervasti, 2007). 
 
1.3.2.2 Strategies for enhancing utrophin expression 
 
Up to now, an enhancement of UTRN expression can be achieved by 3 different strategies: 
substitution of the UTRN gene, up-regulation of gene expression using an artificial  
3 zinc-finger based transcription factor called Vp16-Jazz (Mattei et al., 2007; Desantis et al., 
2009), and delivering or up-regulation of proteins that positively influence UTRN expression. 
Such a favourable impact was demonstrated for heregulin and neuronal NO synthase (nNOS), 
respectively. Heregulin, a nerve-derived growth factor, is able to increase UTRN transcription 
by activation of GABPα/β transcription factor complex of its promoter (figure 4). Injections of 
a small heregulin peptide in vivo induced UTRN up-regulation and a significant functional 
improvement of the dystrophic phenotype in mdx mice (Basu et al., 2007). The myogenic Akt 
signalling can also promote UTRN expression (Peter et al., 2009). Another mediator for 
UTRN expression is the neuronal NO synthase that links to the DGC and catalyses the 
production of nitric oxide (figure 4). The expression of nNOS is reduced at the sarcolemma in 
dystrophin-deficient muscle, and it is thought to function as a protector against muscle 
damage. A study in mdx mice overexpressing nNOS transgene in the dystrophic muscle 
provided compelling evidence that nNOS up-regulation can diminish the dystrophic 
pathology. Muscles from transgenic mdx/nNOS mice showed improvements in muscle 
membrane injuries associated with a large decrease in serum creatine kinase concentrations. 
Substitution of L-arginin, the substrate of nNOS, is reported to increase nNOS expression in 
mdx mice as well. But the mechanism of the effect of L-arginin has not been discovered yet. 
The up-regulation of UTRN is discussed to occur at transcriptional level as a result of 
inhibited calpain-mediated UTRN degradation (figure 4) (Miura and Jasmin, 2006). But 
UTRN up-regulation can also be stimulated via signalling pathways that involve calcineurin 
and nuclear factor of activated T-cells (NFATc) as key components (figure 4). One of the 
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main targets of calcineurin is the NFATc. Calcineurin de-phosphorylates NFATc, and this 
leads to its activation and migration into the nucleus where it can interact as transcription 
factor in concert with other factors such the nuclear respiratory factor 2,  
ets-related GABPα/β transcription factor complex, and PGC1-α on the UTRN promoter  
(figure 4) (Angus et al., 2005). These data imply that UTRN expression is activated by 
signalling pathways with calcineurin and NFATc as key components. In vivo experiments 
using calcineurin*/mdx mice over-expressing calcineurin represent an induction of UTRN 
expression with a concurrent, marked alleviation of the dystrophic pathology (Chakkalakal et 
al., 2004). Interestingly, over-expression of UTRN at high levels does not lead to toxic 
consequences throughout a range of tissues in mdx mice (Fisher et al., 2001). 
 
 
figure 4: Expression and regulation of UTRN. Expression of 
UTRN, in particular UTRN A, is mainly restricted to the 
postsynaptic sarcoplasm in fast and slow muscle fibres of 
normal skeletal muscle. Similar to dystrophin, UTRN 
provides a link between the actin cytoskeleton and the 
extracellular matrix via the DGC at the sarcolemmal 
resulting in a downstream signalling cascade as shown for 
dystrophin (simplified figure, more details are shown in 
figure 5). Expression of UTRN is mediated by several 
transcription factors. The transcription factor complex of 
GABPα and GABPß is promoted by a cascade that is 
triggered by ErbB receptors bound to heregulin. The 
transcription of GABPα can in turn be initiated by PGC-1α.  
Many other transcription factor recognition sequences are found at the UTRNA promoter including for NFATc,  
Sp1 and Sp3. The last 2 are ubiquitously active in numerous genes. NFATc is activated by de-phosphorylation and can also mediate 
UTRNA transcription. RhoA has been found to be involved in UTRN transcription in an unknown manner, but confers stability to 
UTRNA. Stability and localisation of the UTRN transcript is given through the 3’ untranslated region. The 5’UTR stimulates UTRN 
translation for muscle regeneration. Calpain-mediated degradation of UTRN is thought to be induced by TNFα. The protein nNOS 
and its substrate are found to stimulate UTRN exression via nitric oxide (NO). (Miura and Jasmin, 2006)  
figure 4: Expression and regulation of UTRN. 
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Since UTRN expression can be stimulated by activation of the calcineurin/NFAT pathway 
(figure 4), an endogenous up-regulation using pharmacological compounds could also be 
considered, but is often less efficient than a gene transfer-mediated UTRN up-regulation. The 
main difficulty with this strategy is to achieve a restriction of UTRN expression at the 
neuromuscular junction and a widespread expression in myofibers. Among the 
pharmacological approaches glucocorticoids such as deflazacort are especially effective to 
slow down the progression of DMD (Angelini, 2007; Houde et al., 2008; Manzur et al., 
2008a). Although a therapeutic effect is visible, the molecular basis of the pharmacological 
effect is not well understood and is mainly assumed to be anti-inflammatory. Furthermore, the 
potent immunosuppressive substance cyclosporin A (CsA) was reported to benefit muscular 
dystrophy once (Sharma et al., 1993). However, contrary data resulting from the use of mdx 
mice were also reported (Stupka et al., 2004). In addition to anti-inflammatory effects, it is 
well known that the calcineurin inhibitor CsA is involved and that deflazacort is suspected of 
being involved in the NFATc signal transduction pathway (figure 4) (St-Pierre et al., 2004; 
Stupka et al., 2004). Investigations using mdx mice indicated an activation of the calcineurin 
phosphatase associated with an up-regulation of the NFATc target gene UTRN using 
deflazacort (St-Pierre et al., 2004). However, an increased activity of the NFATc/calcineurin 
pathway has to be restricted to the muscle suffering from dystrophic pathology since cardiac 
hypertrophy is associated with induced calcineurin (Molkentin et al., 1998). 
 
 
1.3.3  Dystrophin downstream strategies 
 
1.3.3.1 Dystrophin glycoprotein complex 
 
Dystrophin functions as a connector between the cytoskeleton and the sarcolemma of muscle 
cells. But the expression of dystrophin is not limited to the skeletal and cardiac muscle. 
Truncated isoforms are also found in kidneys, neurons, lymphoblastoid, brain, muscle, 
Purkinje cells, the retina, and in Schwann cells. Interestingly, the shortest forms Dp70 and 
Dp40 are present ubiquitously (Ervasti, 2007). 
Dystrophin is part of the DGC faced at the cytoplasmic membrane of muscle fibres. The DGC 
contains both transmembrane components such dystroglycan and sarcoglycan as well as 
cytoskeletal proteins such as dystrophin and syntrophin (figure 5) (Ervasti and Sonnemann, 
2008). The ß-dystroglycan is the key component of the DGC. It is bound to the cystein-rich 
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domain of the dystrophin and to the sarcoglycans, and provides a direct link to laminin-α2, an 
extracellular matrix protein. The sarcoglycan sub-complex consists of α-, β- ,δ-, ε-, γ- and  
ζ- sarcoglycans. A loss of one of these sarcoglycans has been found to be associated with 
autosomally inherited types of muscular dystrophies, such as the Limb girdle muscular 
dystrophy form 2C, and causes a similar phenotype to DMD. The sarcoglycans are found to 
function for plasma membrane permeability. The tetraspanin family member sarcospan is 
associated to the sarcoglycan facing the cytoplasm. But its function remains elusive. Another 
sub-complex within the DGC is formed by the 5 syntrophins. The syntrophins are connected 
to the C-terminal domain of dystrophin. Additionally, syntrophins can also interact with 
phosphatidylinositol bisphosphate (PIP2), nNOS, calmodulin and the growth factor  
receptor-bound protein 2 (Grb2). The latter activates a complex downstream signalling. Some 
domains may also able to influence sodium channels.  
Other components of the DGC are the dystrobrevins, which own a cysteine-rich and a  
C-terminal domain homologous to those found in dystrophin (figure 5). The 2 isoforms  
α- and β-dystrobrevin interact with dystrophin and UTRN through the coiled-coil domain. 
Because of the similarity to dystrophin, dystrobrevins are thought to be a target for therapeutic 
strategies. Other proteins connected to the DGC are dysferlin, calpain-3, caveolin-3, and 
filamin-C (Ervasti and Sonnemann, 2008). 
 
 
figure 5: Components of the dystrophin-glycoprotein-complex (DGC). Dystrophin mediates conjunction of the contractile elements 
in the cell with the extracellular matrix via the dystroglycan complex. The DGC consists of  
α-, β- ,δ-, ε-, γ- and ζ- sarcoglycans (SG; sarcogylan complex), sarcospan (Spn), 5 syntrophins (Syn), α- and  
β-dystrobrevin (aDG, bDG). Laminin-2 is an extracellular ligand, whereas F-actin and desmin-intermediate filaments (DIF) are 
intracellular binding partners. The proteins dysferlin, calpain-3, caveolin-3, syncoilin (S), and filamin-C are connected to the DGC, 
and connect the complex to signalling proteins as Grb2 and nNOs that initiate a dystrophin downstream signalling cascade.  
(Odom et al., 2007)  
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1.3.3.2 Molecular consequences of the lack of dystrophin  
 
Usually, the absence of dystrophin is associated with DMD while truncated forms of 
dystrophin are correlated with the less severe phenotype of BMD. But, exceptions have been 
reported in both directions suggesting the existence of pathways compensating the dystrophin 
defect (Winnard et al., 1993; Prior et al., 1997; Hattori et al., 1999; Pradhan, 2004; Ferreiro et 
al., 2009).  
The lack of dystrophin leads to a failure of incorporation of the DGC to the sarcolemma. 
Consequently, dystrophin downstream cascades signalling trails away or cannot be 
established. A dramatic increase in intracellular calcium is observed, suggesting that this may 
be a result of physical sarcolemmal breaks or calcium channel leak. In dystrophic muscle 
cells, it was demonstrated that calcium-permeable channels can exhibit an increase of activity 
resulting in calcium-activated proteases as well as modulation of other intracellular regulatory 
proteins and signalling pathways. Calcium channel blockers, e.g. diltiazem and verapimil, are 
used to reduce the calcium content in the diaphragm and cardiac muscle in mdx mice 
(Matsumura et al., 2009). But a significant positive effect of these drugs in DMD patients 
cannot be evidenced (Phillips and Quinlivan, 2008). In this context, feasible functions of 
dystrophin and the DGC are discussed including regulation of calcium ions, storage of 
calcium channels or intracellular calcium, or an indirect alteration of calcium regulation 
caused by membrane tearing (Hopf et al., 2007). Another characteristic of the disease is the 
limited capacity of DMD myoblasts to grow that is directly related to the progressive muscle 
degeneration (Blau et al., 1983b). Concomitantly, muscle cells in culture are found to be fully 
capable of initiating myogenesis and differentiation (Blau et al., 1983a). As investigated in 
this group, the cyclin-dependent kinase inhibitor 1A (p21), which negatively regulates G1 to S 
progression, is increased in DMD patients, and is thought to be related to decreased myoblast 
proliferation (Endesfelder et al., 2000). Transfection of ASO and short interfering RNA 
(siRNA), respectively, against p21 exhibited an increase of proliferation in  
dystrophin-deficient myoblasts, and provides a potential therapeutic strategy, which makes 
allowances for proteins downstream dystrophin (Endesfelder et al., 2003; Endesfelder et al., 
2005). For grasping an extended range of genes that are involved in DMD pathology, 
differences of total transcriptomes or proteoms were investigated (Bakay et al., 2002; Haslett 
et al., 2002; Noguchi et al., 2003; Haslett et al., 2003; Baker et al., 2006; Dogra et al., 2008). 
This group has reported about differences between transcriptomes in the very rare case of  
2 brothers with an intra-familially different course of DMD with the younger brother being far 
INTRODUCTION 
 27 
less affected than the elder one when compared at the same age. To isolate candidate genes 
responsible for the milder course, a cDNA-library enriched with transcripts over-expressed in 
the younger brother was constructed. A PCR-based subtraction hybridisation technique was 
used for the library. Thereby, 11 transcripts were identified as differentially expressed at 
which elevated expression levels in the DMD patient with mild pathology has been confirmed 
by qRT-PCR for casein kinase 1 alpha 1 (CSNK1A1), ras related protein 2B (RAP2B), 
dynactin 3 light chain (DCTN3), myosin light chain 2 (MYL2) and core binding factor beta 
(CBFB), and an hypothetical gene compared to the elder brother (Sifringer et al., 2004). 
Despite this small number of differences, the problem reveals that a correlation of discovered 
genes to dystrophin as well as to each other can apparently not be discovered. In experimental 
studies concerning transcriptome and proteome analyses of DMD patients compared to 
normal individuals, this aspect has not been considered. However, the reports usually result in 
a list of discovered genes and proteins rather than conducting the advancing step of their 
integration in dystrophin associated signal transduction pathways.  
To meet interacting requirements, a network has to be established including primary 
knowledge of dystrophin downstream cascades and experimentally discovered genes. The 
new arising field of computational systems biology provides appropriate approaches for 
modelling, analysing as well as animation of such signal transduction networks. Thus, it 
offers an expert insight into molecular consequences of the lack of dystrophin for the 
development of new experimental applications and consequently dystrophin downstream 
therapy strategies. 
The present thesis applies theoretical modelling techniques to  
(1) summarise pathway information of dystrophin downstream processes into one model 
including visualisation and animation facilities 
(2) identify important parts of the network through theoretical knockout analyses  
(3) design new experiments based on theoretical results. 
 
 
INTRODUCTION 
 28 
Computational systems biology 
 
1.4  Interest of systems biology 
 
The field of biology, molecular biology in particular, has changed considerably over the last 
few years. Traditionally, molecular biology was differentiated in genomics, gene expression 
and protein analysis and thus investigated individually one after another. But, biological 
systems are very complex networks and function rather as a unit by interaction of gene 
expression, metabolic pathways as well as cell internal and external communications than 
autonomously. As a selected and restricted example, figure 6 demonstrates the multifaceted 
interplay of filaments and macromolecular complexes in cell interior of the Dictyostelium 
discoideum cell (Ellis and Minton, 2003). The figure represents a 3-dimensional description 
without the need of functional interaction of depicted macromolecules.  
 
 
figure 6: Cryoelectron tomography of crowded cell interior of the Dictyostelium discoideum cell. The 3-dimensional picture is a 
reconstruction of an image series taken from a range of tilt angles. The actin filaments are shown in orange; grey complexes 
represent the ribosome and other macromolecular complexes. The membranes are illustrated in blue. (Ellis and Minton, 2003) 
 
Functional aspects of components of biochemical networks are illustrated in figure 7 serving 
as a model of the dynamic processes in the cell including DNA, RNA and protein level as 
well as intercellular signals, and of which influence on each other (Arbeitsausschuß 
Bioinformatik der DECHEMA e.V., 2006). In addition, the development of new techniques 
such as micro-array analysis and sequencing facilitate the production of high-throughput and 
large-scale multi-dimensional data sets. 
Altogether, it shows the importance of gradually extending and integrating all these 
information in a hierarchically structured model, which represents all the data in its biological 
system rather than considering them separately and in a reduced state. This inspired the 
development of new computational and mathematical approaches for analysing biological 
information and for network modelling. Accordingly, biology has changed into a  
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cross-disciplinary field including biochemists, computer scientists, engineers, mathematicians, 
bioinformaticians, and physicists to understand biological organisms in their entirety.  
 
 
figure 7: Gene expression is regulated at different hierarchical levels and influenced by numerous positive and negative feedback 
mechanisms resulting in amplification of signal- and product-variety. Hundreds of thousands of proteins are encoded by 
approximately 30,000 genes of the human genome. These proteins correspond to a complex interaction network, which finally 
enables the function of an organism. Examples and more detailed explanations are in red.  
(after (Arbeitsausschuß Bioinformatik der DECHEMA e.V., 2006))  
 
 
The study field combining biological high-throughput data sets, specific methods of analysis 
and mathematical modelling is called systems biology and involves extensive experiments 
and hypothesis-driven modelling. Challenges of computer science and mathematics in 
systems biology take account of full information content of the genome, extraction of protein 
and gene regulatory networks from the genome. Integration and visualisation of  
high-throughput and multi-dimensional data sets as well as modelling of dynamic 
mathematics converted from static networks ensue. Additionally, prediction of protein 
structure and function, identification of different cellular conditions by associated key 
components, building of hierarchical models as well as the reduction of the complexity of 
multi-dimensional models are further benefits of systems biology (Baxevanis and Ouellette, 
2005). Consequently, the most important methods in system biology are databases, 
mathematical models for quantitative as well as qualitative networks, and derived computer 
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simulations. Data can be used to express a hypothesis, and following models are applied to 
design new experiments to verify the hypothesis. Another important aim of theoretical 
modelling is the reduction of time and reagent consuming experimental approaches, animal 
studies, and is in particular of interest for complex events. Cell cycle and apoptosis are first 
examples. In case of the cell cycle, reports represent mathematical models concerning G1/S 
transition and G1-phase (Swat et al., 2004). For apoptosis, a mathematical model was 
reported that identified an implicit positive feedback of 2 apoptosis mediating proteins if the 
same proteins are suppressed by inhibitors of apoptosis (Legewie et al., 2006). A so far 
unreachable aim of systems biology is the model of a virtual cell/organism enabling the 
performance of experiments in silico such as the prediction of the effect of medication as well 
as phenotype/genotype correlation in diseases (Baxevanis and Ouellette, 2005). 
 
 
1.4.1  Theoretical methods in systems biology 
 
In systems biology, a distinction is made between quantitative and qualitative modelling. 
Quantitative networks are mainly used for metabolic pathways. These networks take 
advantage of kinetic data, and are usually based on Michaelis Menten kinetics, its relevant 
stoichiometry, substance fluxes as well as the steady state assumption. In contrast, because of 
the lack of quantitative data, qualitative networks are primarily applied to model signal 
transduction pathways and gene regulation. These pathways do not rely on kinetic data, 
substance fluxes and the steady state assumption, but present fluxes of information or signals. 
Additionally, in most qualitative approaches time properties are not considered. 
 
1.4.1.1 Quantitative modelling 
 
One of the main applications of systems biology are quantitative metabolic networks since for 
these pathways kinetic data are available. On the basis of extensive kinetic data, these 
networks interpret static metabolic systems in dynamic models, and can be expressed 
mathematically. An established mathematical approach to describe the control in metabolic 
pathways is called metabolic control analysis (MCA) (Kacser, 1995; Heinrich and Schuster, 
1998). MCA is an ODE-based (Ordinary Differential Equation) computational method to 
study changes in fluxes and concentrations of metabolic networks. It considers the effects of 
the different enzymes involved by which the managing reaction steps can be examined (Salter 
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et al., 1994). Hence, MCA provides information for changes in the metabolic pathway to 
increase or decrease reaction processes, for example in the case of biotechnological 
production procedure. System behaviour can be described by the control coefficient and the 
elasticity coefficient. The control coefficient reflects the system property of an enzyme 
expressing the differential alteration of the substance flux (resulting in a steady state) by 
metabolic pathways through differential modification of the activity of involved enzymes. 
The elasticity coefficient is the local property of an isolated enzyme in terms of changes in 
metabolite concentrations. The control coefficient and the elasticity as a result of MCA  
(a form of sensitivity analysis) require data of the model structure and its biochemical 
parameters. This control can be determined by application of a perturbation of the enzyme of 
interest and evaluation of system variables after the system is returned to steady state. The 
enzyme kinetic parameters are usually examined in vitro including substance flux and 
intracellular metabolite concentrations (metabolic profiling) (Link and Weuster-Botz, 2007). 
MCA, which is usually used for metabolic pathways, can also be applied to qualitative 
modelling to describe signalling and genetic networks. Based on experimental data, 
theoretical effects of divergence and convergence of selected genes in signalling cascades are 
of particular interest in this case. They often display, for example, 2fold series of connected 
inhibition in feed-forward paths, and multiple activations or blocking of feedback-loops. 
 
1.4.1.2 Qualitative modelling 
 
Qualitative modelling works at another abstraction level than modelling of quantitative 
networks. Graph theoretical analysis and network animations are also essential at this point. 
Stoichoimetry, time properties, and kinetic parameters of these processes to be modelled are 
often unknown. For successful parameter estimation, a critical amount of kinetic data must be 
available. Consequently, a classic kinetic modelling using ODEs is non-applicable. Hence, to 
get nevertheless insight into the system behaviour a qualitative rather than a quantitative 
model can be applied, but would be similar to a static form (Wildermuth, 2000; Cascante et 
al., 2002; Visser and Heijnen, 2002; Arbeitsausschuß Bioinformatik der DECHEMA e.V., 
2006). 
An important purpose of qualitative modelling are medical applications that include gene 
regulatory parameters and complex protein interaction rather than kinetic data and are 
becoming more and more relevant in order to reduce experiments for target finding (Hood et 
al., 2004). For gene regulatory networks that consider such gene regulation as switching of 
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and switching on, a Boolean network would apply. Transcription and signalling processes in 
addition to gene regulation require a mathematical formalism to include different abstraction 
levels in one model. Various abstraction levels are enabled by classic Petri nets that are 
discrete models, and do not rely on kinetic data. There exist different Petri net classes for 
modelling systems of different description levels, e.g. hybrid Petri nets. For biochemical 
systems, hybrid Petri nets are used when some kinetic data are known. Hybrid Petri nets 
include qualitative as well as quantitative characteristics, and has been used for modelling of 
metabolic networks, signal transduction networks, and gene regulation networks (Matsuno et 
al., 2000; Matsuno et al., 2003; Saito et al., 2006). 
 
 
1.4.2  Petri net basics 
 
In 1962, Petri nets were defined by Carl Adam Petri for modelling of systems with concurrent 
processes. Petri nets are discrete models of information and object fluxes to describe systems 
and processes at different abstraction levels. Thus, it does not rely on kinetic data. A Petri net 
is a directed, bipartite and labelled graph. In addition to its graphical representation, its 
animation facilities afford a simple and intuitive evaluation of the biological behaviour of the 
model. Hierarchical elements serve structuring of the complex system (Baumgarten, 1996). 
Formal definitions for Petri nets and invariant analyses and their applications approaches are 
summarised in the glossary (section 9.1). 
 
The Advantages of Petri nets are  
a unique modelling language for different abstraction levels,  
modelling of sequential and mutually excluding and causally independent activities, 
formal analysis, verification and simulation techniques supported by computer software 
tool, 
graphical depiction using comprehensible modules (Baumgarten, 1996). 
 
 
Composition of a Petri net 
Petri nets consist of places (P) and transitions (T), which are connected by directed arcs. 
Because of the bipartite property, a direct link between transitions and transitions, and places 
and places is not allowed. Places are drawn as circles and represent passive system elements 
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e.g. conditions, states or in biological networks proteins, genes, transcriptions factors etc. 
Transitions as rectangular figures (or squares) symbolise the active part of the system such as 
events or biochemical reactions. Transitions without pre-places (post-places) are called input 
(output) transitions (here drawn as flat rectangles). Connecting arcs correspond to causal 
correlations of passive and active system elements. A transition is connected to pre-places, 
which represent pre-conditions via its incoming arcs. Accordingly, post-places that form  
post-conditions are connected via its outcoming arcs. Places may contain tokens, depicted as 
dots within places. Tokens are movable objects, and can represent a number of molecules or 
chemical compounds. The distribution of any number of tokens is called marking (m) and 
represents a certain system state. The initial marking defines the primary state of the system. 
The arc weights specify the number of tokens being produced or used up if an event takes 
place. The event of a transition is triggered if all its pre-conditions are fulfilled. Thus, the 
transition is enabled, and has concession to fire.  
The firing rule describes the dynamic behaviour of the system. A classic discrete 
place/transition net (P/T net) exhibiting a timeless firing rule is considered. A transition has 
concession to fire if all pre-places contain at least as many tokens as the transition charges for 
the event as indicated by the corresponding arc weights (Baumgarten, 1996). Examples for the 
firing rule of a P/T net are exemplarily demonstrated in figure 8a-c. Only the event of the 
transition in figure 8a is triggered because the required number of tokens demanded by the arc 
weights is available in the pre-place in contrast to figure 8b. After an event, all post-places 
contain at least as many tokens as forced by arc weights after the transition as shown in  
figure 8c. 
 
 
2 
a.) 
4 
b.) 
  2 
 4 
  2 
c.) 
 
figure 8: Demonstration of the firing rule for P/T nets: a) The pre-condition of the transition is fulfilled as designated by the number 
of tokens included in the pre-place (2) and the arc corresponding weight (2). b) The transition has no concession to fire since 4 tokens 
are required as represented by the corresponding arc weight (4). c) The post-places receive the number of tokens as specified by arc 
weights, after the transition fired. 
 
Read arcs 
Especially in signal transduction pathways, enzymes or cytoskeletal proteins participate in a 
products-releasing reaction, but are not used up and consequently may return to the system for 
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the next reaction. This special kind of reaction is realised using read arcs, drawn as a  
bi-directed arc. As a result, the number of tokens on the pre- and post-places does not change 
through firing of the considered transition. 
 
Analysis approaches 
Since Petri nets play a major role in many technically as well as biologically oriented fields 
(e.g., computer science, analysis of distributed systems, production processes, and molecular 
biology), various analysis methods have been developed in the last few decades to analyse the 
net behaviour of these systems with concurrent processes.  
For the analysis of biological networks, particular network properties are important and have 
to be defined, e.g. liveness, reachability, support of a vector, invariants, etc. The meaningful 
liveness of a Petri net is described at different levels and indicates a continuously working 
network. The liveness of a transition exists if it is enabled in any reachable state, and can be 
enabled if it is enabled in at least one reachable marking. The marking of a Petri net is called 
reachable if a firing sequence of transitions exists which turns the initial marking back into 
this marking. Finally, the Petri net whose initial marking may be reachable by any achieved 
marking again, is defined as reversible (Baumgarten, 1996). 
For Petri net approaches in biology, a number of analysis techniques are considered that are 
applied to this thesis: invariant analysis, maximal common transition set analysis, cluster 
analysis, and Mauritius map analysis.  
 
 
1.4.3  Invariant analysis 
 
Invariant properties of the system are valid for each initial marking and each reachable state. 
Invariant analysis is a primary study to explore firing properties as a result of the structure. 
The computation of invariants is based on the incidence matrix that corresponds to the 
stoichiometric matrix in metabolic networks. It is distinguished between place and transition 
invariants. In further studies, transition invariants (t-invariant) are explored (Starke, 1990).  
T-invariants represent multi-sets of transitions, their firing, and frequency of firing. Within a 
t-invariant, firing of all included transitions with the firing frequency as indicated in the 
Parikh vector leads to the same marking as before firing. The invariant property can be 
calculated as nontrivial, semi-positive integer solutions of linear equations systems 
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(Lautenbach, 1973), and is independent of any firing in system behaviour. In biology, this 
applies to the steady state assumption for metabolic systems. 
The description of an incidence matrix is exemplarily demonstrated in figure 9. The solution 
vector defines a Parikh vector, and is written as a column vector. It indicates firing 
frequencies for each transition in the t-invariant to reproduce a given marking.  
 
 
         C y = 0 
  y1 – y2 = 0 
–y1 + y2 = 0 
  y1 – y2 = 0 
–y1 + y2 = 0 
 1    –1 
             –1     1 
1    –1 
             –1     1 
C = 
  
1 
m0   = 0 
 1 
 0 
?  
P1 P2 
P4 P3 
T1 T2 
a) b) c) d) e) 
 
 
   1 
 
figure 9: The state of a Petri net , the defined incidence matrix, and the vector describing the initial marking.  
a) The Petri net is live. b) The incidence matrix describes the topology of the Petri net in a.), but not the initial marking. The  
2 columns indicate transitions T1 and T2 and the 4 places P1…P4 are specified by the rows. For example, position p1 and T1 shows  
1 because one token is given to P1 by firing of T1. In contrast, position P1 and T2 presents –1 since a token is taken by firing of  
T2 from P1. c) The initial marking m0 presented in vector form. It indicates the number of tokens on each place. d) The linear 
equation system of the Petri net for the determination of p-invariants (rows). A second linear equation system is setted up for the 
determination of t-invariants (column). e) The solution for each linear equation is 1.   
[modified after http://osg.informatik.tu-chemnitz.de/lehre/old/ss07/vs/12-petrinets.pdf] 
 
 
As shown in figure 9, a Petri net can be represented as incidence matrix and a vector for initial 
marking. Linear equation systems have an infinite solution space. Therefore, minimal 
solutions are of interest. Each possible solution can be computed by linear combination of 
minimal solutions or by multiplication with a positive integer number. Minimal invariants are 
considered in this thesis. Criteria for validation of a biochemical network have been 
formulated.  
Minimal validation criteria for a biological Petri net include a connected net that is covered by 
biological meaningful t-invariants. In case of every transition is integrated in at least one  
t-invariant, the Petri net is covered by t-invariants (CTI). An uncovered Petri net contains at 
least one transition that is not integrated in a t-invariant and may be excluded without 
affecting the system behaviour. A t-invariant defines a connected subnet, consisting of its 
support, its pre- and post-places, and all arcs in between. Thus, it describes the minimal basic 
system behaviour. In molecular pathways, each invariant of a validated Petri net model needs 
to fulfil a biologically correct and meaningful function (Heiner and Koch, 2004; Koch and 
Heiner, 2008). Another tool for identification of subnets within biological network are 
elementary flux modes, which correspond to t-invariants (Schuster et al., 1999). 
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1.4.4  Maximal common transition set  
 
The t-invariant analysis provides the opportunity to decompose a network into basic pathways 
to obtain clarity, which is helpful for studying the network. But the number of t-invariants 
increases exponentially with the number of transitions and arcs in a network model. In 
complex and large Petri nets, the manual study of all t-invariants is very intricate. 
Consequently, a possible way of handling such large numbers of t-invariants is to decompose 
the network into such sub-nets as for example in the case of the transition are subsumed of 
transitions according to their exclusive co-occurrence in t-invariants The summarised number 
of t-invariants is called maximal common transition set (MCT-set). For example, transitions 
of an MCT-set are located in the same minimal t-invariants in any case. This relation results 
in maximal sets of transitions. The MCT-sets can define disjunctive subnets, which may 
represent functional units or, in biological networks, a defined biological function. The 
transitions of an MCT-set always occur together. Thus their up- and down-regulation should 
be relatively. 
Altogether, MCT-sets decompose nets into disjunctive subnets, which are not necessarily 
connected, whereas t-invariants describe subnets, which are always connected (Sackmann et 
al., 2006). 
 
 
1.4.5  Cluster analysis 
 
Cluster analysis techniques are well-established approaches to explore enormous amounts of 
data. Thus, this is another way of decomposing extensive biological pathway models is 
represented by the clustering technique. It is used to cluster t-invariants in biologically 
functional sub-units into t-cluster, which, unlike MCT-sets, can overlap. A cluster analysis 
can be seen as a 3 step process, encompassing the following main steps: (1) selection of a 
distance measure to compute the distance between all pairs of objects, (2) selection of a 
clustering algorithm to group the objects based on the computed distances, and (3) selection 
of a cluster validity measure to identify the optimal number of clusters for interpretation.  
A detailed description of each of these steps is given below (Grafahrend-Belau et al., 2008a). 
The distance measure used in this work is based on the work is the Tanimoto coefficient based 
on the Parikh vector. The method “Unweighted Pair Group Method with Arithmetic mean” 
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(UPGMA) is a technique for hierarchical clustering of tree construction and was initially 
developed for calculating phylogenies (Backhaus et al., 2000). 
For more detailed information see Grafahrend-Belau et al. and Sackmann et al.  
(Sackmann et al., 2007; Grafahrend-Belau et al., 2008a; Grafahrend-Belau et al., 2008b). 
 
 
1.4.6 Mauritius map 
 
A graphical representation of sets belonging to the support of t-invariants is called Mauritius 
map. An application of Mauritius maps is modelling the Petri net as a tree structure. 
Primarily, alterations in network behaviour are analysed when transitions are knocked out. 
This is of particular interest in biological models.  
Mauritius maps are defined as finite binary trees as widely used in computer systems. The 
root of the tree is located in the lower left corner and only branches out to a right sub-tree, but 
not to a left sub-tree. For Mauritius maps, the Petri net model needs to be covered by  
t-invariants since all uncovered transitions are excluded from the right sub-tree (Heiner and 
Koch, 2004; Koch and Heiner, 2008). A transition of a t-invariant corresponds to a vertex. 
Vertices belonging to the same t-invariant are connected by horizontal edges but also by 
vertical edges from the left sub-tree to the right upper sub-tree. The next t-invariant is 
signalised by a branch in the tree. Sub-networks are represented in interior vertices providing 
left and right sub-trees and consist of all intermediate vertices from the root to the considered 
vertex. Parent vertices are indicated by a junction of horizontal and vertical lines, which 
depict the edges of children vertices. 
The distance of a transition and the respective vertex to the root gives an idea of the relevance 
of that transition for the Petri net behaviour. The closer the vertex is located to the root the 
higher the impact of the considered transition for the network model. Transitions located on 
the horizontal line that starts from the root are characterised as the most important transition 
having the highest impact in case of a knockout. This applies to transitions occurring in all  
t-invariants. The number of t-invariants lost by initiation of a knockout of a single transition 
specifies the impact of that transition. All pathways described by the corresponding right child 
and subsequent vertices are affected, i.e. destroyed, whereas the left child and all parents are 
not influenced. Consequently, the sub-net (left child) without the knocked out transition 
remains active (biological functional). In contrast, the biological function of the other sub-net 
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(right child) containing the knocked out transition is discontinued, and according to this, its 
function completely depends on that transition.  
The following figure 10 illustrates a Mauritius map (figure 10b) of a simple signal 
transduction pathway (figure 10a), which can be visually explored. The signal enters tin and 
may reach tout by passing t1 and t2 or alternatively, transitions t3 and t4. Thus, 2 t-invariants 
describe the behaviour of this small net: (1) with (tin, t1, t2, t3 and tout) and (2) with  
(tin, t3, t4 and tout). Obviously, transitions tin, t3, and tout exclusively occur in both t-invariants, 
and represent an MCT-set. Consequently, a lack of one of them would result in a dead Petri 
net. For a knockout analysis, a transition needs to be chosen that is only a member of one of 
the t-invariants such as t1, t2 and t4. For example, the knockout of transition t1 leads to a loss 
of approximately 50% of the net (horizontal line). The functional part is represented by the 
left child at the end of the vertical line, which can be deleted by knocking out t4. 
 
 
figure 10: A simple Petri net (a) and the corresponding Mauritius map (b). ------------------------------------------------------------------------- 
After a signal is initiated by tin, it can either pass transitions t1, t2 or t3, t2 or t3, t4 and is released by tout. Thus, the signal flow is 
described by two t-invariants: (1) with (tin, t1, t2, t3 and tout) and (2) with (tin, t3, t4 and tout). Transitions tin, t3 and tout are present in 
both t-invariants and result in an MCT-set. Their knockout would lead to a dead Petri net. By choosing transition t1, one of the  
t-invariants would lose its function whereas the left child at the end of the vertical line remains. The second t-invariant can be 
knocked out by deletion of t4. (modified after (Grunwald et al., 2008)) 
 
 
1.4.7  Application of Petri nets to biochemical systems 
 
In systems biology, an ever increasing number of metabolic (Reddy et al., 1993; Koch et al., 
2005; Chen and Hofestadt, 2006) and signal transduction pathways (Heiner et al., 2004) have 
been modelled as Petri net networks. For example, in biochemical networks, the sucrose 
breakdown in the potato was modelled using Petri nets (Koch et al., 2005). The authors 
demonstrate a qualitative analysis for structural validation of metabolic networks. A hybrid 
Petri net has been applied to the operon model and the growth pathway control of λ-phage 
(Matsuno et al., 2000). The use of Petri nets can be broadened for simulation of time-resolved 
applications as shown for the time-dependent somatic complementation in a model describing 
the commitment to sporulation regulated by far-red light and glycose in Physarum 
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polycephalum (Marwan et al., 2005). A technique for modelling qualitative gene regulatory 
networks using Petri nets is reported by Chaouiya (Chaouiya et al., 2004). A comprehensive 
overview of biological networks modelled as Petri nets is given by Chaouiya (Chaouiya, 
2007). 
The dynamics of metabolic systems can be investigated by simulation at which appropriate 
kinetic data required for such simulations are established. But for signal transduction 
pathways, kinetic parameters often are not available. Thus discrete models are used. These 
discrete models are considered with or without timing. Another high level of Petri nets are 
coloured Petri Nets (CPN), which apply to complex models to describe them in a manageable 
way. In CPN, the tokens on a place can be distinguished. They represent a refinement of  
p/t nets. CPN also provide formal analysis. The usefulness of CPN was demonstrated in 
studying and analysing the dynamic behaviour of the epidermal growth signal transduction 
pathway (Lee et al., 2006).   
 
The applications of metabolic and signal transduction networks demonstrate transferability of 
well-known pathways to Petri net models. Up to now, applications of Petri nets to signal 
transduction pathways involved in pathogenesis of human neuromuscular disease, in 
particular DMD, have not been reported. For molecular changes in DMD, neither quantitative 
nor qualitative models intended to include protein interactions, transcription factors, and gene 
expression regulations have been developed so far. But this is important as pointed in  
section 1.3.3.2. 
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2 Conceptual formulation 
 
The thesis is based on a study of 2 siblings with an intra-familially different course of DMD. 
Using a cDNA subtraction library, 5 genes were determined which are up-regulated in the 
DMD patient with the mild phenotype and therefore may be responsible for the less severe 
clinical course of the disease.  
 
The first objective of this work is to develop a signal transduction network that involves these 
candidate genes and elucidates an association to dystrophin.  
This includes the following sub-items: 
Establishing of a signal transduction pathway that connects dystrophin downstream cascades 
with genes identified using the cDNA subtraction library.  
 Remodelling of the signal transduction pathway into a Petri net. 
 Structural analysis of the network behaviour for verification of systems consistency 
and biological correctness.  
 Theoretical knockout analysis to study functional dependencies in the model and to 
determine the most important components of the net for the network behaviour and 
consistency. These candidate genes/proteins may also have a great impact in cellular and 
biological studies. 
 
The second objective is to conduct experimental studies to verify the supposition derived from 
Petri net analyses. That includes investigations of gene expression and modulation of selected 
proteins of the network.  
This involves the following studies: 
• Sequencing of a putative promoter region in phenotype-modifying candidate genes 
using both siblings studied by the cDNA subtraction library. 
• Determination of mRNA expression levels of selected genes of the network using  
5 classic DMD patients, the mild DMD patient and 5 normal controls. 
• Modulation of the activity and/or expression of proteins of the network, which are 
chosen through the Mauritius map analysis, using SkMCs of DMD patients and 
normal controls in cell culture. 
• Expression and proliferation analysis of modulated SkMCs at mRNA and protein level 
of selected genes.  
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3 Material and Methods 
Molecular biology 
3.1 Material 
3.1.1  Chemicals 
 
 Designation  Source 
  
 Agarose ultra pure  
Ammonium acetate 
Ammonium hydroxide solution 
Ammonium sulfate (for analysis) 
Ampicillin 
Antioxidant NuPAGE (Western blot) 
APS 
beta-Mercaptoethanol 
Bromphenol Blue 
Bovine serum albumine 
Calcium chloride 
Chloroform 
Cyclosporin A 
Deflazacort 
DEPC 
Dithiothreitol 
DMSO  
dNTP-set 
EDTA (Titriplex III) 
Ethanol 
Ethidium bromide 
Formaldehyde  
Formamide 
Glycine 
Glycogen 
Hexanucleotide pd(N)6 
IC261 
Isopropanol 
 Life Technologies  
Merck 
Fluka  
Merck 
Sigma 
Invitrogen 
Serva 
Roth 
Serva 
Gibco BRL 
Merck 
Roth 
Merck 
Sanofi Aventis 
Fluka  
Invitrogen/ Promega  
Roth  
Invitrogen 
Merck 
Merck 
Merck 
Merck 
Merck 
Serva 
Roche 
Invitrogen/ Promega 
Merck 
Merck 
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 Designation  Source 
  
 Skim milk powder 
Magnesium chloride (for PCR) 
Magnesium chloride 
Methanol 
Neomycin 
Okadaic acid 
Paraformaldehyde 
PBS Dulbecco (50x 
Penicillin 
Phenol/Chloroform/Isoamylalcohol 
Potassium chloride 
Potassium dihydrogen phosphate 
ProLong Antifade 
Reducing agent NuPAGE (Western blot) 
RNase free water 
Sodium acetate 
Sodium chloride 
Sodium citrate 
Di-Sodium hydrogen phosphate dihydrate 
Sodium hydroxide 
Sodium hydroxide solution (50%) 
SDS (Sodiumdodecylsulphate) 
Streptomycin 
TaqMan Universal PCR Master Mix 
No AmpErase UNG 
Triethanolamine 
Tri Pure 
Tri Reagent 
Tris-(hydroxymethyl)aminmethan 
Trypan blue 
Trypsin/ EDTA 
Tween 20 
 Merck 
Applied Biosystems 
Merck 
Merck 
Biochrom KG 
Merck 
Merck 
Biochrom KG 
Biochrom KG 
Roth 
Merck 
Merck 
Invitrogen 
Invitrogen 
Ambion 
Merck 
Merck 
Merck 
Merck 
Fluka 
Merck 
Serva 
Biochrom KG 
Applied Biosytems 
 
Merck 
Roche 
Sigma Aldrich Chemie 
Merck 
Sigma Aldrich Chemie 
PromoCell 
Merck 
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3.1.2 Buffers and solutions 
 
 Designation  Source/ Composition 
  
 BCA protein assay reagent A 
BCA reagent B 
Bromphenolblue solution 
BSA 1% 
Developer solution 
ECL solution I 
 
 
 
ECL solution II 
First strand buffer 
Fixing solution 
LB medium 
 
 
 
 
PCR buffer (10x) 
RIPA buffer 
 
 
 
 
 
 
 
 
Roti®-Load 1 (4x) 
Rotiphorese® buffer (10x) 
Rotiphorese Gel® 30 (37,5 : 1) 
Separating gel buffer (pH 8.8) 
 
Stacking gel buffer (pH 6.8) 
 Th. Geyer Hamburg 
4% (w/v) CuSO4 * H2O 
1% (w/v) Bromphenolblue in ethanol 
1% BSA in TBS-T 
Kodack Medical 
2.5mM Luminol 
0.4mM p-Coumarsäure 
100mMTris-HCl (pH 8.5) 
 
100mM Tris-HCl (pH 8.5) 
Invitrogen/ Promega 
Kodack Medical 
10g/L Trypton 
5g/L yeast extract 
5g/L NaCl 
pH 7.5 
 
Q-Bio gene 
1% NP 40 (100%) (Igepal CA 630) 
0.5% Sodium – deoxycholate 
0.1% SDS 
1mM EDTA 
1mM EGTA 
1mM Sodium orthovanadate 
20mM Sodium fluoride 
0.5mM DTT 
 
Roth 
Roth 
Roth 
0.4% SDS 
1.5 M Tris - HCl (pH 8.8) 
0.4% SDS 
0.5 M Tris - HCl (pH 6.8) 
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 Designation  Source 
  
 TAE buffer 10x 
 
 
 
TBS 10x 
 
 
TBS-T 
 
 
 
TFB-1 
 
 
 
 
 
 
TFB-2 
 
 10mM EDTA (pH 8,0) 
2.3 % Essigsäure 
0.5 M Tris 
 
0.1 M Tris-HCl (pH 7.4) 
1.5 M Natriumchlorid 
 
150mM Natriumchlorid 
10mM Tris - HCl (pH 7.4) 
0.1% Tween 20 
 
100mM rubidium chloride 
50mM magnesium chloride 
30mM potassium acetate 
10mM calcium chloride  
15% glycerol 
pH 5.8 
 
10mM MOPS 
100mM rubidium chloride 
10mM calcium chloride 
15% glycerol 
pH 6.8 adjusted with potassium 
hydroxide 
pH 5.8 
 
 
3.1.3  Media for cell culture 
 
 Designation  Source 
  
 Dulbeccos MEM 
OptiMem® Serum free medium 
SkMC Growth Medium Kit 
SkMC Differentiation Medium Kit 
Trypsin Neutralisation Solution 
Fetal calf serum 
 PAN 
Gibco 
PromoCell 
PromoCell 
PromoCell 
Biochrom 
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3.1.4  Oligonucleotides 
 
3.1.4.1 Conventional PCR 
 
table 2:  Gene-specific primer used in convential PCR and for sequencing.  
(fwd = forward-primer;  rev = reverse-primer) 
Gene 
name 
NCBI-
Accession 
Number 
Oligo name Primer sequences Annealing 
temperature 
CSNK1A1 NT_029289 CSNK1A1_Prom1 fwd AAA TAC CTC AAC CGA CAA GG 
56°C 
rev TCC TCT CAA TCT TCT TTG CAC 
CSNK1A1_Prom2 fwd GAG CGT GCA AAG AAG ATT G 
rev AAA ATG CCT TGC TGA CTC AC 
NFATc NT_010879 NFATc_Prom1 fwd GAC ACG AGT TTA GCC TTT GG 
rev CTG TGG AAA TTT GGA AAA GC 
NFATc_Prom2 fwd TGG GAA TTT CCT TTC TAG GG 
rev TTT AAA GCT GGA AAA CAC CTC 
RAP2B NT_005612 RAP2B_Prom1 fwd ACT TAG GGG TGT CAG ACT CG 
rev ACC TGC CCC ATA GAT TTT TC 
RAP2B_Prom2 fwd AAT CTA TGG GGC AGG TTT G 
rev CTC TCT CCC ACA GCC TCT AC 
 
All gene-specific were designed with the computer program “Primer3”  
(http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi) and ordered from the 
company Biotez in Berlin, Germany. 
The used primer concentration was 10μM at a time. In case of RAP2B, the sequence of 1kb 
upstream of the gene bore a GC-content 60-70%. This resulted in a use of a specific 
amplification procedure as described in section 3.3.9. 
 
 
3.1.4.2 TaqMan PCR 
 
table 3:  Gene-specific TaqMan probes and primer used in TaqMan Real-Time-PCR. Probe and primer sequences of the assays on 
demand are not specified by the manufacturer (ABI).  
(fwd = forward-primer;  rev = reverse-primer; ns = not specified) 
Gene 
name 
Order 
number 
Sequence of the probe Primer sequence 
Calcineurin Hs00174223_m1 n.s. 
c-Jun Hs00277190_s1 n.s. 
CSNK1A1  CTT GTC GGT TGA GGT ATT T fwd GGT AGG CAG CTT CTT TGT TTC TTT rev TGA TTT CTG GCT AAA AGT ATC AAA GGG TTT 
JNK1 Hs00177083_m1 n.s. 
MYF5 Hs00271574_m1 n.s. 
NFATc  CAA GCC GAA TTC TC fwd GGG AGA TGG AAG CGA AAA CTG A rev AAA TGG CGG GAT CTC AAC CA 
p21  CTT CGG CCC AGT GGA CAG fwd ACC CAT GCG GCA GCA A rev CGC CAT TAG CGC ATC ACA 
RAP2B Hs00267932_s1 n.s. 
UTRNA  ATT GTG TTC ATC CAG ATC TG fwd AAT GGG CAG AAC GAA TTC AGT GAT A rev CAT TTG GTA AAG GTT TTC TTC TGT ACG T 
18s rRNA 4308329 n.s. 
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Primers and probes ordered as assay on demand are indicated by their order numbers. All 
others were designed by Applied Biosystems (ABI). In both cases they were delivered as a 
ready to use mixture. The sequence of each mRNA including information of the position of 
exon-exon junctions was send to the company using the ABI software “Assay by design File 
builder” (version 2.0). For that purpose, the whole sequence of each gene and exon-exon 
junctions were verified using the NCBI Evidence Viewer in “LocusLink” 
(http://www.ncbi.nlm.nih.gov/LocusLink/) and the Ensembl Human Genome Server 
(http://www.ensembl.org/). All probes were designed to overlap an exon-exon junction and to 
hybridise between both primers. This characteristic eliminates the possibility of detection of 
nonspecific amplification and also of DNA contamination. 
 
3.1.4.3 LightCycler PCR 
 
table 4:  Gene-specific primer used in LightCycler Real-Time-PCR;  
(cds = coding sequence; fwd = forward-primer;  rev = reverse-primer) 
Gene name NCBI 
accession 
number 
Oligo name Primer sequences Annealing 
temperature 
CSNK1A1 NM_001892 CSNK1A1_cds270 fwd GGA TCT TCT GGG ACC TAG CC 
56°C 
CSNK1A1_cds515 rev TGT TGC CTT GTC CTG TTG TC 
GAPDH NM_002046  fwd GAA GGT GAA GGT CGG AGT C rev GAA GAT GGT GAT GGG ATT TC 
GFP FM883229.1 GFP 
fwd TCA AGG AGG ACG GAA ACA TC 
rev AAA GGG CAG ATT GTG TGG AC 
At DNA level 
CSNK1A1  NM_001892 NT_029289 
CSNK1A1 ORF/XmnI 
fwd GTT CGA ACC ATG GCG AGT AG 
56°C 
rev CCT TTC ATG TTA CTC TTG GTT TTG 
CSNK1A1_Ex3 fwd GGA TCT TCT GGG ACC TAG CC 
CSNK1A1_Int4_176 rev CCA GGT TTT GTC TTA TTC CCA TAG 
ß-Actin NM_001101 NC_000007 
Act.3 fwd TCT ACA ATG AGC TGC GTG TGG CTC 
Act.4 rev GCT CGG TGA GGA TCT TCA TGA GGT 
 
The GAPDH primer were designed by TIB MOLBIOL GmbH (Berlin, Germany). All other 
primer pairs were ordered from Biotez (Berlin, Germany). 
 
3.1.5  Kits 
 
 Designation  Source 
  
 Advantage GC 2 PCR 
BrdU cell proliferation test 
CCK8 cell vitality test 
 Clontech 
Roche 
Dojindo 
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 Designation  Source 
  
 FastStart DNAPlus SYBR Green I Master 
Mix 
mirVana RNA prep Kit 
QIAprep Plasmid Maxi Kit EndoFree 
QIAquick Gel Extraction Kit 
QuantiTect reverse transcription Kit 
Plasmid Maxi Kit 
RNase free DNase set 
Spin Cell RNA Mini Kit 
TaqMan 18s rRNA standard 
Twin Spin Cell Mini Kit 
X-tremeGene siRNA Dicer kit 
 Roche 
Ambion 
QIAGEN 
QIAGEN 
QIAGEN 
QIAGEN 
Promega 
Invitek 
Applied Biosystems 
Invitek 
Roche 
 
3.1.6  Molecular weight marker and plasmid vector DNA 
 
 Designation  Source 
  
 HiMarkTM pre-stained protein standard 
Marker VIII 
λ-Hind III 
ΦX174/HAEIII 
pReceiver M03 CSNK1A1 
TrueClone expression vector CSNK1A1 
 Invitrogen 
Roche 
self made 
self made 
Genecopoeia 
OriGene 
 
 
3.1.7  Enzymes 
 
 Designation  Source 
  
 AmpliTaq 
AmpliTaq Gold 
DNase I (Amp. Grade) 
 Applied Biosystems 
Applied Biosystems 
Roche 
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 Designation  Source 
  
 HaeIII – enzyme + buffer 
RNase H 
RNase Out 
SuperscriptII RT 
EcoRI – enzyme + buffer 
SpeI – enzyme + buffer 
StuI – enzyme + buffer 
 Boehringer I 
Invitrogen 
Invitrogen/ Promega 
Invitrogen 
MBI Fermentas 
MBI Fermentas 
MBI Fermentas 
 
 
3.1.8  Antibodies 
 
 Designation  Source 
  
 Anti ß-actin (human, mouse) monoclonal 
POD-Anti-mouse IgG 
Anti UTRNA (human, rat) monoclonal 
 Santa Cruz 
Oncogene Research 
Santa Cruz 
 
 
3.1.9 Transfection reagents and systems 
 
 Designation  Source 
  
 amaxa NHDF nucleofection kit 
Effectene 
Fugene 6 
Fugene HD 
Lipofectamine 2000 
Targefect/ Virofect 
X-tremeGENE siRNA transfection reagent 
 amaxa 
QIAGEN 
Roche 
Roche 
Invitrogen 
Targeting system 
Roche 
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3.1.10 Equipment 
 Designation  Type  Source 
   
 ABI Prism SDS 
Analytical balance 
Cooling centrifuge 
Econo Spin 
DNA-Sequencer 
Homogeniser tapered, Teflon®  
Horizontal gel electrophoresis 
iBlot blotting system 
Image Master 
Incubator 
Laminar flow 
LightCycler® 
LightCycler® Rotor  
Magnetic stirrer 
Microplate reader 
Micro quartz cuvette 
Microscope 
Multichannel-pipet 
PCR-Cycler 
Pipettes 
Pipet boys 
pH meter 
Photometer 
Precision balance 
Shaker Stovall 
Standard power pack 
Thermomixer 
Precision balance 
Table top centrifuge 
Vortex 
Waterbath 
7000 
CP64 
Sigma-3MK 
 
3100 
358133 series 
Horizon 11-14 
Version C 
VDS 
BR6000 
HLB2472 
2.0 
2.0 
MR 3001K 
VersaMax 
50µL volume 
 
2-200µL 
T3 
Research 
Pipetus®-akku 
CG 820 
Carry 100 
CP2202S 
Belly Dancer 
P25 
Compact 
Excellence 
Mini Spin 
Genie 2 
WB10 
 Applied Biosystems 
Sartorius 
Sigma 
Sorvall Instruments 
Applied Biosystems 
Wheaton Science 
Life Technologies 
Invitrogen 
Pharmacia Biotech 
Heraeus 
Heraeus Instruments 
Roche 
Genaxxon 
Heidolph 
Molecular Devices 
Varian 
Zeiss Jena 
Brand 
Biometra 
Eppendorf 
Hirschmann 
Schott 
Varian 
Sartorius 
Castle Scientific 
Biometra 
Eppendorf 
Sartorius 
Eppendorf 
Bender 
Memmert 
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3.1.11 Consumable supplies 
 
 Designation  Source 
  
 Cryo vials 
Falcon tubes 15mL; 50mL 
iBlot™ Gel Transfer Stack, Nitrocellulose 
LightCycler plastic capillaries 
Microscope slides 
Neubauer counting chamber 
NuPAGE Mini Gels Tris-Acetate 4-12% 
Optical caps, 8 stripes 
Pasteur pipettes 
Pipet tips (0.5μL – 1000μL) 
Reagent reservoirs 
Safe-lock tubes (0.5mL, 1.5mL) 
8 stripes (nuclease free) 
TC flasks 25cm²; 75cm² 
Tubes (0.2mL - 2.0mL) 
UV-cuvette 
X-ray films 
6well cell culture plates 
96well cell culture plates 
96well Optical plates 
 Corning 
Corning 
Invitrogen 
Genaxxon 
Roth 
Labor Optik 
Invitrogen 
Applied Biosystems 
Roth 
Faust 
Costar 
Roth 
GeNunc 
TPP 
Roth 
Eppendorf 
Kodack Medical 
TRP 
TRP 
Applied Biosystems 
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3.2 Software 
 
table 5:  Software and web interfaces for sequencing analysis and database searches 
Name Field of application Version / Internet address 
ABI PrismSDS 
Software for analysis of Real-Time-
PCR results 
Version 1.2x 
BioDocAnalyzer 
Densitometrical analysis tool for 
Western blot results 
Version 2.0 Biometra 
Ensembl Human Human genome, BLAST sequences http://www.ensembl.org/human/ 
File builder 
Sequence checker and text editor to 
build, edit and correct imported 
sequence submission files 
Version 2.0 Applied Biosystems 
(Assay by Design Service) 
GeneCards 
Overview about human genes 
summarised from different databases 
http://www.genecards.org 
Human Genome 
Project working draft at 
UCSC 
Gene maps, 
Alignment and search tool 
http://genome.cse.ucsc.edu/index.html 
KEGG database at 
Biocarta 
Signal transduction pathway database 
and tool 
http://www.biocarta.com 
NCBI 
Homologies, BLAST, 
Cytogenetic map, 
Genetic map, Genetic markers 
http://www.ncbi.nlm.nih.gov/ 
Primer3 Primer design http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi 
OMIM 
catalog of human genes and 
genetic disorders 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM 
Sequencher 
Sequencing analysis and alignment 
tool 
Sequencher Demo Version 4.0.5 
Gene Codes Corporation 
SwissProt Protein database http://us.expasy.org/sprot/ 
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3.3 Methods 
3.3.1  Flow diagram 
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3.3.2  Origination of muscle tissue and human skeletal muscle cells 
 
3.3.2.1 Muscle biopsy tissue 
 
After informed consent according to the declaration of Helsinki muscle biopsies were usually 
taken from M. quadriceps femoris for diagnostic reasons. One section of the samples was 
immediately frozen in liquid nitrogen for immunohistochemical diagnostic as well as research 
and another one was used to generate a cell culture. 
 
Muscle tissue was obtained by biopsy from DMD patients and healthy controls, and kindly 
provided by Dr. med. Arpad von Moers (Charité Berlin, Campus Virchow Clinic), frozen in 
liquid nitrogen and stored at –80°C. DMD patients as well as healthy controls were at 
different ages at the time of biopsy. 
The clinical features and data of molecular diagnosis of the 2 affected brothers were described 
in Sifringer et al. 2004. In short, especially differences in sitting (18 months for the elder one 
versus 9 months for the younger) and walking (40 versus 18 months), and loss of gait  
(9 versus 12 years) make clear that at comparable ages the elder brother is much more 
affected by muscle weakness and remarkable progression of symptoms than the younger one. 
Because the elder brother died at age 16.5 years and muscle material was used for the 
subtraction library (Sifringer et al., 2004) it was not available for further studies. Five DMD 
patients were used as equivalent DMD patients. Patient p1 presents comparable clinical 
features similar to the elder brother. He started walking at 30 months and lost gait at 10 years. 
The time point of muscle biopsy of both siblings was age-matched at age 6. 
In addition, another 4 DMD patients were analysed to confirm the outstanding position of the 
younger brother. As normal controls, 5 specimens of diagnostic biopsies were used that turned 
out to be normal. The age at biopsy of the controls varies between 1 year, 7 months and  
11 years and for the classic DMD-patients between 3 years, 5 months and 8 years.  
An overview of clinical features and molecular diagnosis data of 5 classic DMD patients as 
well as of the brothers is given in table 6.  
 
 
 
 
 
MATERIALS AND METHODS 
 54 
table 6:  Clinical and molecular data of healthy controls and DMD patients who are donors of muscle biopsy tissues used in mRNA 
expression analyses (section 3.3.7) 
 Age at biopsy Muscle type Diagnosis Walking Wheelchair- bound 
Healthy controls 
c1 11 years M.Quadriceps femoris osteochondrom 
n.d. 
c2 28 months M.Quadriceps femoris (intermit.) CK level slightly increased 
c3 19 months M.Quadriceps femoris 
ponto-cerebell. hypoplasy; epilepsy; 
microcephaly 
c4 33 months M.Quadriceps femoris microdeletion 7q36 
c5 3 years  10 months 
M.Quadriceps 
femoris 
mental and physical retardation; (intermit.) 
increased CK level; microcephaly 
DMD patients 
pm 6 years M.Quadriceps femoris  immunhistological dystrophin negative 
18 months 12 years 
ps 6 years M.Quadriceps femoris  immunhistological dystrophin negative 
40 months 9 years 
p1 7 years  5 months 
M.Bizips 
femoris immunhistological dystrophin negative 
30 months 10 years 
p2* 2 years M.Quadriceps femoris immunhistological dystrophin negative 
16 months walks 
(4 years) 
p3 8 years M.Quadriceps femoris immunhistological dystrophin negative 
15 months walks 
(9 years) 
p4 7 years 5 months 
M.Quadriceps 
femoris 
deletion of exon 7-39 
immunhistological dystrophin negative 
18 months 10 years 
p5* 3 years  5 months 
M.Quadriceps 
femoris immunhistological dystrophin negative 
12 months walks 
(6 years) 
c = controls; p = classic DMD patient; pm = mild DMD patient; ps = elder brother of pm 
n.d. = not determined    
For patients pm, ps, p1, p2, p3 and p5 no mutations were found at DNA level. But due to clinical signs and immunohistological dystrophin 
negative data there is no doubt concerning the diagnosis of DMD. 
* in cell culture table 7 
 
 
3.3.2.2 Primary human skeletal muscle cells (myoblasts) used in cell culture 
 
Primary human skeletal muscle cells (SkMCs) were received from biopsy tissue of the right 
or left quadriceps of healthy controls and DMD as well as BMD patients (Dr. med. Arpad von 
Moers, Charité Berlin, Campus Virchow Clinic, Berlin, Germany) and prepared at the MTCC 
(“Muscle Tissue Culture Collection”, Munich, Germany). 
Selection of myoblasts from the biopsy samples was performed according to an established 
procedure of the MTCC, Munich, Germany. To obtain primary human myoblast cultures, 
muscle tissue samples were treated proteolytically. Separation of myoblasts from other cell 
types contained in muscle tissue was carried out in the group of Prof. Dr. Hanns Lochmueller 
by Eva Neugebauer using the MACS method. The magnetic cell separation technique through 
magnetic beads with the use of cell-specific antigens on the surface is very efficient. Vitality 
and purity of the obtained cells are very high (Dickson et al., 1987; Webster et al., 1988; 
Walsh et al., 1989; Walsh, 1990). 
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The separated cells were cryo-preserved for transportation from the MTCC Munich to Berlin. 
After arrival the cells were first cultured for 2 passages before they were frozen in liquid 
nitrogen again (see section 3.3.3). An overview of the primary cells used in subsequent 
experiments is shown in table 7. 
 
table 7: Overview origin of biological samples 
Designation 
Clinical data Cell culture 
Classification Age at biopsy Dystrophy 
Doubling of 
population 
Subjective impression 
cultured cells 
14/00  normal 2 years - 4d normal 
18/01  normal 9 years - 5.5d normal 
43/01  DMD 3 months 
no 
impairment 
6d slightly delayed 
77/02  DMD 4 years 
progressive, 
mild course 
12d 
delayed; 
myoblasts enlarged 
109/03 P5* DMD 3.5 years progressive 12d delayed;  myoblasts enlarged 
145/03 P2* DMD 2 years progressive 7d slightly delayed 
* patients also available for muscle biopsy investigations in table 6 
 
 
 
3.3.3  Culturing of primary human skeletal muscle cells (myoblasts)  
 
Culture conditions 
SkMCs were cultured under humid conditions at 37°C and 5% (V/V) carbon dioxide (CO2) in 
an incubator (Heraeus Instruments). The culture media containing 5% fetal calf serum (FCS) 
and growth factors (PromoCell) was changed every 3 to 4 days at a final volume of 200µl/cm² 
depending on the proliferation rate of the cells. The growth of the cells was examined 
microscopally (Zeiss, Jena) every 24 hours. After the monolayer reached a  
sub-confluence of 80-90%, the cells were passaged. A washing step with 200µl/cm² of  
1 x PBS (Biochrom) was performed followed by trypsinisation of the cells with  
50µl/cm2 Trypsin/EDTA solution (PromoCell). The serine protease trypsin hydrolyses the 
peptide bonds and therefore dislodges adherent cells from the walls of culture flaks. This can 
be advanced by gently tapping the side of the culture flasks. When all cells were detached, 
trypsinisation was stopped using 100µl/cm trypsin neutralisation solution (TNS, PromoCell). 
The cells were harvested and transferred into a 15mL falcon tube (Corning) followed by 
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centrifugation at room temperature for 5min at 200 x g (Econo Spin). The supernatant was 
removed without disturbing the cell pellet. The cell cluster was re-suspended in fresh growth 
medium and distributed according to their proliferation rate into new culture flasks. 
 
Long-time storage 
For long-time storage as well as transportation of the primary human myoblasts, the cells 
were cryo-preserved in Cryo-serum free medium (Cryo-SFM; PromoCell) containing DMSO, 
methyl-cellulose and other cryo-protectant ingredients. Myoblasts were harvested as 
described above but re-suspended in cold Cryo-SFM at a concentration of 1-5 x 106 cells per 
1mL of Cryo-SFM, transferred into a cold cryo tube (Corning) and gradually frozen to  
–196°C for final storage in liquid nitrogen (Thermo N2 container). For thawing the cryo vial 
was gently shaken in warm water (37°C) until most of the Cryo-SFM was thawed. The cell 
suspension was transferred into a 15mL falcon tube with 10mL pre-warmed growth medium. 
Remaining cell suspension in the cryo vial was thawed with warmed medium and also added 
to the falcon tube. After centrifugation as described above, the supernatant was removed and 
the cell pellet was re-suspended in warm growth medium at a concentration of 2 x 105 cells 
per 1mL. The cell solution was displaced in a new pre-warmed culture flask.  
The sizes of the culture flasks and plates are dependent on the cell number distributed to the 
culture vessel. An overview of cell numbers applied to different culture containers is given in 
table 8. 
 
table 8:  The number of primary human skeletal muscle cells applied to used culture flasks and plates. 
Culture vessel Cell Growth Area Cell number 
96well plate 0,32cm2 3 x 103 
6well plate 9cm² 3-4 x 105 
T25 flask 25cm² 1 x 106 
T75 flask 75 cm² 3 x 106 
T150 flask 150 cm² 6 x 106 
 
 
C2C12 myoblasts and HeLa cells were cultured as described for primary human skeletal 
muscle cells, but in Dulbecco's Modified Eagle's Medium (DMEM) including 10% FCS 
instead of SkMC growth medium. 
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3.3.4  Transfection 
 
Various transfection reagents and systems are available. But numerous primary cell types, 
such as the primary human skeletal muscle cells, are very hard to transfect and resist most of 
them. Therefore, 4 different transfection reagents as well as a electroporation system were 
tested to discover the optimal transfection conditions in terms of vitality and transfection 
efficiency: Effectene™ (QIAGEN), Fugene 6 (Roche), Fugene HD (Roche), Targefect 
(Targeting System) and the amaxa nucleofection system (amaxa). In the case of Fugene HD, 
the vector DNA was not only transfected into primary human myoblasts as for the other 
transfection reagents, but also into HeLa and C2C12 cells to examine whether the insert of the 
vector DNA is differentially expressed in different cell types. 
 
Plasmid vector DNA 
Two different types of expression clones with a cDNA insert encoding CSNK1A1 were used 
in transfections: TrueClone™ (Origene) and OmicsLink™ ORF Expression Clones 
(Genecopoeia).  
The OmicsLink™ ORF Expression pReceiver M03 is a full length protein coding ORF clone 
and contains the cDNA insert (from start to stop codon), 2 antibiotic cassettes (neomycin, 
ampicillin) and the green fluorescent protein (GFP) as reporter gene. Both, GFP and the insert 
are regulated through the same cytomegalovirus promoter (CMV) at which translation of GFP 
is initiated by the internal ribosome entry site (IRES). The reporter gene GFP allows the 
observation of successful transfection in a fluorescence microscope without any isolation of 
DNA or RNA. Neomycin can be used as a selection marker in mammalian cells to induce a 
stable transfection. The whole plasmid is about 7kbp in size. 
The Origene TrueClone™ pCMV6-XL5 has the designated full length cDNA cloned 
downstream of the CMV and T7 promoter and contains the resistance gene for ampicillin. A 
reporter gene is not included. The length of the clone is 7.3kbp. 
Before use, both vectors were transformed into E.coli to produce unlimited amounts of 
plasmid DNA. 
 
Preparation of competent E.coli cells 
For the preparation of competent E.coli cells, 100mL of LB-medium containing  
50μg/mL ampicillin were inoculated with cells from the glycerol stock and incubated on a 
shaker at 37°C over-night. Next day, 1mL of the cells was transferred into 100mL  
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pre-warmed LB-medium and again incubated on a shaker (100rpm) at 37°C until the optical 
density (OD600) of 0.5 was reached. A volume of 50mL was moved to a centrifuged tube and 
left on ice for 5min. After centrifugation at 4°C and 4000 x g for 5min, all the following steps 
were performed on ice. The supernatant was discarded and the cell cluster was  
re-suspended in 15mL pre-chilled buffer TFB-1 followed by another incubation for 90min on 
ice. After a second centrifugation step at 4°C and 4000 x g for 5min, the cells were gently  
re-suspended in 2mL pre-chilled buffer TFB-2. The cell suspension was distributed to  
1.5mL reaction tubes with a volume of 100µL per tube and stored at –80°C. 
 
Transformation of DNA in E.coli 
The transformation reaction was set up for chemical competent E.coli cells as described in 
table 9:  
 
table 9:  Reaction set-up for transformation of plasmid DNA into competent E.coli cells  
Reagent Volume [μL] 
Competent E-coli 100μL 
Vector DNA (100ng/µL) 2μL 
LB-Medium 500μL 
Final volume 602μL 
 
 
The reaction containing E.coli and vector DNA was mixed gently and incubated for 15-20min 
on ice. Afterwards, the cells were heat-shocked for 45sec at 42°C without shaking and then 
immediately transferred on ice for 2min. To the reaction, 500μL of to 37°C pre-warmed LB 
medium was added. The tubes were placed on a shaker at 37°C for 2 hours. The total volume 
of each transformation was centrifuged at room temperature for 5min at 3000 x g,  
re-suspended in 100µL LB-medium and then spread on pre-warmed selective plate containing 
ampicillin and incubated at 37°C over night. Next day, a colony was picked and the plasmid 
DNA was isolated using the QIAGEN Plasmid Mini kit. The plasmid DNA was analysed by 
PCR and gel electrophoresis to confirm the presence and the correct length of the insert. For 
transfection, a high amount of plasmid DNA was required. For that purpose, 100mL of  
LB-medium containing 50μg/mL ampicillin was inoculated with cells from original colony 
and incubated at 37°C over-night. Next morning, 1mL of the cell suspension was transferred 
into 250mL fresh LB-medium and incubated again at 37°C for 4-6h. Cells were harvested and 
the plasmid DNA was isolated using the QIAGEN Plasmid Endotoxin Free Maxi Kit. The 
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whole procedure was performed as described in the manual of the kit. The obtained plasmid 
DNA was measured using OD260 and used for further transfection. 
For long-term storage, the original analysed colony was inoculated into 10mL of LB 
containing 50μg/mL ampicillin and the culture was grown over-night. Next day, an aliquot of 
this culture was applied to a solution of 50% LB-medium and 50% sterile glycerol. The 
glycerol stock was stored at -80°C. 
 
Transfection using amaxa nucleofection system (amaxa) 
The amaxa nucleofection system is based on the electroporation technique and was already 
applied successfully for primary human SkMCs by Quenneville et al 2004 (Quenneville et al., 
2004). As suggested by the authors, the human dermal fibroblast (NHDF) nucleofector kit 
was used for transfection (Quenneville et al., 2004). The whole procedure was applied as 
described in the manufacturer’s instruction. Different programs were investigated, but only 
one at a time (table 10).   
 
table 10:  Preparation and programs used for nucleofection for primary human myoblasts 
Primary human 
myoblasts 
NHDF 
solution 
Vector DNA 
(max. 5µL) 
Program 
0.5-1.0 x 106 100µL  2µg  4µg 6µg 8µg X01  P20 U20 U25 
 
Pre-warmed growth medium was added to the cuvette and the cell solution was distributed to 
3 35mm culture dishes. The third dish also contained a sterile cover slip used for fluorescence 
microscopy. The cells were cultured in the incubator at 37°C, 5% CO2, and  
95% humid atmosphere. Negative controls treated either with DNA or the nucleofection 
reagent alone were always performed at the same time. Next day, the medium was replaced 
with medium containing the selection marker neomycin and cover slip was prepared to 
determine transfection efficiency using fluorescence microscopy (see below). The transfection 
efficiency was also investigated by determination of copy numbers and expression rate of 
plasmid DNA using Real-Time PCR (as described below).  
The nucleofection system was not utilised in combination with Origene TrueClone™ 
pCMV6-XL5 vector. 
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Transfection using Effectene (QIAGEN) 
Effectene is a non-liposomal lipid, which is used in combination with a DNA-condensing 
enhancer and optimised buffer to reach high transfection efficiencies. Firstly, the enhancer 
condenses the DNA molecules and the Effectene reagent coats them with cationic lipids. 
Thus, this allows a transfection of primary eukaryotic cells. 
Transfection was applied in 6-well plates with normal primary human myoblasts according to 
manufacturer’s instructions. Effectene was already utilised in transfection of antisense 
oligonucleotides in this group. Therefore, the procedure was performed with the same 
protocol (table 11). After 6h of culturing in the incubator at 37°C, 5% CO2, and  
95% humid atmosphere, the medium was replaced.  
 
table 11:  Effectene transfection conditions performed with 4 x 105 primary human myoblasts 
Buffer EC DNA (in 20µL) Enhancer Effectene 
80µL 1µg 3.2µL 20µL 
5µg 
 
Negative controls treated either with DNA or the transfection reagent alone were 
simultaneously performed. Two days after transfection, the achievement of the transfection 
was monitored using fluorescence microscopy. As mentioned for transfection with amaxa 
nucleofection system, the transfection efficiency was also investigated by determination of 
copy numbers and expression rate of plasmid DNA using Real-Time PCR. 
Effectene was not utilised in combination with Origene TrueClone™ pCMV6-XL5 vector. 
 
Transfection using Fugene 6 and Fugene HD (Roche) 
Fugene 6 as well as Fugene HD are non-liposomal lipids supplied with other components 
in 80% ethanol and suitable for both, stable and transient transfections. The protocol of the kit 
was followed at all times but with various ratios of Fugene : DNA as suggested by the 
protocol. Both, Fugene 6 and Fugene HD are low in toxicity. In the case of Fugene HD, 
transfection was applied to primary human myoblasts, HeLa and C2C12 cells, to examine 
whether the insert of the vector DNA is differentially expressed in different cell types. 
For transfection, the cells were trypsinised and plated into 6-well plates. The number of cells 
used per well is shown in table 12. Contrary to the Fugene HD protocol, the transfection 
was applied directly after seeding of the cells. In the case of Fugene 6®, the transfection took 
place the next day as suggested by the manual, and sterile cover slips were included in the  
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6-well plates. The following procedure as described for Fugene HD below was applied for 
Fugene 6 in the same way.  
 
table 12:  Number of cells for each cell type as used in transfection with Fugene HD in 6-well plates 
Cell type Cell number 
C2C12 myoblasts 5 x 105 
HeLa 1 x 106 
primary human myoblasts 4 x 105 
 
The Fugene HD transfection was performed using different Fugene HD : DNA ratios as 
well as different volumes of the Fugene HD-DNA-complex solution as suggested by the 
protocol. The procedure is published in Grunwald and Speer (Grunwald and Speer, 2007).  
 
table 13:  Different transfection parameters as tested for primary human myoblasts transfection efficiency 
 Negative control  
 DNA only Fugene HD only Fugene HD : DNA 
Ratio 
Fugene HD (µL) / DNA (µg) 0:2 3:0 6:0 12:0 3:2 6:2 12:4 
Volume of complex (%) 
100% 100%   100% 100% 100% 
200% 200% 200% 200% 200% 200% 200% 
    400% 400% 400% 
 
In the case of Fugene 6, transfection efficiency was observed using a fluorescence 
microscope. The Origene TrueClone™ pCMV6-XL5 vector was not applied in transfection 
with Fugene 6, but with Fugene HD. After 72h of transfection with Fugene HD, the 
cells were washed, trypsinised and washed again with 1x PBS before the lysis buffer was 
added. Transfection efficiency was determined by examination of plasmid copy numbers and 
expression rate using Real-Time PCR. Negative controls as shown in table 13 were performed 
in each experiment.  
A second transfection with Fugene HD was performed in order to investigate its influence 
on proliferation and vitality of the cells, 72h after transfection. Since the proliferation test has 
to be applied in 96-well plates but transfection is more efficient in 6-well plates, the cells were 
transferred from 6-well plates to 96-well plates after 24h of transfection. 
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Transfection using Targefect/Virofect (Targeting Systems) 
Targefect F-2 is a non-lipid cationic polymer with DNA-condensing properties and is low in 
toxicity. Targefect F-2 is used in combination with Virofect. Virofect is an  
adenovirus-derived formulation, which has the ability to complex with plasmid DNA via the 
cationic targefect F-2. It can enhance gene transfer by increasing cellular uptake and allows 
the escape of the transfected plasmid DNA from lysosomal degradation because of its ability 
to lyse the endosome. But it does not contain any replication-competent virus. 
Plasmid DNA was diluted in serum free OptiMem®, mixed by vortexing before and after 
addition of targefect F-2 (table 14). Virofect was included, the solution was mixed, and left 
for 20min at 37°C to form complexes. Afterwards, the transfection complex was placed onto 
the cells and the dish was swirled to mix the transfection complex with growth medium. The 
cells were incubated for 24h at 37°C, 5% CO2 and 95% humid atmosphere until the medium 
was changed with an additional wash step using fresh medium, next day. 
 
table 14:  Conditions for transfection with Targefect/ Virofect using 4 x 105 for primary human myoblasts 
Condition OptiMem SFM DNA Targefect F-2 Virofect 
1 0.6mL 6µg 12µL - 
2 0.6mL 6µg 12µL 25µL 
3 1.2mL 3µg 9µL 22.5µL 
 
Negative controls treated either with DNA or the transfection reagent alone were performed at 
the same time. Two days after transfection, the transfection efficiency was determined using 
fluorescence microscopy. 
Targefect/Virofect was not utilised in combination with Origene TrueClone™  
pCMV6-XL5 vector. 
 
Detection of successful transfection using a fluorescence microscope 
The green fluorescent protein GFP is a protein found in the jellyfish aequorea victoria. It 
fluoresces green when it is exposed to blue light. GFP is widely used as a reporter gene in 
DNA constructs as proof of transfection. 
After 48h of transfection, the cover slips included in the 6-well plates were first washed twice 
with 1 x PBS followed by fixation of the cells with 3,7% formaldehyde in 1 x PBS for 1h. 
The cover slips were washed again, briefly dried and covered with ProLong Antifade 
(Invitrogen) mounting medium on a microscope slide. The GFP fluorescence was detected 
using a fluorescence microscope with a filter of 480nm. 
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Detection of successful transfection using Real-Time-PCR (LightCycler) 
For absolute quantification of transfected plasmid vector copy numbers the Real-Time-PCR 
was used (see section 3.3.9). Therefore molecular weight of both plasmid DNA constructs 
were calculated to determine the plasmid copy numbers per ng. The concentration of pure 
plasmid DNA was determined by measurement of optical density (OD260) for both vectors to 
establish a standard curve ranging from 0.05ng to 8ng. These standard curves were used to 
recalculate the plasmid DNA copy numbers in transfected cells.  
 
Preparation and transfection of siRNA 
For transfection of siRNA, esiWay Silencing Resources® (RZPD, Berlin, Germany) was 
applied. The so-called esiRNA uses pools of siRNA molecules (esiRNA) to eliminate 
screening of multiple synthetic siRNAs for an effective knockdown. As specified by the 
manufacturer RZPD, this technique is supposed to reduce off-target effects due to very low 
concentrations of individual siRNA molecules, compared to synthetic siRNAs.  
The sequences were delivered as purified PCR products containing 2 opposing T7 promoter 
sequences. X-tremeGENE siRNA Dicer Kit (Roche) was used to prepare ready-to-transfect  
d-siRNA. The instructions of the manufacturer were followed strictly during set-up and 
procedure. The concentration of siRNA was determined by OD260.  
Transfection of siRNA into primary human SKMCs was employed by using the  
X-tremeGENE siRNA transfection reagent (Roche), a lipid-based transfection reagent that 
forms a complex with siRNA. The instructions were followed at all times with minimal 
changes and with various concentrations of siRNA in initial experiments. 
For transfection, the cells were trypsinised and 4 x 105 cells were plated into 6-well plates. 
The transfection was performed using 3 different amounts of siRNA and a volume of 10µL of 
X-tremeGENE siRNA transfection reagent as suggested by the protocol (table 15). At first, 
1µg of siRNA was diluted in 100µL of serum and antibiotic free medium (OptiMem, 
Invitrogen). In a separate tube, 10µL of the transfection reagent was added to 90µL OptiMem 
medium and transferred into the diluted siRNA followed by an incubation time of 15-20min. 
This mixture was added drop-wise to the cells at once (=200µL). In contrast to the protocol, 
the transfection complex was applied directly after seeding of the cells. The cells were 
incubated and harvested after 48h and 72h, respectively. Negative controls were performed as 
shown table 15. For negative controls, the transferred volume was added to 200µL with 
OptiMem. 
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table 15: Different transfection parameters as tested for primary human myoblasts transfection efficiency 
 Negative controls  
 Untreated siRNA only 
X-tremeGene 
siRNA only 
X-tremeGene siRNA: 
siRNA 
Ratio 
X-tremeGene siRNA (µL) 
/ siRNA (µg) 
0:0 0:1 10:0 3:2 6:2 12:4 
Added Volume 200µL 200µL 200µL 200µL 200µL 200µL 
 
A second transfection was performed in order to investigate its influence on proliferation and 
vitality of the cells after 48h and 72h of transfection. Since a proliferation test has to be 
applied in 96-well plates but transfection is more efficient in 6-well plates, the cells were 
transferred from 6-well plates to 96-well plates after 24h of transfection. 
The success of transfection was investigated by Real-Time-PCR after 48h and 72h of 
transfection. After trypsinisation and an additional washing step with 1x PBS, RNA was 
isolated using the Spin Cell RNA Mini Kit (Invitek) according to manufacturers’ instructions. 
The concentration and purity of the RNA was determined by the OD260 and the ratio to 
OD280, respectively. Reverse transcription was performed using QuantiTect® reverse 
transcription kit (Qiagen) in conformity with the directions. The kit provides reverse 
transcription of RNA and removal of genomic DNA in one step. The gene knockdown was 
examined by relative quantification as described in section 3.3.9. 
 
 
3.3.5  Treatment of primary human myoblasts with chemical substances 
 
The primary human myoblasts were treated with different chemical substances in order to 
investigate their influence on proliferation and vitality of the cells. Additionally, the mRNA 
expression of 3 genes, MYF5, p21 and UTRNA, was examined in treated cells. The 
compounds were chosen according to their effect on proteins such as phosphatases as drawn 
in the signal transduction pathway (figure 11a-d in section 4.1). Nonetheless, the fact needs to 
be taken into consideration that chemical compounds affect a wide range of target proteins.  
For proliferation and vitality studies, the primary human myoblasts were seeded into 96-well 
plates with 3 x 103 cells per well. The reagents were directly applied to myoblasts in 
supension prior to seeding of the cells. Alterations in proliferation (BrdU) and vitality  
(WST-8) of the cells were examined after 24h, 48h, 72h and in some cases also after 96h. For 
longer incubation than 24h, the medium was changed every 24h to fresh medium including 
chemical substances. As negative controls, untreated cells as well as cells treated with the 
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solvent of the compounds were involved in each experiment. The table 16 shows the chemical 
substances used their solvents and the final concentration of the solvent in the cell medium in 
addition to the site of pharmacological effects within the cells. 
 
table 16:  Chemical compounds tested in primary human myoblasts 
Chemical substance Solvent Site of the pharmacological effects 
CsA 
DMSO  
(7mM) 
Antagonist of calcineurin  
(Sharma et al., 1993) 
Deflazacort 
DMSO 
 (7mM/ 70mM) 
Stimulant of proliferation  
(Biggar et al., 2006) 
IC261 
DMSO 
 (70mM/ 7mM) 
Inhibition of casein kinase I  
(Knippschild et al., 2005b) 
Okadaic acid 
DMSO  
(7mM) 
Phosphatase inhibitor  
(Rodova et al., 2004) 
 
 
Cyclosporine A, Deflazacort, IC261 and okadaic acid were dissolved in  
14M dimethoxysulfoxide (DMSO). Because of the toxicity of DMSO, the first dilution step 
(1:10) was performed using pure skeletal muscle growth medium, not only to dilute the 
chemical compound but also to dilute DMSO down to 1.4M (except for CsA as described 
below). All the following dilution steps were carried out with 1.4M DMSO suspended in 
growth medium. A final concentration of 7mM DMSO was applied to the cells. 
  
Cyclosporine A 
The immunosuppressive drug CsA is widely used in organ transplantation. It leads to a 
decrease of the activity of the immune system and prevents organ rejection. CsA binds to 
cyclophilin resulting in a complex formation, which leads to inhibition of calcineurin and 
inactivation of calcium dependent activation of the cell, especially T-lymphocytes. 
At high molar concentrations (>10mM), CsA is not soluble in 1.4M DMSO. Hence in 
experiments with final CsA concentrations ranging between 1-100µM the stock solutions 
were diluted in 14M DMSO resulting in a final concentration of 70mM in the respective 
experiment. All other concentrations were supplied in 1.4M DMSO. A review of the applied 
concentration in each experiment is given in table 17. 
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table 17:  Concentration of CsA used in different primary cells at several time points and the final concentration of its solvent DMSO 
Cells Range of final concentrations used in the respective experiment Time points 
(Dys+) 18/01 
1-50nM CsA (7mM DMSO)  
1-100µM CsA (70mM DMSO) 
24h 
48h 
72h 
96h 
(Dys-) 
43/01 
77/02 
109/03 
145/03 
 
 
Deflazacort 
Deflazacort is a glycocorticoid. It is used to reduce inflammation and allergic responses such 
as asthma. Thus, similarly to CsA, it can also prevent the rejection of organ transplants. 
Deflazacort is not soluble in physiological saline and 1.4M DMSO at high molar 
concentrations (>1mM). 
The range of concentrations of deflazacort used in different primary cells is shown in table 18. 
The solvent of deflazacort acid and the procedure of solving are described at the beginning of 
this section 3.3.5. 
 
table 18: Concentration of deflazacort used in different primary cells at several time points and the final concentration of its solvent 
DMSO 
Cells Range of final concentrations used in the respective experiment Time points 
(Dys+) 
14/00 
1µM – 1mM deflazacort (7mM DMSO) 
10mM – 200mM deflazacort (70mM DMSO) 
 
48h 
72h 
18/01 
(Dys-) 
43/01 
77/02 
109/03 
145/03 
 
 
IC261 
IC261 (3-[(2,4,6-trimethoxyphenyl)methylidenyl]-indolin-2-one) was selected because of its 
ability to inhibit all isoforms of casein kinase 1. Members of this protein family are  
CSNK1 epsilon, CSNK1 delta and CSNK1 alpha. It has been suggested that CSNK1 delta and 
CSNK1 epsilon are involved in DNA repair and chromosomal segregation. The protein 
CSNK1A1 inactivates the transcription factor NFATc, whereby expression of p21, a negative 
regulator of the cell proliferation, may be reduced. IC261 inhibits CK1d  
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(IC50 = 0.7 - 1.3 mM), CK1e (IC50 = 0.6 - 1.4 mM) and CK1a1 at much higher 
concentrations (IC50 = 11 - 21 mM). 
In table 19, the range of concentrations of IC261 used in different primary cells is shown. The 
solvent of IC261 and the procedure of solving are described at the beginning of this  
section 3.3.5. 
 
table 19: Concentration of IC261 used in different primary cells at several time points and the final concentration of its solvent 
DMSO 
Cells Range of final concentrations used in the respective experiment Time points 
(Dys+) 14/00 
1-100nM IC261 (7mM DMSO)  
1-100µM IC261 (7mM DMSO) 
24h 
48h 
72h 
(Dys-) 
43/01 
77/02 
 
 
Okadaic acid 
Okadaic acid is a toxin which was originally isolated from the sponge Halichondria okadai. 
The okadaic acid sold on the market is produced by the dinoflagellate Prorocentrum. It 
potently inhibits serine/threonine phosphatases such as calcineurin. 
The range of concentrations of okadaic acid used in different primary cells is shown in  
table 20. The solvent of okadaic acid and the procedure of solving are described at the 
beginning of this section 3.3.5. 
 
table 20:  Concentration of okadaic acid used in different primary cells at several time points and the final concentration of its 
solvent DMSO.    [OA = okadaic acid] 
Cells Range of final concentrations used in the respective experiment Time points 
(Dys+) 18/01 0.1-1nM OA (7mM DMSO) 
1-100nM OA (7mM DMSO)  
1-100µM OA (70mM DMSO) 
24h 
48h 
72h 
(Dys-) 
43/01 
77/02 
 
 
3.3.6  Cell Proliferation and vitality tests 
 
Proliferation and vitality of the primary human myoblasts were determined after transfection 
or treatment with chemical substances. Both tests were performed in 96-well plates with 
100µL cell growth medium per well and 24h after treatment of the cells with chemical 
substances and 48h after transfection at the earliest. 
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Cell proliferation assay using BrdU (Roche) 
Proliferation of the cells correlates directly with DNA synthesis. The  
5-bromo-2'-deoxyuridine (BrdU)-assay is a colorimetric immunoassay for quantification of 
cell proliferation, based on the measurement of BrdU incorporation during DNA synthesis. 
The protocol of the kit was followed at all times and all reagents used were provided by the 
kit. The colour development was photometrically measured after 10min, 20min and 30min 
using an ELISA reader at 370 nm (reference wavelength: 492 nm). 
 
Cell vitality assay using WST-8 (Dojindo) 
The test is based on the intra-cellular reduction of the tetrazolium salt WST-8 (2-(2-methoxy-
4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt) by 
cellular de-hydrogenases to an orange formazan. Formazan is soluble in cell culture medium 
and the amount is directly proportional to the number of living cells. The assay was 
performed by adding 10µl of the WST-8 solution directly to the cells. Approximately 2h after 
incubation at 37°C, 5% CO2 and 95% humid atmosphere, the absorbance of the samples was 
measured in a microplate reader at 450nm (reference wavelength: 650nm). 
 
 
3.3.7  Isolation of DNA and RNA 
 
RNA was isolated from muscle tissue and from primary human skeletal muscle cells by 
TriReagent (Sigma) and Spin Cell RNA Mini Kit (Invitek)/Twin Spin Cell Mini Kit (Invitek), 
respectively. DNA and protein isolation was performed for primary human skeletal muscle 
cells. Highly purified plasmid DNA was received from transformed E.coli using the EndoFree 
Plasmid Maxi Kit (QIAGEN). 
 
 
Plasmid DNA isolation using EndoFree Plasmid Maxi Kit (QIAGEN) 
For transfection of primary human myoblasts a higher amount of plasmid was required. 
Transformation of E.coli with plasmid DNA is described in section 3.3.4. The plasmid DNA 
was isolated using the EndoFree Plasmid Maxi Kit (QIAGEN) to receive highly purified 
plasmid DNA. The whole procedure was performed as described in the manual of the kit. 
DNA concentration was determined using OD260. 
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Genomic DNA isolation using Twin Spin Cell Mini Kit (Invitek) 
For absolute quantification of transfected plasmid copy numbers, DNA was isolated from 
transfected cells using Twin Spin Cell Mini Kit according to manufacturer’s instructions. 
DNA concentration was determined using OD260. 
 
RNA isolation using TriReagent® (Sigma) 
The disruption of cells in culture and muscle tissue was performed in different ways.  
Muscle tissue 
The frozen muscle tissue sample were cut and transferred into a mortar including 1mL of 
TriReagent®. The tissue was homogenised using a tapered tissue grinder with a Teflon® 
pestle. The subsequent procedure was performed as described for cells from cell culture 
below. 
Cells 
Cells dissolved in 1mL of TriReagent® were vortexed and stored for 5min at room 
temperature to ensure complete lysis of the cells. Afterwards a phenol-chloroform extraction 
and ethanol precipitation were applied. For that purpose, 200μL chloroform was added to the 
homogenate. After vortexing for 15sec and incubation for 15min at room temperature, the 
samples were centrifuged for 15min at 12.000 x g and 4°C. The aqueous phase was 
transferred into a new 1.5mL tube containing 0.5mL of isopropanol. The samples were mixed 
by inversion, incubated for 30-60min at –20°C and centrifuged for 20min at 12.000 x g and 
4°C. The supernatant was carefully discarded and the pellet was washed twice with 500μL of 
70% ethanol. The ethanol was removed completely and the pellet was dried under air 
conditions before it was dissolved in 30-50μL DEPC water. 
The RNA was treated with DNase I to receive DNA-free total RNA. 
 
RNA isolation using Spin Cell RNA Mini Kit or TwinSpin Cell Mini Kit (Invitek) 
For RNA-extraction from primary human myoblasts, Spin Cell RNA Mini kit was primarily 
applied. In case of RNA isolation from transfected cells, the TwinSpin Cell Mini kit was used 
for simultaneous DNA/RNA isolation from the same cells. The very similar protocols of both 
kits were followed at all times and all used buffers and spin filters were provided by the kit 
except for ethanol and ß-mercapto ethanol. The RNA was treated with DNase I to receive 
DNA-free total RNA. 
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Treatment of RNA with DNase I 
To obtain DNA-free total RNA, incubation with DNaseI was required. For that purpose, a 
reaction mix was prepared as shown in table 21. RNA isolated from transfected or chemical 
substance treated cells was reverse transcribed by the QuantiTect reverse transcription kit, 
which already includes a step to remove DNA beforehand and was proving the  
DNaseI treatment unnecessary.  
 
table 21:  DNase I reaction mix for removing DNA in RNA samples 
Compound Volume 
DNaseI nix 10µL 
RNA dissolved in water 25µL 
Water 55µL 
10U/µL DnaseI (pure 
enzyme) 
10µL 
∑ 100µL 
 
 
The reaction mix was added to each RNA sample and incubated at 37°C for 20min. The 
reaction was stopped by a denaturation step at 95°C for 5min. Afterwards a  
phenol-chloroform extraction and ethanol precipitation were used to purify DNA-free RNA. 
For that purpose, 100μL of DEPC water and 200μL of Roti 
phenol/chloroform/isoamylalcohol (25:24:1) were added to the RNA. After vortexing for 
10sec, the samples were centrifuged for 10min at 12.000 x g. The aqueous phase was 
transferred into a new 1.5mL tube containing one volume of chloroform/isoamylalcohol 
(24:1). The tubes were vortexed for 30sec followed by another centrifuge step. Again, the 
aqueous phase was transferred into a new 1.5mL tube containing 1/10 volume of 3M sodium 
acetate (pH 5.2), 1.0µL of glycogen and 3 volumes of absolute ethanol. The samples were 
mixed by inversion of the tubes and stored at –20°C for 1-2h followed by centrifugation for 
30min at 12.000 x g and 4°C. The supernatant was carefully discarded and the pellet was 
washed twice with 200μL of chilled 70% ethanol. The ethanol was removed completely and 
the pellet was dried under air conditions before it was dissolved in 20-50μL DEPC water. 
The concentration of the RNA was determined using OD260. The RNA was stored at –80°C 
for long term. 
 
 
MATERIALS AND METHODS 
 71 
3.3.8  Reverse transcription of DNA-free RNA 
 
The small amount of RNA obtained from muscle tissue was reverse transcribed using random 
priming in 0.5ml tubes by the SuperScript II reverse transcriptase (Invitrogen). The 
SuperScript II enzyme has a reduced RNase H activity, which consequently eliminates 
degradation of RNA molecules during first-strand cDNA synthesis and leads to a greater yield 
of full-length cDNA. The reaction was performed under the following conditions (table 22): 
 
 
table 22:  Reverse transcription of RNA from muscle tissue using SuperScript II RT kit (Invitrogen) 
Compound Volume [μL] or Quantity [μg] 
DNA free total RNA 500ng to 1.0μg 
10mM dNTP’s (Invitrogen) 1.0μL 
50ng/μL pd(N)6 (Invitrogen) 2.0μL 
Nuclease-free water (QIAGEN) To a final volume of 16.0μL 
Incubation: for 5min at 70°C tubes on ice 
5x 1st strand buffer (Invitrogen) 5.0μL 
0.1M DTT (Invitrogen) 2.5μL 
rRNasin – RNase inhibitor  
(40U/μL – Invitrogen) 
0.5μL 
Incubation: for 2min at 42°C 
SuperScript II RT (200U/μL – Invitrogen) 1.0μL 
Incubation: for 60min at 42°C 
Deactivation: for 15min at 70°C 
Storage: forever at -20°C 
∑ 25.0μL 
 
 
 
In later experiments, the RNA from human SkMCs was reverse transcribed under the use of 
Quantitect reverse transcription kit. This kit provides efficient removal of residual DNA and 
reverse transcription in one step and eliminates the loss of RNA through the purification steps 
of RNA after DNA digestion. The reaction was performed as suggested by the manufacturer 
table 23. 
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table 23: Reverse transcription of RNA from SkMCs using Quantitect reverse transcription kit (Qiagen) 
Compound Volume [μL] or Quantity [μg] 
total RNA 500ng to 1.0μg 
gDNA Wipeout Buffer 7x 2.0μL 
Nuclease free water (QIAGEN) to a final volume of 14μL 
Incubation: for 4min at 42°C  
afterwards tubes on ice 
Quantiscript reverse transcriptase 1.0μL 
5x Quantiscript RT buffer 4.0μL 
RT primer mix 1.0μL 
Incubation: for 15min at 42°C 
Deactivation: for 3min at 95°C 
Storage: forever at -20°C 
∑ 20.0μL 
 
 
3.3.9  PCR 
 
PCR is an acronym, which stands for polymerase chain reaction. The PCR technique is 
basically a primer extension reaction for amplifying specific nucleic acids in vitro. 
 
Conventional PCR 
A conventional PCR was performed using standard PCR condition. All utilised PCR 
compounds were manufactured by Q-Bio gene. The samples were prepared as follows  
(table 24):  
 
table 24:  Preparation of reaction mix for conventional PCR 
Compound Volume [μL] 
ddH2O 8.5μL 
25mM MgCl2 (2,5mM) 5.0μL 
10x PCR buffer (1x) 2.0μL 
4mM dNTP-mix (250μM) 2.0μL 
10μM gene-specific forward primer (1μM) 0.5μL 
10μM gene-specific reverse Primer (1μM) 0.5μL 
Taq Pol (5U/μL) 0.5μL 
1st strand cDNA (100ng) 1.0μL 
∑ 20.0μL 
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At first a master mix was prepared by combining all the components except the cDNA and 
subsequently sub-divided into 0.2mL PCR tubes into equal parts. Afterwards cDNA (~100ng) 
was added, the tubes were mixed briefly and the reaction was performed in the PCR machine 
from Biometra immediately using the following settings: 
 
               
 
As negative controls samples with water and not reverse-transcribed RNA instead of template 
(cDNA) were used to exclude DNA contamination in any of the compounds. To check the 
success of any PCR, a gel-electrophoresis was performed each time. For that purpose 2μL of 
10x DNA-loading buffer was added to 10μL of PCR-product and loaded into each well of a 
1% agarose gel in 1x TAE-buffer. A molecular-weight marker was also used for fragment 
sizing. Electrophoresis was usually performed for 60min at 80V. Afterwards, the agarose gel 
was stained with ethidium bromide, visualised on a UV transilluminator, and documented.  
The 1kb upstream sequence of RAP2B presented a high GC content (60-70%) which arose in 
difficulties to amplify this region. The PCR amplification kit “Advantage GC 2 PCR” from 
Clontech was be successfully applied in this procedure. The kit was utilised as described by 
the manufacturers.  
 
Real-Time-PCR using LightCycler 
Real-Time-PCR analysis using LightCycler was performed to measure the amount of 
transfected vector DNA. Additionally, RNase H and the restriction enzyme StuI, which cuts 
the plasmid once, were added to the isolated DNA to remove RNA contamination and to 
linearise the circular plasmid DNA. SYBR Green I was used as fluorescence stain instead of 
oligonucleotide probes. The Real-Time-PCR reaction was prepared according to 
manufacturers’ instructions of the FastStart DNA MasterPlus SYBR-Green I mix (Roche) 
(table 25). The protocol was used as published in Grunwald and Speer (Grunwald and Speer, 
2007). 
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table 25:  Preparation of Real-Time PCR reaction using FastStart DNA MasterPlus SYBR-Green I 
 Endogenous DNA Exogenous DNA 
Forward primer (10µM) 0.5µL 
Reverse primer (10µM) 0.5µL 
FastStart DNA MasterPlus 
SYBR-Green I 
4µL 
Water 10µL 
DNA 5µL (50ng) 5µL (1ng) 
Σ 20µL 20µL 
 
 
Real-Time PCR using TaqMan 
For Real-Time PCR the ABI Prism 7000 Sequence Detector from Applied Biosystems was 
used. Theoretically, a quantitative relationship exists between the starting amount of the target 
sequence and the amount of the product at the end of any given PCR cycle. That means the 
higher the fluorescence signal and the earlier it is detectable the higher the numbers of initial 
copy number. TaqMan is a hydrolysation probe relying on fluorescence resonance energy 
transfer (FRET) for quantification. The protocol and the calculation procedure were 
performed as published in Sifringer et al. (Sifringer et al., 2004) 
For relative quantification, 18S rRNA was used as an internal standard but prepared for each 
cDNA separate to the other samples. For each sample, 3 replicates were prepared to prove the 
equability of each reaction.  
The Real-Time PCR was performed using the TaqMan Universal Master Mix and MicroAmp 
Optical plates and caps. The following pipetting scheme was performed (table 26): 
 
table 26:  Real-Time PCR reaction using TaqMan 
Component Volume [μL] 
20X working stock of Gene Expression Assay Mix 1.0 
cDNA template + RNase-free water 9.0 
2x TaqMan Universal Master Mix 10.0 
∑ 20.0 
 
For each analysed gene, a water control was included. The real time mix was prepared and an 
aliquot was applied to each well of a 96-well plate. The plate was briefly centrifuged to avoid 
air bubbles in the reaction mix. The real time PCR was performed using the following 
conditions: 
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The data were analysed using the appropriate TaqMan Real-Time PCR software from Applied 
Biosystems. 
 
 
3.3.10 Sequencing 
 
For DNA-Sequencing the chain termination method of Sanger was used. The cycle 
Sequencing was performed with ABI PRISM® BigDye™ Terminators  
v3.0 Cycle Sequencing Kit using a different protocol to Applied Biosystems. The labelled 
DNA was detected through ABI PRISM® 3100 Genetic Analyser. The ABI PRISM®  
3100 Genetic Analyser is an automated, multi-colour fluorescence-based DNA analysis 
system using the technology of capillary electrophoresis. Samples are prepared in 96-well 
plates. 
Preparing the reactions 
First PCR was performed as described in 0, the whole PCR volume was loaded on a  
1% agarose gel and the DNA bands were cut under UV-light. Clean and purified DNA was 
obtained using the QIAGEN gel extraction kit. Yields of DNA following cleanup were 
determined by Agarose gel analysis. The amount of sample DNA loaded was estimated by 
visual comparison of the band intensity with that of the standards of the λ-HindIII-ladder. 
Template quantities of 1-3ng per 100bp of PCR-products were required for the BigDye™ 
terminator chemistry for a 1x cycle sequencing run. For each reaction, the following reagents 
were added to a separate 0.2μL tube (table 27): 
 
table 27:  Composition of sequencing reaction 
Reagent Quantity 
Terminator Ready Reaction Mix 2.5μL 
PCR product DNA 1-3ng per 100bp (max. 100ng) 
10μM Primer (fwd or rev) 1.0μL 
Deionised water ad to 10μL 
∑ 10.0μL 
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The tubes were mixed well and spun briefly followed by performing the cycle sequencing 
under the conditions below: 
 
              * primer-specific annealing temperature 
 
These settings differ from the standard protocol suggested by Applied Biosystems. 
In the next step unincorporated dye terminator must be completely removed before the 
samples can be analysed. For this purpose an ethanol precipitation of the extension products 
was performed. The tubes were removed from the cycle sequencing run and to each tube  
8µL of deionised water and 32µL of 96% ethanol were added. The tubes were left at room 
temperature for 15min to precipitate the extension products followed by centrifuge for  
45min at 3200 x g. The supernatant was discarded by inverting the tubes onto a paper towel. 
A volume of 150μL of 70% ethanol was added to each well to rinse the pellet followed by 
another centrifuge step for 15min at 3200 x g. The supernatant was discarded again and the 
pellets were left to dry under air conditions for at least 10min. The pellets were dissolved in 
20μL milli-Q water for 30min at room temperature placed on a shaker. Finally, the solutions 
were delivered to the Institute of Medical Molecular Diagnostics GmbH (IMMD, Berlin) 
where the sequencing process was performed. The sequence data were analysed using 
Sequencher demo version 4.0.5 (Gene Codes Corporation). 
 
 
3.3.11 Protein analysis  
 
Protein isolation 
A cell number of 1 x 106 was lysed in 200µL RIPA buffer by repeated up- and  
down-pipetting of the solution followed by centrifugation for 10min at 3000 x g and 4°C. The 
supernatant was centrifuged again for 20min at 17,000 x g and 4°C to obtain the cytosolic 
protein fraction. The samples were stored at –80°C for long term.   
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Quantification of proteins  
The bicinchoninic acid (BCA) assay was applied for protein quantification in 96-well plates. 
The BCA assay is based on the biuret reagent and included a series of known standard 
concentrations of the protein bovine serum albumin (0-200µg/mL). Both, the samples and the 
standard proteins were performed in duplicates. For determination, a volume of 200µL of the 
BCA reagent combined with 1M copper sulphate (50:1) was added to 50µl of the sample or 
standard followed by an incubation at 50°C for 30min. The optical density was investigated at 
550nm using a micro-titre-plate reader. Finally, the protein concentration was examined by 
linear regression of the known concentration of the standard protein. 
 
Western blot  
SDS-PAGE (sodium dodecyl sulfate poly-acryl-amide gel electrophoresis) is a widely used 
technique for Western blots. 
Because of the difference in molecular weight of (UTRN) and the standard protein ß-actin, the 
Western blot analyses was performed using a gradient Tris acetate mini gel (4-12%). For 
determination of UTRN, 40µg of the protein sample was applied. The protein samples were 
mixed with 2x NuPAGE protein sample buffer, 1µl antioxidant and 10x reducing agent  
(table 28), and were incubated at 85°C for 5min. The proteins are so prepared for separating 
their polypeptide chains according to their molecular weight by PAGE (Laemmli, 1970) and 
transferring to an immobilised membrane (blotting) for detection with specific antibodies.  
 
 
table 28:  Preparation of protein samples for SDS-PAGE and Western blot 
Component Volume 
Protein sample (40µg) xµL 
2x NuPAGE sample buffer 20µL 
NuPAGE Antioxidant 1µL 
10x Reducing agent 4µL 
DEPC-dH2O xµL 
∑ 40µL 
 
 
The HiMarkTM pre-stained high molecular weight protein standard was included in each  
SDS-PAGE. The electrophoresis was carried out at 125V for 100min. The proteins contained 
in the SDS-gel were transferred onto the surface of a nitrocellulose membrane (iBlot™ gel 
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transfer stack, nitrocellulose) using the iBlotTM dry blotting system. The protein transfer was 
accomplished using the program P3 (20V) for 13min. The pre-stained protein standard was 
visible on the membrane and indicated a protein transfer performed. To verify the successful 
transfer of the protein samples, the membrane was stained for 30sec with Ponceau S (Roth) 
followed by 2 washing steps in TBS-T for 10min to remove the stain. The nitrocellulose 
membrane was blocked using 5% skim milk in TBS-T over-night. Next day, the membrane 
was washed 4 times in TBS-T for 10min and incubated in an antibody solution  
(1% BSA/TBS-T) including the antibody UTRN (1:100) or ß-actin (1:50000) over-night. 
Afterwards, the membrane was washed again 4 times in TBS-T for 10min followed by 
incubation with the second peroxidase-bound antibody solution (mouse IgG; 1:2000 in  
1% BSA/TBS-T) for 120min. Another wash step followed as described above. The next steps 
were performed in the dark under red light. For incubation with the substrate, 1.8µl H2O2 was 
added to 3mL of ECL-solution II, mixed briefly, transferred to 3mL ECL-solution I and 
thoroughly mixed again. The combination was spread onto the membrane surface and 
incubated for 60sec. The membrane was removed and placed into a film cassette and covered 
with an X-ray film. The exposition time was continued for approximately 120min and  
3sec for UTRNA and ß-actin, respectively. Developing of the X-ray film was performed by 
the successive use of a developer solution, a water bath and a fixing dilution. Subsequently, 
the protein signals were densitometrically analysed and quantified using the  
BioDocAnalyzer 2.0. 
For the detection of the second protein, the standard protein ß-actin, the membrane was 
washed twice in TBS-T for 10min and the incubated in stripping buffer for 30min at room 
temperature to remove the bound antibodies of the first detection (UTRN). Afterwards, the 
membrane was washed again 4 times in TBS-T for 10min followed by blocking the 
membrane using 5% skim milk in TBS-T (Roth) over-night. All subsequent steps were 
performed as described above. 
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3.4 Bioinformatics tools 
 
The graphical Petri net editor and animator Snoopy (Fieber, 2004) was applied for modelling 
the Petri net. Clustering was done with PINA (Grafahrend-Belau, 2006). Both tools are 
available free via http://www-dssz.informatik.tu-cottbus.de/swwwdssz/. The Integrated Net 
Analyzer – INA (Starke and Roch, 1999) was used for the analysis of structural and dynamic 
properties. For computation and representation of the Mauritius map we used an as yet 
unpublished tool of our own (Ackermann, 2008). 
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4 Results 
  
Outlier patients with abnormalities in genotype/phenotype correlations, in particular patients 
experiencing an unexpected mild course of DMD, suggest modifications in gene expression 
and/or signal transduction pathways partially compensating the dystrophin defect. The 
identification of appropriate candidates which might be responsible for this phenomenon is 
one main basis for dystrophin downstream therapy strategies. In this group a first analysis of 
the transcriptom of such rare mild cases revealed 6 over-expressed cDNA clones (Sifringer et 
al., 2004). However, neither connections to dystrophin nor relations between them were 
obvious. The same fact was found in other studies investigating the transcriptoms of DMD 
patients (Bakay et al., 2002; Haslett et al., 2002; Noguchi et al., 2003; Haslett et al., 2003; 
Baker et al., 2006). But in further experiments such knowledge is absolutely crucial for 
establishing strategies to slow down the dystrophic process or, more ambitiously to restore 
muscle-function. Therefore the first part of this thesis is the identification of such connections 
by the use of experimentally gained data, as mentioned above. Additionally, these findings are 
supplemented by the results of the determination of p21 levels in DMD patients (Endesfelder 
et al., 2000), scientific publications and data bases.  
 
 
4.1 Signal transduction pathways connecting genes which were 
found differentially expressed in transcriptoms of selected 
DMD patients 
 
The 3 genes, casein kinase 1 alpha 1 (CSNK1A1), ras related protein 2B (RAP2B), and p21, 
were connected to signal transduction pathways involving the transcription factor NFATc as a 
key component, figure 11a.  
 
The resulting schematic network is grouped into 3 sections:  
(1) the phosphorylation pathway of NFATc 
(2) the de-phosphorylation pathway of NFATc 
(3) and the expression of target genes of NFATc 
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figure 11a: Outline of the biological processes. ------------------------------------------------------------------------------------------------------------- 
The pathways are grouped into 3 parts. On the left side, the dystrophinglycoprotein complex (DGC) downstream cascade, which 
phosphorylates and de-activates NFATc. The de-phosphorylation and activation part of NFATc via RAP2B-calcineurin signalling is 
shown on the right side. The transcription factor NFATc mediates gene expression of several target genes, e.g. MYF5, p21, UTRNA.  
 
 
The above-mentioned 3 parts are described in figure 11b-d in more detail. 
The phosphorylation pathway (figure 11b) connects the DGC with NFATc and c-Jun via 
kinases such as c-Jun NH2-terminal kinase-p46 (JNK1) (Chow et al., 2000) and CSNK1A1. 
In the presence of a functional DGC, binding of laminin recruits RAC1 via syntrophins 
followed by phosphorylation of JNK1 and the transcription factor c-Jun itself (Oak et al., 
2003). Phosphorylated c-Jun is capable of inhibiting the transcription of p21 followed by an 
increase in proliferation as demonstrated for C2C12 cells (Schreiber et al., 1987; Shaulian et 
al., 2000). For de-phosphorylation of c-Jun, only few experimental data are available. For 
example, LPS is described as a reagent to induce de-phosphorylation of c-Jun (Morton et al., 
2003; Yu and Shah, 2004). 
 JNK1 as well as CSNK1A1 have the ability to phosphorylate the transcription factor NFATc 
(Schulz and Yutzey, 2004). Phosphorylated NFATc is inactive and located within the cytosol 
of the cell (Hogan et al., 2003). 
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figure 11b: DGC downstream cascade leading to activation of JNK1 and c-Jun. JNK1 or CSNK1A1 are able to phosphorylate and 
de-activate NFATc. 
 
In the de-phosphorylation pathway (figure 11c) of NFATc, RAP2B and calcineurin are 
principal components bridging this signal transduction cascade (Chin et al., 1998; Schmidt et 
al., 2001). Phospholipase C epsilon (PLCe) is activated by RAP2B (Keiper et al., 2004) 
followed by the release of calcium from the endoplasmatic reticulum via inositoltrisphosphat 
(IP3) (Evellin et al., 2002; Groenendyk et al., 2004). Calmodulin binds free calcium and 
activates calcineurin, which then can de-phosphorylate NFATc (Crabtree and Olson, 2002; 
Groenendyk et al., 2004).  
 
 
 
figure 11c: RAP2B-calcineurin-pathway. Active calcineurin mediates de-phosphorylation and activation of NFATc that lead to 
migration of NFATc into the nucleus. 
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De-phosphorylated NFATc migrates into the nucleus and acts as transcription factor for the 
expression of several target genes (figure 11d) (Macian, 2005), such as MYF5 (Friday and 
Pavlath, 2001), UTRNA (Chakkalakal et al., 2003), and p21 (Santini et al., 2001). Other 
examples of target genes are alpha actin (aActin), myosin (Hogan et al., 2003), and atrial 
natriuretic factor (ANF), which, for clarity, are not included in figure 11d. In all the cases 
mentioned additional factors regulating these genes are involved. These genes form a complex 
with NFATc, e.g. SP1, SP3, GATA, GABP, MEF2 (Santini et al., 2001).  
The target gene UTRNA is homologous to dystrophin, and its function is described in section 
1.3.2.1. MYF5 belongs to the myogenic regulatory factors family (MRF). MRFs are 
transcription factors specific to skeletal muscle cells. They regulate cell differentiation, and 
induce transcription of skeletal muscle-specific genes, e.g. creatine kinase, myosin light 
chains, and myosin heavy chains (MHC). MYF5 is one of the first genes expressed in 
differentiation events of myoblasts, and commits somatic cells to the myogenic lineage 
(Kosek et al., 2006).  
The protein p21 is not only regulated by NFATc but also by p53. It is also able to inhibit the 
cyclin-dependent kinases 2 and 4 (CDK2, CDK4) resulting in the diminishment of cell 
proliferation (Seoane et al., 2002). The main target protein of CDK2 and CDK4 is the 
retinoblastoma protein (RB-protein). The de-phosphorylated RB-protein acts as 
transcriptional repressor by forming a complex with the E2F transcription factor whose 
function is required for the entry into cell proliferation (Zhang et al., 2004). Sequential 
phosphorylation of RB by CDK4/CDK6 or CDK2 prevents the RB-protein from binding and 
inactivating of E2F, which results in the expression of S-phase genes (Harbour et al., 1999).  
 
 
figure 11d: Expression of NFATc target genes. De-phosphorylation of NFATc by calcineurin unmasks the nuclear localization signal 
of NFAT, allowing its migration into the nucleus and initiation of specific genes carrying NFAT-responsive elements.  
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The signal transduction pathways as shown in figure 11b-d form the basis of the subsequent 
Petri net model. The comparison of the transcriptome of one mild and one typically severe 
DMD phenotype patient provided the foundation for these pathways (for clinical features see 
sections 4.2.1 and 4.4.1 ). In addition to modelling a Petri network, these experimental 
expression data were verified using an increased number of typically severe DMD patients 
and normal controls. Furthermore, not only CSNK1A1 and RAP2B but also other genes from 
the Petri net were analysed. 
Comparison of the transcriptomes of a mild and a typically severe DMD phenotype patient 
provided the foundation for these pathways 
 
 
4.2 Verification and extension of mRNA expression data 
 
4.2.1  Muscle tissues originating from Duchenne muscular dystrophy 
patients and controls 
 
In the first study, the very rare case of 2 brothers with an intra-familially different course of 
DMD was researched using the subtraction library technique. The clinical features and data of 
molecular diagnosis of the 2 affected brothers were described in (Sifringer et al., 2004). 
Because the elder brother died at 16.5 years and muscle material was used up for a subtraction 
library, an equivalent DMD patient (p1) as reference was applied for further investigations. 
Patient p1 exhibite clinical features similar to the elder brother. He started walking at  
30 months and lost gait at 10 years. In addition, another 4 DMD patients were analysed to 
confirm the outstanding position of the younger brother. Muscle biopsies were obtained from 
classic DMD patients between aged 3 years 5 months and 8 years. For both brothers, biopsy 
was performed at age 6 years. As normal controls, 5 dystrophin positive specimens of 
diagnostic biopsies were used, which turned out to be normal.  
An overview of clinical features and molecular diagnosis data of all patients and controls is 
given in section 3.3.2.1. 
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4.2.2  Expression analysis of selected genes at mRNA level 
 
In addition to CSNK1A1, RAP2B, and p21, expression analysis included calcineurin, c-Jun, 
and NFATc, and its target genes MYF5 and UTRNA.  
In, figure 12 mean values of expression data of 5 normal individuals, 5 DMD patients and the 
DMD with a mild course of the disease are shown. DMD patients differed in 4 genes from 
controls. They showed a significant increase at mRNA level for p21 and CSNK1A1 (P<0.01) 
compared to (Dys+) controls. Expression studies of RAP2B, UTRNA, and MYF5, also 
revealed an increase at mRNA level, which was not significant. In contrast, calcineurin as 
well as NFATc, JNK1, and c-Jun were not differentially expressed.  
Expression level of patient pm noticeably differed from DMD patients. The results gave 
strong evidence that mRNA expression of p21 and CSNK1A1 were significantly decreased in 
patient pm compared to DMD patients (P<0.05), but unchanged compared to normal controls. 
Compared to the mean value of DMD patients, expression levels of RAP2B, NFATc, 
UTRNA, and MYF5 were reduced, but not significantly. The mRNA levels of calcineurin, 
JNK1, and c-Jun remained unaltered. In comparison to (Dys+) individuals, the expression 
levels of NFATc and JNK1 (P<0.05) were significantly decreased in patient pm, whereas 
calcineurin, UTRNA, and MYF5 were determined as differentially expressed. 
 
 
 
figure 12: Statistical analysis (students t-test, Box Whisker Plot) of relative mRNA expression data received from 8 genes involved in 
signal transduction network that is described in section 4.1. Skeletal muscle biopsy tissue of 5 DMD patients with typical course of 
disease and compared with 5 control individuals as well as a DMD patient presenting mild clinical findings. The median is indicated 
by a black rectangle. c = control; p = DMD patient; pm = mild DMD patient 
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In summary, differences in mRNA levels first determined in the 2 brothers with a varying 
course of the disease were partly also detected when comparing an increased number of DMD 
patients and controls. Interestingly, a milder phenotype seems to be associated with p21, 
CSNK1A1 and restricted with RAP2B expression. Whereas p21 was already subject of 
previous investigations (Endesfelder et al. 2000, 2003, 2005), CSNK1A1 and RAP2B are new 
candidates for interventions into pathways downstream dystrophin (section 4.4). However, the 
expression data of the 2 brothers were not confirmed, and especially the direction of the 
alteration of the CSNK1A1expression level is controversial. The schematic network presented 
in section 4.1 provides basic fundamentals for the insight into a part of dystrophin 
downstream processes. However, it does not allow for modelling and incorporation of gene 
regulation and protein interactions. In contrast, Petri nets facilitate such modelling of gene 
regulations and thereby allow the simulation of pathological processes. Using Petri net theory 
the model could be checked for consistency by exploring the whole system behaviour. It 
opens up new potentialities to perform knockout experiments in silico for the determination of 
essential processes within the net. These results are described in the next chapter. 
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4.3 Systems biology 
 
The objective of this work is modelling and analysis of a part of pathomechanisms of DMD in 
a Petri net. It is based on new experimentally gained data (4.2), literature data, and on the 
graphical representation of the dystrophin-enclosing signal transduction pathways presented 
in section 4.1.  
 
 
4.3.1  The Petri net model 
 
For the first time, modelling of a network connecting dystrophin, p21, CSNK1A1 and RAP2B 
was performed using Petri nets. The Petri net is depicted in figure 13. The net contains  
64 places and 88 transitions. The complete list of both places and transitions including 
denotation is to be found in Grunwald et al. [Supplementary material (Grunwald et al., 
2008)]. 
Places represent genes, proteins, protein complexes, and complexes between proteins and 
nucleic acids. In the case of genes, a distinction was made between silencers and enhancers 
for gene regulation. Transitions stand for complex formation, binding, de-/activation,  
de-/phosphorylation, transcription etc. In addition to literature knowledge and experimentally 
obtained data, the network models some hypotheses regarding those processes which are not 
described in the literature and cannot be experimentally verified yet. Hypotheses have been 
introduced to fill gaps in the current knowledge to make the model consistent. For example, 
the location of NFATc phosphorylation by JNK1 or CSNK1A1 is not clearly known. Due to 
the fact that NFATc needs to be inactivated by phosphorylation and consequently to remigrate 
into the cytosol, the phosphorylation process mentioned above should also be feasible in the 
nucleus. Modelling this suggestion, transitions 81.deact NFATc_CSNK1A1 and 
82.deact_NFATc_JNK1 were introduced. Other examples concern the places 
62.hypo_Silen_UTRNA and 63.hypo_Silen_MYF5, which represent the initiation of silencing 
processes after up-regulation of the transcription of the corresponding protein. Since in gene 
regulatory networks no stoichiometry is given, arc weights were in general set to one. 
Deviations from this rule were motivated by experimental data and the dynamic behaviour in 
simulations. According to experimental data of the patients, the arc weights were increased to 
indicate the delay of down-regulation in the following cases: t42.down_reg_UTRNA, 
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41.down_reg_MYF5, 28.down_reg_RAP2B, 53.down_reg_JNK1, 37.down_reg_CSNK1A1, 
and 84.bind NFATc_DNA_genes. Because of increased incoming arc weights of transitions, 
pre-conditions (i.e. the pre-places) had to carry more tokens to enable firing of transitions. For 
example in figure 14, the transition 53.down_reg_ JNK1 is enabled if there are at least  
2 tokens on place JNK1. Thus, the transition 53.down_reg_JNK1 is delayed compared to the 
transitions 53.up_reg_JNK1 and act_JNK1. Arc weights in cases of protein interaction were 
also increased to reflect the experimental results. They are summarised in table 29.  
 
table 29: The transitions describing protein interactions, which are indicated by a larger arc weight than one according to 
experimental data. For DGC, a special subnet structure has been chosen as exemplarily depicted in figure 14. 
Protein interaction Transition 
DGC activation t56 
Phosphorylation of NFATc by CSNK1A1 t9 
Phosphorylation of NFATc by JNK1 t60 
Phosphorylation of RB t65 
Phosphorylation of E2F t68 
 
 
To avoid accumulation of tokens, arc weights were increased for t78.reg_p21_p53 and 
t87.degrad_calcineurin. Modelling of inhibitions into the Petri net was performed in different 
ways. A transition-induced inhibition was modelled as the removal of tokens from the system. 
For example, the kinase CDK2 was inhibited in the presence of p21, whereas E2F, 
phosphorylated by CDK2, inhibited the dissociation of the E2F_RB_compl. 
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figure 13: The Petri net model of the dystrophin downstream cascade and converging pathways based on the graphically represented 
signal transduction network in section 4.1. 
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For modelling of mRNA expression patterns, another structure was introduced for genes 
whose mRNA expression was experimentally determined. Alterations in gene expression 
were modelled by 2 places following a suggestion firstly described by Chaouiya et al. 
(Chaouiya et al., 2004). One place represents up-regulation (enhancing) and the other  
down-regulation (silencing). Genes that exhibit transitions for up- and down-regulation are 
listed in table 30.  
 
table 30: Experimentally explored genes and their transitions for up- and down- regulation. The transitions are indicated by a larger 
arc weight (>1) according to experimental data. For RAP2B, CSNK1A1, JNK1, UTRNA and MYF5 a special subnet structure has 
been chosen as exemplarily depicted in figure 14. 
Gene name 
Transition for 
up-regulation 
Transition for 
down-regulation 
RAP2B t29 t28 
CSNK1A1 t38 t37 
JNK1 t52 t53 
NFATc t46 t45 
Calcineurin t49 t50 
UTRNA t18 t42 
MYF5 t19 t41 
 
 
Moreover, a place for the gene product was introduced. As shown below, analysis techniques 
facilitated a differentiation between enhancing and silencing because of this type of 
modelling. These situations were modelled as special subnets (figure 14) occurring 6 times in 
the net. There are 3 places representing the different expression states of JNK1: the protein 
JNK1 (p11.JNK1) by itself, the enhanced JNK1 (p39.E+JNK1), and the silenced JNK1 
(p40.Si_JNK1).  
 
 
 
2 
 JNK1 
   down-reg_JNK1 
 E+JNK1 
init_E+JNK1 
   Si-JNK1 
    up-reg_JNK1 
rem_Si-JNK1 
 
figure 14: A subnet that describes up- and down-regulation of genes. The modelled gene regulation is exemplarily depicted and 
described for JNK1. 
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The transition t55.initE+JNK1 produces the protein p11.JNK1 through up-regulation of 
t52.up_reg_JNK1. The down-regulation of p11.JNK1 took place when at least 2 tokens of 
p11.JNK1 were produced, indicated by an arc weight of 2. This down-regulation removes 
tokens from p11.JNK1 through the transition t53.downreg_JNK1 and produces tokens for 
p11.JNK1 again. However, the structure of the net does not avoid a situation at which both 
places, p39.E+JNK1 and p40.Si_JNK1, were marked. The regulation of most of the genes 
(except for several proteins only expressed in developmental stages) including JNK1 does not 
necessarily mean a complete shut-down or turning-on of its expression. For example, 
enhancing of JNK1 (p39.E+JNK1) resulted in an increased expression by positive 
transcription factors comprising a low effect of negative regulators (p40.Si_JNK1) as well as 
the other way around. This special subnet was also used for RAP2B, CSNK1A1, UTRNA and 
MYF5 as well as for activation of the DGC (table 29 and table 30). In the case of calcineurin 
and NFATc, no differences in the mRNA expression levels in patients compared to normal 
controls were determined. Therefore, an equilibrium between up- and down-regulation of 
calcineurin and NFATc, respectively, occurred, which was modelled as initiation, up- and 
down-regulation, and removal of both substances. 
 
 
4.3.2  Structural analysis of the model 
 
When models grow larger, it becomes difficult to test them for completeness and biological 
meaning. One way is the simulation of the dynamic network behaviour using ordinary 
differential equations, and comparing of simulation results with known experimental data. 
However, this requires the knowledge of all kinetic data. To obtain informations on systems 
consistency and the general system behaviour, static and dynamic properties of the Petri net 
were computed and analysed. The following minimal criteria were suggested by [Heiner & 
Koch (2004)], [Koch & Heiner (2008)]: (1) the net is connected, (2) the net is covered by  
t-invariants (CTI), and (3) each t-invariant and p-invariant has a biological meaning. Whereas 
the first criterion can be checked effortlessly, the second and, in particular, the third criterion 
can become impossible to check in large and complex nets, i.e. dense network graphs. 
Computation of all t-invariants is feasible, but their analysis is not manually manageable for 
large amounts of t-invariants. Therefore, MCT-sets and cluster analysis were used for further 
network decomposition and to explore t-invariants in terms of their biological meaning. The 
following basic properties were considered and computed using the software INA. The net is 
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connected. It exhibits no places without pre- and/or post-transitions, but does exhibit 
transitions without pre- or post-places representing the systems interface to the surroundings. 
The net is unbounded, which means that there are places with possibly infinite token number. 
The net is live, which indicates that the net is always working continuously and has no dead 
transitions in the initial marking represented in figure 13. 
 
4.3.2.1 Invariant analysis 
 
t-invariants 
The net contained no p-invariant because a gene-regulatory network was considered involving 
protein-interaction that excluded substance conservation. Substances like ATP, ADP, or AMP 
were not specially modelled because of their conserved amount and general availability 
within the cell. A number of 107 t-invariants were computed. The results are given as 
supplementary material in Grunwald et al. [Supplementary material (Grunwald et al., 2008)]. 
These t-invariants are graphically represented using different colours in separate files. 
The smallest t-invariants consist of 3 transitions, e.g. t-invariant Inv5 includes transitions 
t48.init_E_Calcineurin, t49.up reg_Calcineurin, and t87.degrad_Calcineurin. The 4 largest  
t-invariants, Inv96, Inv97, Inv98, and Inv99, contain 32 transitions each. All of the  
4 t-invariants lead to a transcription that belongs to cluster C11. Cluster C11 starts with the 
DGC downstream pathway which activates up-regulated JNK1, and leads to  
de-phosphorylation of NFATc by the RAP2B-calcineurin pathway. NFATc is then active, and 
migrates into the nucleus to mediate transcription of MLC2, aActin, and ANF. In the nucleus, 
NFATc can be phosphorylated and therefore inactivated by JNK1. 
The following transitions are crucial for the network behaviour because of their occurrence in 
more than 70% of all t-invariants: t0.bind_PIP2, t1.act_IP3, t6.bind_CAM_Ca, t7.gen_CAM, 
t8.act_Calcineurin, t10.dephosph, t30.act_PLCe, and t61.Transfactor_in_nuc, as well as 
t83.Transfac_in_cyt which was found in more than 67% of all t-invariants. 
Except for one t-invariant (Inv55), all other t-invariants contained both input and output 
transitions. The t-invariant Inv55 has 4 input transitions and no output-transition. Hence, it 
describes a cyclic pathway. In this t-invariant, de-phosphorylation of NFATc by calcineurin, 
which was activated by the RAP2B downstream pathway and phosphorylation by the kinase 
CSNK1A1, are balanced. Consequently, at no time NFATc was able to migrate into the 
nucleus and to act as transcription factor. That is an active way of the cell to down-regulate 
subsequent gene transcription without the need of protein degradation or gene silencing. 
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MCT-sets 
Another analytical approach used are MCT-sets. Transitions in an MCT-set are assumed to be 
always active together. Thus they should coherently be up- and down-regulated. MCT-sets are 
interpreted as building blocks leading to a network reduction. The network can be constructed 
using these building blocks. For example, to perform an exhaustive knockout analysis of the 
network it suffices to knock out only one arbitrary transition of an MCT-set. A number of  
33 MCT-sets were calculated using PInA software (Grafahrend-Belau, 2006). MCT-sets 
consisting of at least 2 transitions (25) are compiled in table 31. The net with the coloured 
MCT-sets is given in the supplementary material in Grunwald et al. [Supplementary material 
(Grunwald et al., 2008)]. 
 
table 31: The MCT-sets of t-invariants containing more than one t-invariant. Transitions of one MCT-set were always found 
together. The MCT-sets M1 and M22 are disconnected MCT-sets. 
MCT-set Composition  Biological interpretation 
M1 t0, t1, t6, t7, t8, t10, t30 Initiation of calcium release out of ER 
M2 t2, t5 Calcium-channel-mediated calcium release depending on 
concentration gradient between ER and cytosol 
M3 t3, t4 Calcium release regulated by calreticulin 
M4 t11, t12, t13, t14, t56, t57, t58 Activation of DGC downstream pathway that activates 
JNK1 
M5 t15, t17 Transcription of p21 by transcription factor complex 
including NFATc 
M6 t16, t20, t21, t22, t84 Transcription of MLC2, aActin, ANF, by NFATc and 
other factors 
M7 t18, t24, t40, t42, t85 Regulated transcription of UTRNA by NFATc and other 
factors 
M8 t19, t25, t41, t43, t86 Regulated transcription of MYF5 by NFATc and other 
factors 
M9 t26, t28 Down-regulation of RAP2B 
M10 t27, t29 Up-regulation of RAP2B 
M11 t31, t33, t34 Initiation of dystrophin followed by generation of DGC 
and simulation of DMD by DGC loss 
M12 t35, t37 Down-regulation of CSNK1A1 
M13 t36, t38 Up-regulation of CSNK1A1 
M14 t39, t59 Inhibition of p21 transcription by phosphorylated c-Jun 
M15 t45, t47 Down-regulation of NFATc 
M16 t49, t87 Up-regulation of calcineurin 
M17 t50, t51 Down-regulation of calcineurin 
M18 t52, t55 Up-regulation of JNK1 
M19 t53, t54 Down-regulation of JNK1 
M20 t63, t67 Initiation of CDK4 and phosphorylation of RB by CDK4 
M21 t64, t66 Initiation of CDK6 and phosphorylation of RB by CDK6 
M22 t68, t71, t75 Initiation of RB, phosphorylation of E2F by CDK2 
which inhibits RB phosphorylation (preservation of E2F-
RB complex) 
M23 t69, t70, t76 Initiation of E2F followed by initiation of E2F-RB 
complex and de-phosphorylation of RB 
M24 t72, t73 Transcription of S-phase gene 
M25 t77, t78, t79 Initiation and phosphorylation of p53 by CSNK1A1 
which regulates transcription of p21 
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Except for M1 and M22, all MCT-sets (23) represent connected sub-networks. The MCT-set 
M1 describes the initiation of the calcium release out of the ER, binding of calcium to 
calmodulin, activation of calcineurin, and de-phosphorylation of NFATc by calcineurin. 
Starting with transition t30.act_PLCe followed by transitions t0.bind_PIP2 and t1.act_IP3, the 
MCT-set stops at place p2.compl_Ca_channel where the pathway splits into 2 possible ways. 
One way represents the calcium release regulated by calreticulin through the transitions 
t3.reg_CALR and t4.free_CALR which form MCT-set M2. The other way is the  
Ca-channel-mediated calcium release, which is dependent on the concentration gradient 
between ER and cytosol. This pathway is characterised through the transitions  
t2.red_Ca-channel and t5.free_channel which build MCT-set M3. The MCT-set M1 continued 
with the transitions t6.bind_CAM_Ca, t7.gen_CAM, t8.act_Calcineurin, and t10.dephosph.  
The MCT-set M22 consists of the transitions t68.phos_E2F, t71.init_RB, and 
t75.inhib_E2F_RB_phos where t71.init_RB is not connected to t68.phos_E2F or 
t75.inhib_E2F_RB_phos, which are in turn connected. This disconnected MCT-set occurs 
because of the branching of the pathway represented by the t-invariants Inv1, Inv2, and Inv3.  
All these t-invariants describe the process of inhibition of the E2F-RB complex via an 
initiation of RB. They share transitions in that MCT-set, which always occur together but also 
contain transitions that are exclusively in one of these 3 t-invariants. After generation of RB 
and E2F and forming of the E2F-RB complex, the pathway can emerge in different ways due 
to the fact that 3 different kinases were able to phosphorylate the RB protein. Whereas  
Inv1 describes phosphorylation of RB (t65.phosph_RB) by CDK2, Inv2 includes 
phosphorylation by CDK4 (t67.phosp_RB), and Inv3 models phosphorylation of RB 
(t66.phos_RB) by CDK6. The active E2F structure, the phosphorylation of active E2F, and 
the subsequent pathway have 3 transitions (t68.phos_E2F, t71.init_RB, 
t75.inhib_E2F_RB_phos) in common. Thus, the kinases CDK2, CDK4, and CDK6, which 
were responsible for phosphorylation of the same protein, are the reason for the disconnected 
MCT-set. That means that these transitions work independently. 
A number of 15 cases were determined consisting of one transition only (table 32).  
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table 32: The MCT-sets consisting of only one transition. 
MCT-set Transition MCT-set Transition 
M26 t80.degrad_NFATc M34 t32.rem_Dys 
M27 t61.Transfactor_in_nuc M35 t65.phosph_RB 
M28 t81.deact_NFATc_CSNK1A1 M36 t46.up-reg_NFATc 
M39 t83.Transfac_in_cyt M37 t62.init_CDK2 
M30 t82.deact_NFATc_JNK1 M38 t60.phosph_NFATc_JNK1 
M31 t9.phosph_NFATc_CSNK1A1 M39 t23.rem_p21 
M32 t48.init E+Calcineurin M40 t44.rem_Si-NFATc 
M33 t74.inhib_p21_CDK2   
 
 
Cluster analysis 
The application of the established data mining technique, such as the cluster analysis which is 
a well-known method in phylogenetic tree analysis, is another way of network decomposition 
and reduction. It provides a better overview of processes taking place and facilitates network 
validation. The clustering tree calculated is shown in figure 15 (page 98). For clustering of  
t-invariants, the technique and software as reported in (Grafahrend-Belau, 2006; Grafahrend-
Belau et al., 2008a) were applied. The UPGMA algorithm with a threshold of 65% was used 
for clustering based on the Tanimoto coefficient as distance measure between t-invariants. 
Biological meaning and function of each cluster are described in table 33.  
The composition of MCT-sets and transitions of all 34 clusters are given in the supplementary 
material in Grunwald et al. [Supplementary material (Grunwald et al., 2008)]. 
 
table 33: Biological interpretation of  t-invariants clusters. Clusters were calculated using UPGMA with a threshold of 65%, based 
on the Tanimoto coefficient as distance measure. 
Cluster Biological interpretation 
C1 Initiation and down-regulation of calcineurin 
C2 Initiation, up-regulation and degradation of calcineurin 
C3 Initiation of dystrophin followed by generation of DCG and simulation of DMD by DGC loss 
C4 Initiation, up-/down-regulation of JNK1 
C5 Initiation and up-regulation of CSNK1A1, which activates p53, followed by p21 transcription, which inhibits 
CDK2 
C6 Initiation and down-regulation of CSNK1A1, which activates p53, followed by p21 transcription, which inhibits 
CDK2 
C7 DGC downstream pathway, which activates up-regulated JNK1, followed by a c-Jun phosphorylated dependent 
p21 inhibition, up-regulation of CSNK1A1, which activates p53, followed by p21 transcription 
C8 DGC downstream pathway, which activates up-regulated JNK1, followed by a c-Jun phosphorylated dependent 
p21 inhibition, down-regulation of CSNK1A1, which activates p53, followed by p21 transcription 
RESULTS 
 96 
Cluster Biological interpretation 
C9 DGC downstream pathway, which activates up-regulated JNK1, followed by a c-Jun phosphorylated dependent 
p21 inhibition, RAP2B-calcineurin pathway, which de-phosphorylates NFATc, followed by a p21 transcription 
inhibiting CDK2, and phosphorylation of NFATc in nucleus by regulated CSNK1A1 and JNK1 
C10 DGC downstream pathway, which activates up-regulated JNK1, followed by a c-Jun phosphorylated dependent 
p21 inhibition, regulated RAP2B-calcineurin pathway, which de-phosphorylates NFATc, followed by a p21 
transcription, and phosphorylation of NFATc in nucleus by JNK1 
C11 DGC downstream pathway, which activates up-regulated JNK1, regulated RAP2Bcalcineurin pathway, which  
de-phosphorylates regulated NFATc, followed by a transcription of MLC2, aActin, ANF, and phosphorylation of 
NFATc in nucleus by JNK1  
C12 DGC downstream pathway, which activates up-regulated JNK1, followed by phosphorylation of NFATc in cytosol 
by JNK1, regulated RAP2B-calcineurin pathway, which de-phosphorylates regulated NFATc, which does not 
result in transcriptional activity 
C13 DGC downstream pathway, which activates up-regulated JNK1, followed by a c-Jun phosphorylation dependent 
p21 inhibition, regulated NFATc mediates p21 transcription, followed by a degradation of NFATc in nucleus 
C14 Down-regulated RAP2B-calcineurin pathway, which de-phosphorylates NFATc, followed by a p21 transcription 
inhibiting CDK2, and phosphorylation of NFATc in nucleus by regulated CSNK1A1 
C15 Up-regulated RAP2B-calcineurin pathway, including Ca release depending on concentration gradient between ER 
and cytosol, which de-phosphorylates NFATc, followed by p21 transcription inhibiting CDK2, and 
phosphorylation of NFATc in nucleus by regulated CSNK1A1 
C16 Down-regulated RAP2B-calcineurin pathway, including Ca release depending on calreticulin, which  
de-phosphorylates NFATc, followed by p21 transcription inhibiting CDK2, and followed by phosphorylation of 
NFATc in nucleus by regulated CSNK1A1 
C17 Up-regulated RAP2B-calcineurin pathway, including Ca release depending on calreticulin, which  
de-phosphorylates NFATc, followed by a p21 transcription, inhibiting CDK2, and followed by phosphorylation of 
NFATc in nucleus by regulated CSNK1A1 
C18 Regulated RAP2B-calcineurin pathway, which de-phosphorylates regulated NFATc, followed by a transcription of 
MLC2, aActin, ANF, and phosphorylation of NFATc in nucleus by regulated CSNK1A1 
C19 Phosphorylation of NFATc in cytosol by regulated CSNK1A1, regulated RAP2B-calcineurin pathway, including 
Ca release, depending on concentration gradient between ER and cytosol, which de-phosphorylates regulated 
NFATc, which does not result in transcriptional activity 
C20 Phosphorylation of NFATc in cytosol by regulated CSNK1A1, regulated RAP2B-calcineurin pathway, including 
Ca release, depending on calreticulin, which de-phosphorylates regulated NFATc which does not result in 
transcriptional activity 
C21 Down-regulated RAP2B-calcineurin pathway, including Ca release depending on concentration gradient between 
ER and cytosol, which de-phosphorylates NFATc, followed by transcription of UTRNA and MYF5, and 
phosphorylation of NFATc in nucleus by regulated CSNK1A1  
C22 Up-regulated RAP2B-calcineurin pathway, including Ca release, depending on concentration gradient between ER 
and cytosol, which de-phosphorylates NFATc, followed by transcription of UTRNA and MYF5, and 
phosphorylation of NFATc in nucleus by regulated CSNK1A1 
C23 Down-regulated RAP2B-calcineurin pathway, including Ca release, depending on calreticulin, which  
de-phosphorylates NFATc, followed by transcription of UTRNA and MYF5, and phosphorylation of NFATc in 
nucleus by regulated CSNK1A1 
C24 Up-regulated RAP2B-calcineurin pathway, including Ca release, depending on calreticulin, which  
de-phosphorylates NFATc, followed by transcription of UTRNA and MYF5, and phosphorylation of NFATc in 
nucleus by regulated CSNK1A1 
C25 DGC downstream pathway, which activates up-regulated JNK1, regulated RAP2B-calcineurin pathway, which de-
phosphorylates regulated NFATc, followed by a transcription of UTRNA and MYF5 and phosphorylation of 
NFATc in nucleus by JNK1 
C26 Initiation and down-regulation of NFATc 
C27 Regulated NFATc mediates p21 transcription inhibiting CDK2, followed by degradation of NFATc in nucleus 
C28 Regulated NFATc mediates transcription of MLC2, aActin, and AFN followed by degradation of NFATc in nucleus 
RESULTS 
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Cluster Biological interpretation 
C29 Regulated NFATc mediates transcription of MYF5, followed by degradation of NFATc in nucleus 
C30 Regulated NFATc mediates transcription of UTRNA, followed by degradation of NFATc in nucleus 
C31 CDK6-dependent RB-E2F cell cycle pathway, resulting in transcription of S-phase genes 
C32 CDK4-dependent RB-E2F cell cycle pathway, resulting in transcription of S-phase genes 
C33 CDK2-dependent RB-E2F cell cycle pathway, resulting in transcription of S-phase genes 
C34 RB-E2F cell cycle pathway, inhibited by CDK2-phosphorylated E2F 
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figure 15: The cluster tree. The edges are labelled according to the distinguishing features between clusters before the first branch 
and the common properties after the first branch. 
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4.3.2.2 Knockout analysis using Mauritius map 
 
Knockout experiments are a valuable method of gaining insights into molecular processes. 
The methods used are rather formal and can be applied to any Petri net. On the one hand, 
findings of the analysis should be consistent with the biological meaning and information on 
which the model is based. On the other hand, the findings also inspire new questions and 
experiments for future work. 
At first, the knockout impact of a single activity was studied to analyse the knockout 
behaviour of the model. Activities were represented either by an MCT-set or a single 
transition. The impact of a knockout of a transition was measured by the percentage of the 
number of t-invariants affected by its loss. This corresponds to the rate of reduction of the 
functional diversity or combinatorial complexity of the system. 
In table 34, the most important activities are listed as observed in the Petri net model.  
De-phosphorylation of the transcription factor NFATc (M1), its migration into the nucleus 
(t61.Transfactor_in_nuc), and transport back to the cytosol (t83.Transfactor_in_cyt) play a 
crucial role. Whereas the overall impact of a single knockout can be simply studied by 
deleting the corresponding activity, the dependency of the functional entities on each other 
can become very complex. 
 
table 34: Most important activities according to their combinatorial knockout impact. The impact of a knockout is measured by the 
percentage of the number of t-invariants affected by it. Activities with a knockout impact below 20% are not listed. 
MCT-set/ transition Activity Knockout impact 
M1 De-phosphorylation of NFATc  78% 
t61 NFATc migrates into nucleus  73% 
t83 Transportation of NFATc back to cytosol  67% 
t81 Deactivation of NFATc by CSNK1A1  45% 
M2 Ca release mediated by Ca-channel  39% 
M3 Ca release regulated by calreticulin  39% 
M9 Down-regulation of RAP2B  39% 
M10 Up-regulation of RAP2B  39% 
t32 Removal of dystrophin  37% 
t52 Removal of silenced calcineurin  37% 
t55 Initiation of enhancer of JNK1  37% 
M4 Activation of the DGC pathway  36% 
M5 Transcription of p21  36% 
M12 Down-regulation of CSNK1A1  29% 
M13 Up-regulation of CSNK1A1  29% 
M15 Down-regulation of NFATc  29% 
t46 Up-regulation of NFATc  28% 
t82 Deactivation of NFATc by JNK1  22% 
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Mauritius maps have been introduced to visualise this relationship (section 1.4.6). The entire 
Mauritius map for the Petri net model is shown in figure 16. It gives a visual impression of the 
complexity of functional dependencies in the model. For the sake of clarity, the labels of most 
of the edges have been dropped. For detailed examination, please refer to the file  
pn2_0803_fullb.eps in the supplementary material in Grunwald et al. [Supplementary material 
(Grunwald et al., 2008)]. On inspection of figure 16 it becomes obvious that the interrelations 
of molecular processes in the gene regulation of DMD are very complex in detail. Some of the 
edges are drawn as rather thick lines, i.e. they cover large parts of the net, whereas other lines 
are thin, i.e. they have only local influence.  
 
 
figure 16: The complete Mauritius map of the gene regulation in DMD. It gives a visual impression of the complexity of the 
functional dependencies in the model. Whereas the interrelations of the molecular processes in the gene regulation are very complex 
in detail, some of the edges cover large parts of the net (drawn as thick lines). To explore the completely lettered graph, please see the 
file pn2 0803 fullb.eps in the supplementary material in Grunwald et al. [Supplementary material (Grunwald et al., 2008)]. 
 
The dominant part of the Mauritius map is presented in figure 17. All the edges of the tree, 
which belong to a relative knockout impact below 20%, were dropped. That means, only 
transitions were considered whose knockout would lead to a destruction of more than 20% of 
all t-invariants. It was assumed that the importance of a transition or of a set of transitions was 
related to the percentage of invariant destruction when it is knocked out. Obviously, the right 
edge of the root represents the most important activity, namely the molecular processes of  
M1 covering the transitions t0.bind_PIP2, t1.act_IP3, t6.bind_CAM_Ca, and t7.gen_CAM  
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(table 34). In the model, the central role of M1 corresponds to the key role of the  
de-phosphorylation of NFATc (t10.dephosph). De-phosphorylation of NFATc relies on the 
activation of PLCe by RAP2B (t30.act_PLCe), the generation of calmodulin (t7.gen_CAM), 
the binding of calcium to calmodulin (t6.bind_CAM_Ca), and the activation of calcineurin by 
calmodulin (t8.act_Calcineurin). These activities are indispensable to de-phosphorylation of 
NFATc in this model, whereas alternatives exist for other processes of the calcium release 
from the endoplasmatic reticulum (ER). 
 
 
 
figure 17: Dominant part of the Mauritius map. The edges with relative knockout impact below 20% have been omitted. The 
dominant part of the Mauritius map describes the interrelation of molecular processes contributing to the de-phosphorylation of 
transcription factor NFATc. The name of a transition is concatenated with its transition number and MCT-set. 
 
Considering the functional part of the model that depends on de-phosphorylation of NFATc, 
the most important transitions are t61.Transfactor_in_nuc and t83.Transfactor_in_cyt. These 
are the labels between the second and the third edge in the Mauritius map (figure 16), and are 
part of M1. The corresponding molecular processes, more precisely the migration of the 
transcription factor NFATc into the nucleus (t61.Transfactor_in_nuc) and its transport back to 
the cytosol (t83.Transfactor_in_cyt), act as an MCT-set. These transitions resulted in identical 
knockout effects in this context. The left edge denotes the deactivation of NFATc by 
CSNK1A1 (t81.deact_NFATc_CSNK1A1). De-activation of NFATc is a pre-condition for 
transportation of NFATc back to the cytosol. 
The phosphorylation was mediated either by CSNK1A1 or via the DGC downstream pathway 
by JNK1. Consequently, molecular processes indispensable for the activation of JNK1 via the 
DGC downstream pathway are the labels of the right edge. These processes only result in an 
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MCT-set in the context of phosphorylation of NFATc, but might participate in different ways 
to other activity groups of the net. 
The child node of the activity of CSNK1A1 includes phosphorylation of the transcription 
factor NFATc (t81.deact_NFATc_CSNK1A1). Since phosphorylated NFATc cannot enter the 
nucleus, the phosphorylation activity of NFATc would lead to an accumulation of the 
transcription factor deactivated in the cytosol. The high level of phosphorylated NFATc in the 
cytosol has to be compensated by an effective de-phosphorylation process, i.e. by an 
advanced activity of calcineurin. However, the activation of calcineurin is mediated by the 
calcium regulated calmodulin. One of the main storages of calcium is the endoplasmatic 
reticulum. Its release into the cytosol can be initiated depending on the calcium concentration 
gradient between the endoplasmatic reticulum and the cytosol (M2) or by calreticulin 
dependent processes (M3). Both of these 2 functional groups represent alternative ways to 
provide free calcium for binding to calmodulin or other proteins. Consequently, the molecular 
processes of M2 and M3 are the labels of the following right and left edges. A complete 
knockout of the function of calcineurin only is achievable by a knockout of molecular 
processes of both MCT-sets. 
A special Mauritius map was constructed to study the dependency of a particular function on 
other transitions rather than the detailed structure of functional dependencies in the entire net. 
A transition of interest was chosen that was now exhibiting the highest impact by definition. 
The transition selected was highlighted, and appeared as one label of the left edge of the root. 
For example, the modified phosphorylation of c-Jun by active JNK1 (t59.phos_c-Jun) is 
depicted in figure 18. A knockout of this transition caused an impact of around 13% whereas 
other phosphorylation processes usually exhibited knockout impacts below 5%. In the entire 
network (figure 16), MCT-set M14 includes phosphorylation of c-Jun (t59.phos_c-Jun) and 
inhibition of the transcription of p21 (t39.inhib_transcr_p21). Considering the functional 
subnet only, which was participating in this process, M14 was then a member of a much 
larger MCT-set as shown on the label of a left edge of the root in figure 18.  
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figure 18: Mauritius map for the phosphorylation of c-Jun by active JNK1 (t59.phos_c-Jun). This transition becomes a member of a 
rather large MCT-set in this sub-network. The interrelations of the molecular processes exhibit a complex structure. 
 
 
The knockout of any transition of this set would result in a complete knockout of this 
phosphorylation pathway. The interaction of other knockouts, which partly influence this 
function only, was exhibiting a rather complex structure. These functional dependencies may 
be tested by performing systematic knockout experiments. 
To summarise, the RAP2B-calcineurin pathway turned out to be one of parts most relevant to 
network behaviour. This suggested that an influence on calcineurin would also have a vital 
impact on NFATc. Experiments were proposed using chemical compounds affecting 
calcineurin and phosphatases in general (section 4.4.4). 
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4.4 Modulation of gene expression of CSNK1A1 by plasmid vector 
cDNA as well as siRNA and modification of CSNK1A1 and 
calcineurin activities using chemical substances 
 
Based on the results of Petri net modelling and subsequent analysis approaches, candidate 
genes and proteins were selected for manipulation of their expression state and protein 
activity. In the Petri net model, CSNK1A1 and calcineurin are involved in a signal 
transduction subnet whose lack had the highest impact in Mauritius map analysis. Since 
CSNK1A1 was also discovered as significantly differentially expressed at mRNA level in 
both directions in muscle biopsy tissues, it was intended to experimentally influence its gene 
regulation with regard to up-regulation and down-regulation. The manipulations of CSNK1A1 
and calcineurin were expected to result either in down-regulation of MYF5, p21, and UTRNA 
via phosphorylation and inactivation of the transcription factor NFATc or vice versa. 
Although MYF5, p21 and UTRNA were modelled with NFATc as the same transcription 
factor, it is questionable whether expression regulation of all of them is equivalently 
governed. For the DMD therapy 2 objectives are of special interest:  
 Down-regulation of p21 expression to increase myoblast proliferation without a 
concurrent decrease in UTRNA expression. 
 Up-regulation of UTRNA expression and maintaining or increasing myoblast 
proliferation. 
 
Such interventions are feasible using transfection of plasmid vector cDNA constructs or 
siRNAs and the substitution of chemical compounds. The application of chemical compounds 
is faster, more convenient and technically simpler than genetic engineering but the influence 
affects a wide range of proteins rather than a specific one. Accepting this disadvantage, 
experiments were started using chemical compounds in cell culture. 
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4.4.1  Characterisation of cell cultures originating from DMD patients and 
controls 
 
Primary cells derived from DMD patients used in subsequent experiments and patients’ 
clinical features are characterised in table 35. The cell culture 109/03 is equivalent to patient 
P5 as well as 145/03 to patient P2 (section 3.3.2). The preparation of skeletal muscle biopsies 
tissue to obtain primary myoblasts cell cultures is described in section 3.3.2.2.  
 
table 35: Summary of clinical features and cultivation specification of DMD-patients and controls used as SkMCs in cell culture. 
Proliferation data were determined by Stefanie Endesfelder; PhD thesis (Endesfelder, 2004) 
Designation 
Clinical data Cell culture 
Classification Age at biopsy Dystrophy Doubling of population 
Subjective impression 
cultured cells 
14/00  normal 2 years - 4d normal 
18/01  normal 9 years - 5.5d normal 
43/01  DMD 3 months no impairment 6d slightly delayed 
77/02  DMD 4 years progressive, mild course 14d 
delayed; 
myoblasts enlarged 
109/03 P5* DMD 3.5 years progressive 12d delayed; myoblasts enlarged 
145/03 P2* DMD 2 years progressive 7d slightly delayed 
* patients also available for muscle biopsy investigations 
 
 
4.4.2  Applications governing CSNK1A1 activity and expression 
 
4.4.2.1 Inhibition of CSNK1A1 by IC261 at protein level 
 
IC261 (3-[(2,4,6-Trimethoxyphenyl)methylidenyl]-indolin-2-one) is a specific inhibitor of the 
protein family casein kinase I. Members of this family include alpha, delta, gamma, and 
epsilon. The most potent effect of IC261 is observed for casein kinase I delta and epsilon, but 
it also inhibits CSNK1A1 at higher concentrations (c>10µM). Since CSNK1A1 can 
phosphorylate and de-activate transcription factor NFATc, a reduction of p21 mRNA levels 
was assumed. Consequently, an increase in proliferation was expected. 
In addition to the determination of cell proliferation, vitality tests were performed using  
WST 8. All the data were acquired from cells at optimal vitality. IC261 was dissolved in 
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DMSO. Concentrations are given as final concentrations. For each experiment, untreated as 
well as DMSO-treated cells were included as negative controls. Unless otherwise noted, 
proliferation data of cells influenced by chemical compounds were compared to untreated 
samples. Data were revealed from 3 experiments repeated with n=6 each. The alteration of 
cell proliferation proposed as consequence of p21 expression depending on IC261 
concentration is shown in figure 19. Optimal concentration of IC261 applied to SkMCs turned 
out to be specific for each cell culture originating from different DMD patients. 
 
 
figure 19: Proliferation (BrdU) data of (Dys+) and (Dys-) SkMCs treated with IC261 for 48h. DMSO-treated cells (grey with dots) 
were compared to untreated cells (100%) to introduce the effect of DMSO to SkMCs. The bar diagram demonstrates developing of 
proliferation rate depending on IC261 concentration of each treated cell culture. Thus, the dark grey bar indicates best revealed cell 
proliferation rate whereas striped light grey bars specify concentration next to the optimal one. White bars show the toxic level. 
(Dys+) SkMCs: 14/00 (Dys-) SkMCs : 43/01; 77/02 
 
A concentration below 1nM was not performed since no effect of IC261 was expected at that 
low molar concentration, in particular for CSNK1A1. Both, proliferation and vitality were 
diminished using concentrations above 1µM, which was the concentration at which an effect 
was microscopically visible. SkMCs exhibited dramatic but reversible morphological 
changes. SkMCs usually spread out longitudinally with a smooth cell membrane. Using 
IC261 (c >1µM) morphology of the cells appeared rounded and jagged. No changes in 
proliferation were determined for 77/02. A slight but non-significant increase in proliferation 
was observed for 14/00 and 43/01 using 1nM IC261, but is equivalent to the values of SkMCs 
treated with DMSO. In the literature, concentrations between 0.1µM and 1µM were suggested 
as effective (see http://www.emdbiosciences.com/product/d/400090). The results suggest that 
the effect of IC261 on casein kinase delta and epsilon may be predominant. Casein kinases 
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delta and epsilon are involved in regulating DNA repair and chromosomal segregation. 
Consequently, IC261 was shown to inhibit cytokinesis by causing a transient mitotic arrest 
(Behrend et al., 2000). A positive influence of IC261 through inhibition of CSNK1A1 might 
be not detectable. A specific inhibitor for CSNK1A1 was not available at the time when 
experiments were performed. For this reason, further experiments were performed using 
plasmid vector cDNA and siRNA to modulate CSNK1A1 more specifically. 
 
 
4.4.3  Up-regulation of CSNK1A1 using plasmid vector cDNA 
 
Optimisation of transfection 
Most primary cells and in particular SkMCs are very difficult to transfect. Therefore, a 
transfection technique was needed that provides a high efficiency and low toxicity, especially 
since (Dys-) SkMCs are more sensitive to transfection reagent and demonstrate a lower 
proliferation rate than (Dys+) SkMCs. In the literature, only few and partly contradictory data 
are published regarding transfection of primary human SkMCs (Espinos et al., 2001; 
Campeau et al., 2001; Pampinella et al., 2002). In this thesis, numerous transfection 
techniques were examined, such as Fugene HD® and Fugene 6® (Roche), EffecteneTM 
(Qiagen), Lipofectamine 2000® (Invitrogen) and Targefect® (Targeting Systems) as well as 
the electroporation system amaxa (amaxa). Amaxa is an electroporation system using cell 
type specific solutions and is also termed nucleofection. Quenneville et al. published a 
successful introduction of DNA plasmids containing an enhanced GFP (eGFP) construct by 
nucleofection (Quenneville et al., 2004). Fugene HD®, Fugene 6® and EffecteneTM are  
non-liposomal lipid formulations that are used in transfection approaches of a broad range of 
cell types and cause minimal cytotoxicity. 
Two different cDNA plasmid vectors were applied for transfection. Both of them carry a 
cDNA insert encoding for CSNK1A1. The cDNA plasmid purchased from Genecopoeia is 
7kb in size, also contains a neomycin cassette and GFP as reporter gene connected via an 
IRES site to the CSNK1A1 insert. However, a poly-A signal is lacking 
(http://www.genecopoeia.com). The second CSNK1A1 vector was obtained from Origene 
carrying a full length cDNA including a poly-A signal but not a reporter gene. Controls 
included positive controls using eGFP plasmid vector at 2kb in size (eGFP; supplied with the 
amaxa kit) and negative controls treated with the transfection reagent or system without 
cDNA plasmids.  
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Transfection experiments using Lipofectamine 2000® and Targefect® did not succeed since 
no fluorescence signal and negative Real-Time PCR results were received. Both reagents 
were not considered in the further report.  
Fluorescence data were only received from transfections using Genecopoeia cDNA plasmid 
vector and EffecteneTM, Fugene 6® and the amaxa system. Transfection results are 
exemplarily shown for EffecteneTM used in the (Dys+) SkMCs 14/00 (figure 20 - 22). 
Equivalent results were revealed for transfections using Fugene 6® and the amaxa system. 
The following experiments were performed: 
 
(1) Negative controls: Cells treated with EffecteneTM, but without DNA, demonstrated a 
faint auto-fluorescence when exposed to FITC filter (figure 20b, but also showed less 
toxicity of the reagent (figure 20a). 
(2) Positive controls: SkMCs were transfected using the 2µg amaxa control vector which 
resulted in bright fluorescent cells, but with low efficiency (figure 21b). The toxicity 
was as low as shown for the negative control (figure 21a).  
(3) CSNK1A1 transfection: Fluorescence of transfected cells appeared very faint similar 
to untransfected cells (figure 22b). Cytotoxicity was increased compared to the 
negative control. That may be due to an increased amount of plasmid DNA used in 
these experiments. The number of cells decreased during transfection and cells 
exhibited more inclusions (figure 22a).  
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figure 21: Positive control: (Dys+) 
SkMCs transfected with 5µg amaxa 
eGFP plasmid vector using EffecteneTM 
(resolution factor 200). a) Bright field 
image which represents the same area 
as shown in b) Bright eGFP 
fluorescence of SkMCs using FITC 
filter. 
 
figure 22: (Dys+) SkMCs transfected 
with 5µg CSNK1A1 plasmid 
(Genecopoeia) using EffecteneTM 
(resolution factor 200). a) Bright field 
image which represents the same area 
as shown in b) Faint GFP fluorescence 
of SkMCs using FITC filter whose 
intensity is similar to the negative 
control (figure 20b). 
figure 20: Negative control: 
Transfection of (Dys+) myoblasts using 
EffecteneTM but without DNA 
(resolution factor 200). a) Bright field 
image which represents the same area 
as shown in b) Auto-fluorescence of 
SkMCs using FITC filter. 
 
figure 20: Negative control: Transfection of (Dys+) myoblasts using EffecteneTM but without DNA (resolution factor 200) 
 
figure 21: Positive control: (Dys+) SkMCs transfected with 5µg amaxa eGFP plasmid using EffecteneTM (resolution factor 200) 
 
figure 22: (Dys+) SkMCs transfected with 5µg plasmid (Genecopoeia) using EffecteneTM (resolution factor 200) 
 
To summarise, for EffecteneTM, Fugene 6® and the amaxa system, a sufficient GFP signal 
was not detected. 
According to published data, the results suggested that too low or ineffective transfection 
rates were responsible for the negative outcome, and a detection limit of wild type GFP, in 
particular if expressed via an IRES site. In the literature, experiments that investigated the 
visibility of eGFP fluorescence depending on the received copy number found that injections 
of 103 cDNA plasmid copies per cell only resulted in a faint eGFP fluorescence signal in  
30-50% of the cells. For a bright signal, a plasmid DNA copy number of 105 per cell was 
required (Schindelhauer and Laner, 2002). The Genecopoeia CSNK1A1 cDNA plasmid 
construct carries a wild type GFP, which is less fluorescent than eGFP and is expressed via an 
IRES site. So it has been proposed that the transfected copy number is too low for a detectable 
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GFP signal, but might be sufficient for up-regulation of CSNK1A1 expression. For the 
determination of the transfection efficiency, quantitative Real-Time PCR was applied to 
examine not only the absolute copy number of transfected cDNA plasmid vectors but also 
relative up-regulation of CSNK1A1. At DNA level, 2 primer pairs were used. The first primer 
pair detected the cDNA insert of the vector as well as 2 known endogenous  
pseudo-genes of the insert as found at http://www.pseudogene.org. Pseudogenes of 
CSNK1A1 would explain a positive transfection result of untransfected controls. Since the 
cells used in all the experiments originated from the same donor, the whole genome and 
consequently the number of pseudogenes were identical and disregarded. The second pair led 
to amplification of genomic DNA, and was applied to correct variations of the amount of 
endogenous DNA utilised in each reaction. A standard curve was calculated with an 
efficiency of 1.99 for both cDNA plasmid vectors used and is exemplarily shown for the 
vector purchased from Genecopoeia (figure 23). The adjusted results of all samples were 
applied to the standard curve to retrieve the copy numbers of each experiment. 
 
 
 
figure 23: Standard curve of cDNA plasmid vector CSNK1A1 purchased from Genecopoeia with an efficiency of 1.99. The equation 
was used to calculate the copy numbers of transfected plasmid DNA. 
 
 
The results of the comparison of transfection efficiencies for Fugene HD®, Fugene 6®, 
EffecteneTM and the amaxa system are presented in figure 24, which gives the copy numbers 
of each sample. For Fugene HD®, different ratios of transfection reagent : DNA are 
exemplarily given, and were omitted for the other transfection methods. The optimal 
transfection efficiency was obtained with Fugene HD® : DNA ratio of 6:2 and 200% complex 
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volume at which a total copy number of 2,4 x 1010 of cDNA plasmid vectors was determined, 
isolated from 4 x 105 primary SkMCs (6 x 104 copies/cell). Although, this value appears 
extremely high at first, such a copy number was determined by Schindelhauer in 2002 for 
several primary cells (Schindelhauer and Laner, 2002). Thus, the values as shown in  
figure 24 can be interpreted as realistic. By contrast, the negative controls, treated with 
Fugene HD® only, still displayed a weak signal in Real-Time-PCR which is thought to be 
resulting from 2 known pseudogenes of the insert rather than from cDNA plasmid vectors. 
Finally, a decrease of volume of Fugene HD® or a complex volume of 400% reduced the 
transfection efficiency. The latter may also be a result of toxicity. By contrast, an increase of 
Fugene HD® and DNA (12:4) also revealed satisfying transfection rates but only for a 
complex volume of 100%. 
 
 
 
Copy numbers of transfected plasmid vector DNA
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figure 24: Plasmid DNA copy numbers isolated from 4 x 105 primary SkMCs derived with transfection reagents Fugene HD®, 
Fugene 6 ® (F) and EffecteneTM (E) as well as with amaxa (A). 
 
 
The reagents EffecteneTM, Fugene 6® and the amaxa system reached a very low percentage of 
detected vector copies compared to Fugene HD®. Even though the transfection reagent 
EffecteneTM showed the best efficiency of these 3, the transfected plasmid copy number was 
1/25 of the highest Fugene HD® transfection result. But in addition it revealed a considerable 
toxicity in contrast to Fugene HD®. In general, the impression of toxicity was 
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microscopically monitored 24h after incubation of cells with the Fugene HD®-DNA-complex 
as well as the other reagents and systems. No toxicity could be determined for the  
Fugene HD®-DNA-complex volumes of 100% and 200% and less toxicity for 400%, whereas 
30-40% of the cells died during transfection using the reagents EffecteneTM and Fugene 6® as 
well as the amaxa system (data not shown). 
 
Transfection results using CSNK1A1 plasmid cDNA vector from Genecopoeia 
Having the transfection efficiency rated as being satisfactory, optimal transfection conditions 
were performed to study the expression rate of CSNK1A1, the influence of  
CSNK1A1 up-regulation on proliferation and vitality of the transfected cells as well as on the 
RNA expression level of MYF5, p21, and UTRNA. The results are summarised in table 36. 
Expression and proliferation results were compared to Fugene HD®-treated cells (100%). An 
optimal transfection was determined using the Fugene HD® : DNA ratio of 6:2 with  
200% complex volume which resulted in different amounts of entered plasmid DNA (in ng) 
and a 1,5-16fold increase of expression levels of CSNK1A1 in SkMCs. The DNA uptake and 
the resulting up-regulation of CSNK1A1 appeared to be cell type specific. No correlation 
between inserted plasmid DNA and up-regulation of CSNK1A1 was observed, in particular 
with regard to the number of patients and controls. The (Dys+) cells 14/00 showed the most 
elevated expression level of CSNK1A1 whereas the lowest up-regulation of CSNK1A1 was 
investigated for SkMCs 77/02. Interestingly, these cell cultures showed the lowest and 
highest, respectively, population doubling time (table 35), which might be the cause for the 
variation in DNA uptake. The proliferation of (Dys+) cells was not altered, but was slightly 
reduced in (Dys-) cells except for cell culture 145/03. This cell culture demonstrated a 
decrease to 34% compared to Fugene HD-treated cells. But changes in proliferation were 
obviously not associated with a reduction of p21 expression. Since CSNK1A1 is able to 
phosphorylate and inactivate the transcription factor NFATc, the mRNA expression levels of 
NFATc target genes, MYF5, p21, UTRNA, were determined by Real-Time-PCR (table 36), 
and were expected to be reduced. However, a correlation between an up-regulation of 
CSNK1A1 and mRNA expression levels of any of the genes could not be discovered. The 
calculation of the relative expression levels using transfected and Fugene HD-treated SkMCs 
resulted in equal values compared to relative quantification of tranfected and untreated 
SkMCs. 
 
table 36: Transfection experiments in (Dys+) and (Dys-) cells using cDNA plasmid vector from Genecopoeia. After 48h of 
transfection, the optimal ratio and the appropriate transfection efficiency were revealed in cell cultures of DMD patients and 
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controls. The proliferation rate was determined using the BrdU test and compared to Fugene HD®-treated cells (100%). The mRNA 
expression levels of CSNK1A1 and the NFATc target genes MYF5, p21, and UTRNA in transfected cells were compared to Fugene 
HD-treated cells (corresponds to 1 and 100%, respectively). A comparison with untreated SkMCs resulted in the same outcome. 
Genecopoeia  
 
cDNA 
Plasmid 
vector 
CSNK1A1 
Analysis on proliferation 
and mRNA expression level 
Cell type 
(Dys+) (Dys-) 
14/00 18/01 43/01 77/02 109/03 145/03 
Optimal ratio  
(Fugene HD®:DNA) 
6:2 
200% 
6:2 
200% 
6:2 
200% 
6:2 
200% 
6:2 
200% 
6:2 
200% 
Transfection efficiency (ng) 15ng 9ng 0.3ng 0,8ng 1,6ng 12ng 
Up-regulation of 
CSNK1A1expression  
(Fugene HD®-treated cells = 1) 
16x 2,5x 6x 1,5x 2,8x 2,8x 
Proliferation 
(Fugene HD®-treated cells = 100%) 94% 100% 87% 73% 65% 34% 
Real-Time-
PCR 
MYF5 936% 176% 143%, 100% 48% 467% 
p21 472% 105% 144% 75% 87% 487% 
UTRNA 267% 97% 51% 360% 44% 134% 
 
 
An up-regulation of CSNK1A1 was demonstrated, but did not suffice when the cDNA 
plasmid vector purchased from Genecopoeia was used. This may be due to an incomplete 
cDNA insert which lacks a Poly-A signal. For this reason, another cDNA plasmid vector 
carrying a cDNA insert for CSNK1A1 from Origene was applied in subsequent experiments. 
 
Transfection results using CSNK1A1 plasmid cDNA vector from Origene 
The transfection results using the Origene cDNA plasmid vector are summarised in table 37. 
The expression and proliferation results were compared with Fugene HD-treated cells 
(100%). An optimal transfection was determined using a Fugene HD® : DNA ratio of  
6:2 with 200% complex volume which resulted in different amounts of entered plasmid DNA 
(in ng) and a 1,5-82fold increase of expression levels of CSNK1A1 in SkMCs. In comparison 
to Genecopoeia results, the transfection efficiencies and the up-regulation of CSNK1A1 
expression was considerably improved using the Origene cDNA plasmid vector. The 
transfection efficiencies were comparable for all used SkMCs. As shown for Genecopoeia 
plasmid DNA, no clear correlation between transfection efficiency and up-regulation of 
CSNK1A1 was observed. Again, the (Dys+) cells 14/00 showed the most elevated expression 
level of CSNK1A1 whereas 77/02 exhibited the lowest up-regulation of CSNK1A1. For both  
(Dys+) and (Dys-) cells, a correlation was not determined for transfection efficiency and 
proliferation rate. Contrary to expectation, the proliferation was not elevated but slightly 
reduced, and that was not a consequence of p21 up-regulation. Overall, a correlation between 
an up-regulation of CSNK1A1 and mRNA expression levels of MYF5, p21, and UTRNA was 
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not detected. Equal values were determined by the calculation of the relative expression of 
transfected and Fugene HD®-treated SkMCs compared to transfected and untreated SkMCs. 
 
table 37: Transfection experiments in (Dys+) and (Dys-) cells using cDNA plasmid vector from Origene. After 48h of transfection, the 
optimal ratio and the appropriate transfection efficiency were revealed in cell cultures of DMD patients and controls. The 
proliferation rate was determined using the BrdU test and compared with Fugene HD®-treated cells (100%). The mRNA expression 
levels of CSNK1A1 and the NFATc target genes MYF5, p21, and UTRNA in transfected cells were compared with  
Fugene HD®-treated cells (corresponds to 1 and 100%, respectively). A comparison with untreated SkMCs resulted in the same 
outcome. 
Origene 
 
cDNA 
Plasmid 
vector 
CSNK1A1  
Analysis on proliferation 
and mRNA expression level 
Cell type 
(Dys+) (Dys-) 
14/00 18/01 43/01 77/02 109/03 145/03 
Optimal ratio  
(Fugene HD®:DNA) 
6:2 
200% 
6:2 
200% 
6:2 
200% 
6:2 
200% 
6:2 
200% 
6:2 
200% 
Transfection efficiency (ng) 14ng 14ng 8ng 14ng 16ng 22ng 
Up-regulation of 
CSNK1A1expression  
(Fugene HD®-treated cells = 1) 
82x 7x 8,5x 1,5x 4,7x 5,5x 
Proliferation 
(Fugene HD®-treated cells = 100%) 78% 61% 50% 82% 66% 45% 
Real-Time-
PCR 
MYF5 1200% 200% 500% 84% 41% 272% 
p21 662% 116% 106% 107% 80% 192% 
UTRNA 479% 111% 200% 42% 35% 131% 
 
 
In summary, the transfections succeeded in both experiments using 2 different cDNA plasmid 
vectors. However, substantial variations between different DMD patients, and also between 
both controls, were remarkable. But neither the expected down-regulation of  
MYF5, p21, and UTRNA nor a general increase in proliferation due to reduced p21 
expression levels was detected through a CSNK1A1 up-regulation.  
The CSNK1A1 expression of the DMD patient with mild phenotype demonstrated an 
increased mRNA level compared to his elder brother, but reduced CSNK1A1 expression 
compared to 5 other typical DMD patients (see section 4.2.2).  
Therefore, experiments considering an up-regulation of CSNK1A1 were complemented with 
the study of CSNK1A1 down-regulation using siRNA. 
 
4.4.3.1 Down-regulation of CSNK1A1 using siRNA 
 
The experiments were similarly conducted as described for the up-regulation of CSNK1A1. 
The results are summarised in table 38. Expression and proliferation results were compared to  
X-tremeGene® siRNA transfection reagent treated cells (100%) and in case of proliferation 
also to cells added to pure siRNA (100%). The optimal transfection was determined for an  
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X-tremeGene® : siRNA ratio of 10:1 with 100% complex volume. The transfection resulted 
in differently decreased expression levels (0,08-1,04fold) of CSNK1A1 in SkMCs. The 
CSNK1A1 mRNA expression levels of both (Dys+) cell cultures were not affected by a 
siRNA transfection. By contrast, the down-regulation of CSNK1A1 in (Dys-) cells succeeded 
and was at the lowest after 48h of transfection. Since CSNK1A1 is able to de-activate NFATc 
by phosphorylation, an increase in transcription of MYF5, p21, UTRNA was expected. This 
correlation was not determined in all cell cultures. Furthermore, the proposed increase in p21 
expression was expected to lead to a reduced proliferation rate. Except for one control cell 
culture, the cell proliferation of SkMCs differed in both directions depending on the sample 
used for comparison. If transfected SkMCs were compared with SkMCs treated with 
transfection reagent alone, a correlation between proliferation and down-regulation of 
CSNK1A1 expression was not discovered. If these cells were compared with SkMCs treated 
with pure siRNA, an elevated proliferation rate was detected. Moreover, this discrepancy 
disappeared after 72h of transfection. However, a down-regulation of CSNK1A1 was not 
detected for cells treated with siRNA alone. These data suggest that the transfection reagent 
might influence the vitality of the cell without visible changes in cell morphology resulting in 
an inhibition of cell proliferation. However, an immune response cannot be excluded. 
Calculated values of the relative expression of transfected and siPur-treated SkMCs did not 
differ to the results determined by relative quantification of untreated and X-tremeGene® 
transfection reagent treated SkMCs. 
 
table 38: Transfection experiments in (Dys+) and (Dys-) cells using siRNA against CSNK1A1. After 48h of transfection, the optimal 
ratio and the down-regulation of CSNK1A1 were revealed in cell cultures of DMD patients and controls. The proliferation rate was 
determined using the BrdU test. The results were compared with X-tremeGene®-treated (100%) as well as with siPur-treated cells 
(100%). The mRNA expression levels of CSNK1A1 and the NFATc target genes MYF5, p21, and UTRNA in transfected cells were 
compared with siPur-treated cells (corresponds to 1 and 100%, respectively).  
siRNA 
transfection 
affecting 
CSNK1A1 
Analysis on proliferation 
and mRNA expression level 
Cell type 
Dys+ Dys- 
14/00 18/01 43/01 77/02 109/03 145/03 
Optimal ratio  
(X-tremeGene® : siRNA) 10:1 10:1 10:1 10:1 10:1 10:1 
Down-regulation of CSNK1A1 
expression  
(siPur-treated cells = 1) 
1,04x 0,88x 0,08x 0,12x 0,45x 0,25x 
Proliferation 
siPur compared to 
untreated (100%) 130% 103% 127% 139% 130% 120% 
compared to  
X-tremeGene®-
treated (100%) 
78% 97% 111% 67% 68% 75% 
Real-Time-
PCR 
MYF5 300% 125% 130% 72% 120% 96% 
p21 131% 84% 100% 87% 84% 126% 
UTRNA 140% 68% 200% 83% 56% 78% 
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In summary, a down-regulation of CSNK1A1 was successfully obtained for DMD patients, 
but not for both controls. The results noticably varied between each DMD patient and 
controls. The expected relation between a CSNK1A1 down-regulation, a diminished 
proliferation and increased expression levels of MYF5, p21, and UTRNA could not be 
demonstrated.  
That missing relation was tested for the specific up- and down-regulation of CSNK1A1 as 
well as the unspecific regulation using IC261. It was suspected that the modulation of 
CSNK1A1 leads to alterations of and/or interventions in certain other signalling pathways 
rather than a specific influence of NFATc. In the literature, several other proteins were 
suggested as substrates for CSNK1A1, e.g. p53 (Knippschild et al., 2005a; Knippschild et al., 
2005b).  
This means that neither up-regulation nor down-regulation of CSNK1A1 resulted in an 
alteration of NFATc target gene expression, i.e. MYF5, p21, and UTRNA. Moreover, 
proliferation and UTRNA expression were not positively influenced, which was the aim of 
these approaches as modelled in the NFATc de-activation sub-net of the signalling network.  
NFATc is modelled and found to be primarily de-phosphorylated and activated by calcineurin 
(Chakkalakal et al., 2003). The analysis of the Petri Net by means of Mauritius maps showed 
that a theoretical knockout in the RAP2B-calcineurin sub-net leads to a malfunction of  
78% of the net. Consequently, this sub-net has the highest impact on the net’s behaviour. 
Therefore, applications modulating the calcineurin activity by chemical substances were 
performed. 
 
 
4.4.4  Modulation of calcineurin signalling 
 
The calcineurin signal transduction pathway has repeatedly been shown to be essential for 
skeletal muscle growth (Michel et al., 2004; Stupka et al., 2004; Chakkalakal et al., 2006; 
Michel et al., 2007; Stupka et al., 2008). Among others, the activity of the phosphatase 
calcineurin can be influenced by several chemical substances, e.g. okadaic acid, CsA, and 
deflazacort.  
Subsequent experiments were designed as described for IC261 (see section 4.4.2.1). Briefly, 
optimal concentrations of each drug were identified for each patient and control using 
proliferation and vitality tests. The experiments were performed at optimal vitality of the 
SkMCs. DMSO was the solvent for all drugs. Concentrations are given as final 
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concentrations. Negative controls include untreated as well as DMSO-treated cells. If not 
otherwise indicated, proliferation data of cells influenced by chemical compounds were 
compared to untreated samples. The data were revealed from 3 repeated experiments with  
n=6 each. Because of the restricted number of patients and controls, a value of more than  
20% was considered as an increase in cell proliferation. 
The alterations of cell proliferation depending on the concentration of the chemical substances 
are exemplarily shown for okadaic acid. Similar experiments were also performed for  
CsA and deflazacort but the range of molar concentration varied. The depiction of these data 
was left out to concentrate on more relevant data. In either case, optimal concentration of each 
substance applied to SkMCs turned out to be specific for each cell culture originating from 
different DMD patients. 
 
4.4.4.1 Okadaic acid 
 
The toxin okadaic acid is a potent and selective inhibitor of serine/threonine-specific protein 
phosphatases, in particular protein phosphatases 1 (PP1) and 2A and to a lesser extent 
calcineurin, and is used in studies of de- and phosphorylation processes (Bialojan and Takai, 
1988; Dounay and Forsyth, 2002). Calcineurin de-phosphorylates and activates NFATc, 
which would lead to an enhanced transcription of its target genes. 
Since treatment with okadaic acid was assumed to inhibit calcineurin dependent NFATc 
activation, a decrease in mRNA expression of NFATc target genes MYF5, p21, and UTRNA 
was expected. An increase in proliferation was suggested as a consequence of p21 reduction. 
A concurrent decrease of UTRNA expression was not assumed as shown once (Rodova et al., 
2004). 
The figure 25 shows cell proliferation rates determined after 48h of incubation. Alterations of 
cell proliferation have been assumed to be a consequence of changes in p21 expression 
dependent on okadaic acid concentrations.  
A concentration below 0.1nM was not performed since no effect of okadaic acid was expected 
at that low molar concentration. In the literature, effective concentrations were specified 
above 0.1nM (http://www.merckbiosciences.co.uk). Both, proliferation and vitality were 
dramatically diminished at concentrations exceeding 10nM and for the SkMCs 18/01 already 
at concentration of 3nM of okadaic acid. Additionally, (Dys-) cells were more sensitive to the 
drug so that lower optimal concentrations were determined.  
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figure 25: Proliferation (BrdU) data of (Dys+) and (Dys-) SkMCs treated with okadaic acid for 48h. DMSO-treated cells (grey and 
dotted bars) were compared with untreated cells (100%) to introduce the effect of DMSO to SkMCs. The bar diagram demonstrates 
the developing proliferation rate depending on okadaic acid concentration of each treated cell culture. The black bars indicate the 
best cell proliferation rate gained whereas shaded bars specify concentrations next to the optimal one. The white bars show the toxic 
level.  
[OA = okadaic acid]         (Dys+) SkMCs: 14/00; 18/01 (Dys-) SkMCs : 43/01; 77/02 
 
 
The figure displays values of DMSO-treated cells, which exceed proliferation rates of 
untreated SkMCs (=100%) in some cases. In the following, to exclude the effect of DMSO on 
SkMCs, the changes in proliferation are specified as the difference between DMSO and 
okadaic acid treated cells. The (Dys+) myoblasts 14/00 showed a higher increase in 
proliferation than (Dys-) SkMCs. In comparison to DMSO-treated cells, the elevation in 
proliferation was determined at 42% for 14/00 and at 20% for 18/01. By contrast, the  
(Dys-) SkMCs 43/01 revealed no induction (7%) and 77/02 showed a slight stimulation of 
14% in proliferation. This positive impact on proliferation disappeared after another 24h of 
incubation. It seems reasonable to assume that the substance accumulates and reaches its toxic 
concentration. Obviously, the difference in concentration that results either in increased cell 
proliferation or toxic events is very minimal. Taking into account this fact, an application of 
okadaic acid to DMD patients is infeasible even if the proliferation of myoblasts was elevated.  
In summary, if an optimal concentration was found for the particular SkMCs, an increase in 
proliferation was demonstrated as expected and modelled in the Petri net. But for all that, the 
toxicity of okadaic acid is high and very close to its beneficial concentration. For this reason, 
another chemical substance, CsA, was introduced for inhibiting calcineurin in further 
experiments. 
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4.4.4.2 Cyclosporin A 
 
In addition to the anti-inflammatory effects, it is well known that the calcineurin inhibitor 
CsA is involved in the NFATc signal transduction pathway (St-Pierre et al., 2004; Stupka et 
al., 2004). CsA was reported to benefit muscular dystrophy once (Sharma et al., 1993). But, 
contrary results using mdx mice were also reported (Stupka et al., 2004). Currently, a clinical 
study using CsA in DMD patients is being conducted at the paediatric clinic in Freiburg, 
Germany (Korinthenberg, 2008).  
As described for okadaic acid (section 4.4.4.1), an increase in proliferation with a 
simultaneous decrease in NFATc-mediated expression of p21 and MYF5 was expected.  
A reduction of UTRNA mRNA level by calcineurin inhibition is also supposed and was 
shown in C57BL/6 mice by Chakkalakal et al. (Chakkalakal et al., 2003) and would be an 
undesired effect.  
The SkMCs were treated using a wide range of concentrations of the drug as well as at 
different time points to identify the optimal dilution in terms of an increase in proliferation 
and vitality (table 39). The range of optimal concentration of each patient and control 
individual slightly diverges. A toxic concentration was reached above 1µM. 
 
table 39: Optimal concentrations of CsA after 48h treatment investigated in SkMCs using proliferation and vitality tests as well as 
expression studies. 
Cells CsA 
Dys+ 
14/00 5nM 
18/01 10nM 
Dys- 
43/01 10nM 
77/02 50nM 
109/03 1nM 
145/03 50nM 
 
 
The cell proliferation results of (Dys+) and (Dys-) SkMCs treated with CsA are shown in 
figure 26a. Except for 43/01, the cell proliferation was increased for all (Dys-) cell cultures 
(>20%). A slight elevation was observed for 43/01 and the (Dys+) SkMCs 18/01 (>10%). For 
the BrdU cell proliferation assay, a variance of 10% was determined for the absorbance values 
by the manufacturer. The second control myoblasts cell culture 14/00 remained unchanged. 
The positive impact on cell proliferation was diminished after another 24h incubation as 
described for okadaic acid (section 4.4.4.1). 
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figure 26: (Dys+) and (Dys-) SkMCs treated with CsA for 48h.----------------------------------------------------------------------------------------- 
a) The altered proliferation rates were normalised to DMSO-affected SkMCs. The cells applied to the solvent DMSO are indicated 
by the 100% curve. b) The mRNA expression of MYF5, p21 and UTRNA were examined in myoblasts treated with the optimal 
concentration of CsA. The results were calculated relatively to DMSO-affected SkMCs (=100%). 
(Dys+) SkMCs: 14/00; 18/01 (Dys-) SkMCs : 43/01; 77/02; 109/03; 145/03 
 
 
The (Dys+) and (Dys-) SkMCs treated with the optimal concentrations of CsA were studied at 
their mRNA levels of MYF5, p21 and UTRNA (figure 26b). The myoblasts affected by 
DMSO are indicated by the 100% curve. The quantification of CsA-treated cells was 
relatively calculated to DMSO-affected SkMCs as well as untreated SkMCs (data not shown), 
and produced equal results. Because of the restricted number of patients and controls, a 
relative difference of more than 200% and less than 50% was considered as an increase and 
decrease, respectively, in mRNA expression. Contrary to expectation, for all 3 genes, no 
alterations in mRNA expression were determined. Consequently, the increase in proliferation 
was not a consequence of a reduction of p21 expression.  
To summarise, the administration of CsA led to an increase of proliferation as expected and 
desired. But no changes at mRNA expression levels of NFATc target genes MYF5, p21, and 
UTRNA were detected which was unexpected (Chakkalakal et al., 2003). Hence, other 
signalling pathways are involved that participate in the induction of cell proliferation. Finally, 
deflazacort, which was suspected of being involved in the calcineurin/NFATc pathway, was 
tested using SkMCs. 
 
4.4.4.3 Deflazacort 
 
Up to now, only corticosteroids are routinely used with a slight beneficial outcome in DMD 
therapy (Biggar et al., 2006; Angelini, 2007). In mice, deflazacort was mentioned as 
positively influencing the calcineurin/NFATc pathway which led to an increased nuclear 
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translocation of NFATc and UTRNA expression. This effect was diminished using CsA.  
(St-Pierre et al., 2004) Several other mechanisms of action are also discussed including an 
anti-inflammatory effect. As modelled in the signalling network, it can be assumed that 
deflazacort decreases cell proliferation accompanied by increased expression of NFATc target 
genes MYF5, p21, and UTRNA.  
Experiments using deflazacort were designed similarly to CsA (see section 4.4.4.2). Optimal 
concentrations of deflazacort resulting in an increase in proliferation and vitality are shown in 
table 40. It is noticeable that the optimal concentration of each patient and control individual 
varies in the molar range from µM to mM. A toxic concentration was not reached (>200mM).  
 
table 40: Optimal concentrations of deflazacort after 48h treatment investigated in SkMCs using proliferation and vitality tests as 
well as expression studies. 
Cells Deflazacort 
Dys+ 
14/00 1mM 
18/01 10µM 
Dys- 
43/01 1mM 
77/02 1µM 
109/03 10µM 
145/03 1mM 
 
 
The cell proliferation results of (Dys+) and (Dys-) SkMCs treated with deflazacort compared 
to DMSO-affected cells are shown in figure 27a. The data demonstrate an increase of cell 
proliferation for 3 of 4 DMD patient cells of 30-50% and for both controls of 21 to 61%. The 
(Dys-) SkMC 43/01 indicated a slight stimulation of proliferation. This positive impact on 
proliferation disappeared after another 24h incubation time as described for okadaic acid and 
CsA (sections 4.4.4.1 and 4.4.4.2).  
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figure 27: (Dys+) and (Dys-) SkMCs treated with deflazacort for 48h. -------------------------------------------------------------------------------- 
a) The proliferation data were normalised to DMSO-affected SkMCs. The cells treated with the solvent DMSO are indicated by the 
100% curve. b) The mRNA expression of MYF5, p21 and UTRNA was determined in myoblasts treated with the optimal 
concentration of deflazacort. The results were calculated relatively to DMSO-affected SkMCs (=100%). 
(Dys+) SkMCs: 14/00; 18/01 (Dys-) SkMCs : 43/01; 77/02; 109/03; 145/03 
 
The mRNA expression levels of NFATc target genes MYF5, p21, and UTRNA in myoblasts 
influenced by deflazacort are displayed in figure 27b. The SkMCs treated with DMSO are 
indicated by the 100% curve. In the calculation of the relative expression levels no differences 
were found using either DMSO-treated or untreated SkMCs for the comparison to 
deflazacort-treated SkMCs. For all 3 genes no alterations in the mRNA expression MYF5, 
p21, and UTRNA were determined. 
In summary, the treatment of human SkMCs with deflazacort did not lead to an elevation of 
UTRNA expression as found in mice. An increase in proliferation was demonstrated for both 
(Dys+) and (Dys-) SkMCs, but was not a consequence of reduced p21 expression. The 
outcome is similar to okadaic acid and CsA, but it remains unclear which interference in 
NFATc signalling or other signalling pathways involved in the cell cycle are addressed by 
deflazacort. 
 
A modification of NFATc target gene expression of MYF5, p21, and UTRNA could not be 
demonstrated for inhibition of calcineurin using okadaic acid and CsA. In this context, the 
consideration of deflazacort is restricted, since the mechanism of action of deflazacort is 
unknown. However, all the substances used exhibit a conspicuous tendency to trigger an 
elevation of cell proliferation when applied to human SkMCs as proposed by the Petri net 
model and the outcome of the Mauritius map analysis. So the question arose whether a 
combined administration of CsA and deflazacort would lead to an added increase in cell 
proliferation, and was investigated in subsequent experiments. For toxicity reasons okadaic 
acid was excluded.  
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4.4.4.4 Combination of cyclosporin A and deflazacort 
 
Deflazacort and CsA are described as having a contrary impact on signal transduction 
pathways in skeletal muscle cells (St-Pierre et al., 2004). However, a positive effect on DMD 
patients was noticed when a routine administration of deflazacort was combined with CsA 
(von Moers, 2007). Furthermore, a clinical study has been conducted using both CsA and 
prednisolone. Deflazacort is an oxazoline derivative of prednisolone with less severe side 
effects.  
But, based on results from previous experiments, an increase in cell proliferation was 
expected at higher values than achieved with each substance accompanied by unchanged 
mRNA expression levels of the NFATc target genes MYF5, p21, and UTRNA.  
The optimal concentrations of CsA and deflazacort were applied to SkMCs as a combination 
of both substances (table 41). An incubation time of 48h also turned out to be most sufficient 
as independently found for both compounds.  
 
table 41: The concentrations of deflazacort and CsA used as combination in SkMCs. Proliferation and vitality tests as well as 
expression studies were performed after 48h treatment. 
Cells Deflazacort / CsA 
Dys+ 
14/00 1mM / 5nM 
18/01 10µM / 10nM 
Dys- 
43/01 1mM / 10nM 
77/02 1µM / 50nM 
109/03 10µM / 1nM 
145/03 1mM / 50nM 
 
 
The treatment of (Dys+) and (Dys-) SkMCs with both CsA and deflazacort resulted neither in 
the expected elevation nor in a reduction of cell proliferation (figure 28a). The enhancing 
impact as particularly found for CsA and deflazacort was diminished. A slight increase of cell 
proliferation was observed for 3 (Dys-) cell cultures and the (Dys+) SkMC 14/00, and was not 
a consequence of reduced p21 expression (figure 28b).  
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figure 28: (Dys+) and (Dys-) SkMCs treated with deflazacort and CsA for 48h.--------------------------------------------------------------------- 
a) The altered proliferation was normalised to DMSO-affected SkMCs. Cells applied to the solvent DMSO are indicated by the 
100% curve. b) The mRNA expression of MYF5, p21 and UTRNA was determined in myoblasts treated with optimal concentrations 
of deflazacort and CsA. The results were calculated relatively to DMSO-affected SkMCs (=100%). Whereas the (Dys+) SkMCs were 
not altered by any of the drugs, the combination of both compounds shows a significant increase (P < 0.05) in UTRNA mRNA 
expression (3-7fold). The statistical analysis was performed using the students t-test. 
(Dys+) SkMCs: 14/00; 18/01 (Dys-) SkMCs : 43/01; 77/02; 109/03; 145/03 
 
The (Dys+) and (Dys-) SkMCs influenced by deflazacort and CsA were studied at mRNA 
level for NFATc target genes MYF5, p21, and UTRNA (figure 28b). The cells treated with 
DMSO are indicated by the 100% curve. The calculation of the relative mRNA expression of 
drug-treated SkMCs compared to DMSO-treated or untreated SkMCs produced equal results. 
Because of the restricted number of patients and controls, a relative difference of more than 
200% and less than 50% was considered as an increase and decrease, respectively, in mRNA 
expression. For p21 and MYF5, the combination of both drugs exhibited no alteration in 
mRNA expression. In the (Dys+) SkMCs the mRNA expression of UTRNA remained 
unchanged (< 200%) as found for (Dys+) and (Dys-) myoblasts separately treated with the 
chemical substances. However, (Dys-) SkMCs treated with both deflazacort and CsA showed 
a significant increase (P<0.05) in UTRNA expression. An elevation of about 3- to 7fold was 
observed relative to DMSO-affected SkMCs. Since an increase at mRNA level only suggests 
an augmentation of the UTRNA protein expression, these findings were confirmed at protein 
level.  
 
4.4.4.5 Expression analysis at protein level 
 
The mRNA expression level does not necessarily correlate with the abundance at protein 
level. Regulation processes after transcription of the mRNA including splicing of the mRNA, 
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transport into the cytosol, miRNA, half-life of the mature mRNA, and translation of the 
protein play a decisive role.  
The mRNA expression of UTRNA was particularly increased in 2 DMD patients: 77/02 and 
145/03. These SkMCs were chosen to verify the UTRN expression at protein level. To extract 
the proteins, the cells were grown in T25 flasks and treated for 72h. The optimal 
concentrations for each SkMCs cluture were used as determined before. The samples included 
in these experiments are specified in table 42.  
 
table 42: The samples of all treated SkMCs and the respective drug concentration of 2 DMD patients (77/02 and 145/03) used for the 
detection of UTRN at protein level. 
Treatment 77/02 145/03 
Untreated 
DMSO  
Deflazacort 
CsA  
Deflazcort / CsA  
- 
7mM 
50nM 
1µM 
50nM / 1µM 
 - 
7mM 
50nM 
1mM 
50nM / 1mM 
 
 
The antibody against UTRN detects UTRNA and UTRNB. A specific antibody against 
UTRNA was not purchasable at the time experiments were performed. The western blot 
analyses were performed using 30µg and 40µg protein for 77/02 and 145/03, respectively. 
The house-keeping gene ß-actin was used to standardise the amount of protein used for each 
sample. The protein determination by the BCA method resulted in an average protein 
concentration of 1µg/µL. Although similar amounts of protein were used for each sample, the 
intensities of each band of ß-actin were different. The mRNA expression of UTRNA was 
increased for deflazacort in combination with CsA but not for the other samples. Thus, an 
elevated protein level was expected for deflazacort and CsA in comparison to DMSO-treated 
or untreated SkMCs. The results are representatively shown for DMD cell culture 77/02 in 
figure 29 A and B for UTRN and ß-actin, respectively.  
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figure 29: The UTRN protein expression (A) was detected in treated and untreated (Dys-) SkMCs of the patient 77/02 by a 
monoclonal anti-UTRN antibody. As loading control, ß-actin (B) was used. 
 
Since the intensities of the loading control vary between the samples, the differences in 
protein levels are not immediately determinable. Therefore a relative semi-quantitative 
determination of the UTRN protein expression of each sample was performed by comparing 
UTRN-specific signals with signals of the internal standard using the software 
BioDocAnalyzer 2.0 (Biometra). The results are shown in table 43. 
 
table 43: Semiquantitative determination of UTRN protein levels in untreated and treated samples compared to DMSO-treated 
samples (100%). The house-keeping protein ß-actin was used as internal standard. The investigation was performed for the (Dys-) 
SkMCs 77/02 and 145/03. 
* n.d. = not determined. Because of a gap in the protein band of the untreated cell sample 145/03, the band could not be analysed by 
the software.  
Sample 77/02 145/03 
untreated 101% n.d.* 
DMSO 100% 100% 
CsA 102% 112% 
Deflazacort 128% 229% 
Deflazacort + CsA 167% 233% 
 
The data show an increase in UTRN expression at mRNA as well as protein level. 
Interestingly, the treatment with deflazacort alone also resulted in elevated UTRN protein 
expression, which was not determined at mRNA level. For the validation, the mRNA 
expression data were verified using the same samples as employed for the protein analysis. 
Again increased mRNA UTRNA expression values were found for the samples treated with 
deflazacort and CsA but not with deflazacort or CsA alone. As found in previous experiments, 
mRNA levels of utrophin B are not detectable in human myoblasts, and are therefore not 
expected to impair the results. 
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5 Discussion 
 
DMD is one of the most frequently inherited neuromuscular diseases in children. The disease 
is caused by mutation(s) in the dystrophin gene that result in a loss of the protein dystrophin. 
This loss is followed by the primary structural dysfunction and in addition it also influences 
several downstream processes. An efficient therapy is not available, but cell culture and 
animal model experiments as well as first clinical studies are in progress. These therapy 
strategies are based on: 
a) external substitution of dystrophin by gene or myoblast transfer 
b) reconstitution of patient’s own dystrophin expression by skipping of mutated exons, 
trans-splicing, read-through of nonsense mutations  
c) enhanced expression of dystrophin homologue protein UTRN by gene transfer or 
regulation of transcription factors 
d) increase of patient’s own muscle mass and/or muscle cell number by the use of gene 
technique such as transfection, RNAi or pharmaceutical substances  
e) compensation of the dysfunction of processes downstream dystrophin.  
(Bertoni, 2008; Scime and Rudnicki, 2008; Manzur et al., 2008a) 
 
 
The purpose of strategies (I) and (II) aim at substitution or production of dystrophin. Their 
effects are locally and temporally restricted and also involve the risk of provoking an immune 
response. In dystrophin-deficient skeletal muscle cells, a newly expressed dystrophin or its 
delivery system may be identified as neoantigen. An administration of immunosuppressant 
drugs is necessary.  
The development of strategy alternatives that do not primarily concern dystrophin itself 
includes the attempt to compensate the loss of dystrophin [(III)-(V)]. In this context, the most 
interesting protein is the dystrophin homologue protein UTRN (III). Similarly to dystrophin, 
UTRN is able to link intra-cellular proteins of the DGC to the extracellular matrix but mainly 
at embryonic stages in contrast to dystrophin. Moreover, UTRN and dystrophin have different 
primary locations in muscle fibres. Whereas dystrophin is found throughout the length of 
muscle fibres, UTRN is primarily located at the postsynaptic membrane of the neuromuscular 
junction. The expression of the protein is up-regulated in DMD patients compared to normal 
individuals. In research studies an up-regulation of UTRN in vivo resulted in a rescue of the 
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dystrophic pathology, but is not connected with muscle regeneration (Weir et al., 2004; 
Michel et al., 2007).  
Regeneration of myoblasts (IV) was induced by several growth factors, e.g. myostatin 
inhibition (Bogdanovich et al., 2005; Nakatani et al., 2008), fibroblast growth factors 
(Neuhaus et al., 2003), the insulin-like growth factor (Schertzer et al., 2008), and calpain 
(Tidball and Spencer, 2000). First clinical approaches that also take into consideration these 
results in animal models or human cell culture include calpain inhibitors (Santhera 
Pharmaceuticals, Liestal, Switzerland) and myostatin repression (Wyeth-Ayerst, Madison, 
New Jersey, United States). Myostatin is a protein that is known to control skeletal muscle 
cell homeostasis. Human patients and animals suffering from a lack of myostatin show a 
remarkable muscle hypertrophy. The mdx mice treated with myostatin inhibitors show 
increased muscle mass and strength associated with an increase in fibre size (Manceau et al., 
2008; Bradley et al., 2008). However, different opinions exist regarding muscle function and 
endurance. Whereas Bogdanovich et al. reported an improvement in muscle function and 
endurance (Bogdanovich et al., 2002), Qiao et al. discovered reduced endurance of treated 
mdx mice compared with untreated mice (Qiao et al., 2008). Results similar to Qiao et al. 
were previously found in cattle breeds that have double-muscle conditions caused by 
mutations in the myostatin gene. The cattle suffer from problems with fertility, calf viability, 
stress tolerance and endurance (Kambadur et al., 1997). A myostatin blockade does not 
produce an increase in myoblast proliferation and muscle fibre number. An augmentation of 
muscle mass by inhibition of myostatin therefore seems insufficient without an increase in 
skeletal muscle cell numbers.  
Another strategy of DMD therapy is the enhancement of cell proliferation and differentiation 
including the reduction of fibrosis and necrosis of myoblasts [(IV)-(V)]. With regard of cell 
proliferation, the p21 expression was found to be significantly increased in skeletal muscle of 
DMD patients (Endesfelder et al., 2000). That provides a molecular explanation for reported 
considerable changes in proliferation and differentiation behaviour of (Dys-) skeletal muscle 
(Blau et al., 1983b). Application of ASO and siRNA in cell culture reduced p21 expression 
followed by an increase in cell proliferation (Endesfelder et al., 2003; Endesfelder et al., 
2005). Interestingly, it was found that the p21 protein is consistently increased whenever the 
transcription factor cardiac ankyrin repeat protein (CARP) is up-regulated in mdx mice (Laure 
et al., 2009). A recent study reports on another protein, the fast myosin light chain 1 (MLCf1), 
that inhibits the transition from G1 to S phase of the cell cycle. The authors showed that the 
protein level of MLCf1 is increased in the diaphragm and gastrocnemimus and the cell 
DISCUSSION 
 129 
proliferation is decreased. By contrast the extraocular muscle, which is less affected in DMD 
patients, had much lower level of MLCf1 and a higher proliferation rate (Zhang et al., 2008). 
That supports our strategy. But what still needs to be clarified using animal models and 
clinical studies is whether an increase in proliferation through a decrease of p21 expression 
has a positive impact on the function of skeletal muscle cells lacking dystrophin.  
Regarding necrosis, the treatment with proteasome inhibitors resulted in a blockage of the 
proteasomal-dependent degradation pathway in mdx mice, and rescued the expression and 
membrane localisation of dystrophin associated proteins and led to a histological 
improvement of the dystrophic muscle (Spencer and Mellgren, 2002; Bonuccelli et al., 2007; 
Briguet et al., 2008). Muscle fibrosis was reduced by elevation of tissue inhibitor of matrix 
metalloproteinases expression at mRNA level (von Moers et al., 2005). A diminishment of 
muscle fibrosis and an increase in myoblast proliferation could ameliorate the dystrophic 
pathology of DMD patients in advanced cases. 
The attempt to compensate the loss of dystrophin downstream dystrophin (V) relies on 
extensive expression studies on the one hand. These comparisons between DMD patients and 
normal controls are performed at RNA as well as protein level, and are partly based on chip 
technique (Bakay et al., 2002; Haslett et al., 2002; Haslett et al., 2003; Pescatori et al., 2007). 
For example, the cholesterol trafficking protein Nieman-Pick C1 is found to attenuate the 
dystrophic phenotype of the mdx mice and therefore suggested as potential therapeutic target 
for DMD (Steen et al., 2009). The expression of the delta-sarcoglycans at low level is 
proposed to attenuate the muscular dystrophy as studied in mdx mice (Li et al., 2009). On the 
other hand, it is also based on reports of DMD and BMD outlier patients which suggest that 
the lack of dystrophin might result in an altered activation of several signal transduction 
pathways in skeletal muscle (Tidball and Wehling-Henricks, 2004). In this context, it has 
been considered that dystrophin is part of a large complex of interacting proteins and that its 
absence is therefore associated with partly unknown pathophysiological downstream 
cascades.  
Two siblings with an intra-familially different course of the disease were studied concerning 
differences at RNA level using a subtraction library that forms the basis of this work. A 
number of 5 genes was determined (CSNK1A1, RAP2B, DCTN3, CBFb, MYL2) which are 
increased and may trigger the mild phenotype of the younger DMD brother. All these studies 
supply information for several proteins of different signal transduction pathways. For most of 
them a link to dystrophin and the dystrophin downstream cascade is not self-evident. 
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The compilation of these processes and the simulation of different case scenarios in silico 
necessitate the application of a mathematical model. As a result of the lack of kinetic data the 
Petri net theory was chosen for the model development. This thesis firstly reports on a 
theoretical model connecting 2 main signal transduction pathways encompassing dystrophin. 
The network includes processes which are influenced by own experimental data, the loss of 
dystrophin downstream dystrophin and it considers parts of the cellular pathways which are 
important for the dystrophin signalling. However, it makes no claim to be complete. Analyses 
of this model resulted in experimental modulation of selected members of the network. The 
consequences of this modulation were studied at mRNA and protein level using human 
SkMCs in cell culture. 
 
Using Petri net analysis techniques such as invariant and cluster analyses, the complex 
network was validated and decomposed in biologically meaningful sub-nets, which can be 
summarised in 2 main parts:  
 
(1) dystrophin downstream part connecting dystrophin with p21 and UTRNA via 
phosphorylation of NFATc through CSNK1A1 and JNK1 and  
(2) the RAP2B-calcineurin part leading to de-phosphorylation of NFATc.  
Both parts have contrary influences on the transcription level of NFATc target genes. 
 
 
5.1 Sub-net connecting dystrophin with p21 and UTRNA via 
phosphorylation of NFATc through CSNK1A1 and JNK1 
 
5.1.1  Petri net analyses of the dystrophin downstream sub-net 
 
This sub-net connects dystrophin with the DGC and the subsequent reaction cascade 
including the following main components: JNK1, c-Jun, CSNK1A1, and NFATc. It focuses 
on phosphorylation of NFATc through CSNK1A1. Although NFATc is the transcription 
factor of target genes, e.g. UTRNA, MYF5, and p21, its migration into the nucleus and 
transcriptional activity is disregarded since this sub-net only focuses on the inactivated 
phosphorylated form of NFATc. Therefore NFATc and its target genes are discussed in the 
de-phosphorylation sub-net in section 5.2.  
DISCUSSION 
 131 
Dystrophin initiates a complex downstream cascade, according to paper published by Oak et 
al. (Oak et al., 2003), but is extended after JNK1. The pathway leads to the phosphorylation 
of the transcription factors c-Jun and NFATc. Whereas c-Jun, a negative regulator of p21, is 
phosphorylated and activated by JNK1, the transcription factor NFATc can be phosphorylated 
and de-activated by JNK1 or CSNK1A1 and other kinases (Oak et al., 2003). CSNK1A1 is a 
member of the serine/threonine casein kinase I family (CKI), which contains another  
6 isoforms encoded by distinct genes. The CK1 family phosphorylates numerous substrates, 
e.g. NFATc, p53, and myosin (Knippschild et al., 2005a). The NFATc target gene p21, the 
negative regulator of cell cycle signalling, implicates another pathway that includes the 
CDKs, the RB protein and its regulator E2F. This pathway is modelled in the signal 
transduction network to include proliferation deficits and the role of p21 in DMD patients. 
Considering this network and the subtraction library results, the following hypothesis was 
proposed:  
 
In classic (Dys-) SkMCs, the phosphorylation of NFATc through JNK1 is decreased and 
associated with predominance of the de-phosphorylation pathway. This can consequently lead 
to an enhanced expression of NFATc target genes such as UTRNA, MYF5, and p21. It is 
supported by the DMD patient with the mild phenotype whose increased expression level of 
CSNK1A1 is proposed to compensate the decrease of JNK1.  
 
The dystrophin downstream cascade and the resulting phosphorylation pathway were studied 
by invariant analyses and Mauritius maps. The latter indicate the impact, defined as a 
theoretical value, of a gene or protein on the network after its knockout. These investigations 
support the importance of CSNK1A1. A knockout of the de-activation of NFATc by 
CSNK1A1 has an impact of 45% on the network. Other knockout events concern dystrophin 
(37%) and the initiation of JNK1 expression (37%). Hence, the CSNK1A1 represents a most 
effective point of application to achieve a manipulation of NFATc activity and the expression 
of UTRNA, MYF5, and p21.  
Another structural analysis, the invariant analysis, produced similar results. There is one 
exception that describes the t-invariant Inv55, which contains the cyclic pathway of 
phosphorylation (by CSNK1A1) and de-phosphorylation of NFATc, and combines both  
sub-nets. A knockout of CSNK1A1 would destroy this cyclic pathway, which represents a 
balanced ratio between phosphorylation and de-phosphorylation of NFATc. An increase in 
nuclear localisation of NFATc and the expression of the NFATc target genes are the 
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consequence as hypothesised. The invariant and the Mauritius map results conform to 
expression data of CSNK1A1 of the subtraction library.  
The refined invariant analysis through MCT-sets showed that the gene-regulation sub-nets 
modelled are in separate MCT-sets with regard to up-regulation or down-regulation of the 
gene. This is biologically meaningful and confirms the Petri net. The MCT-sets containing 
initiation of RB-protein-mediated cell cycle control are also separated concerning positive and 
negative cell cycle regulation and the different CDKs involved. This branching of the 
pathway led to a disconnected MCT-set as expected. Consequently, the Petri net and 
especially its Mauritius map analysis allow and, what is more, simplify the search for target 
proteins for the application of chemical substances as well as for candidate genes used in 
vector-DNA or siRNA experiments. Chemical compounds can influence pathways at protein 
level more easily than other techniques. However, the fact needs to be taken into 
consideration that chemical compounds may affect a wide range of target proteins rather than 
a specific protein. Vector-DNA and siRNA approaches are specific for one gene but do not 
directly have an effect on protein activities, which makes it reasonable to have a tool for a 
selection of those candidate genes which can be assumed to have the greatest impact on 
myoblasts of DMD patients.  
 
 
5.1.2  RNA expression studies of selected components  
 
The results of the subtraction library showed an increased mRNA expression level of 
CSNK1A1 in the DMD patient with the mild phenotype compared to that of the elder brother, 
a classic DMD patient. This indicated a potential role of CSNK1A1 for the mild DMD 
phenotype. This supposition was to be verified using 5 other classic DMD patients and  
5 normal controls. Additionally further components of the pathway were determined. 
Starting with the DGC, the phosphorylation of the transcription factors c-Jun and NFATc is a 
next major step. In (Dys-) patients, c-Jun, phosphorylated and activated by JNK1, is expected 
to be decreased compared to (Dys+) myoblasts. The mRNA expression level of c-Jun is not 
altered in all DMD patients. But its phosphorylation state is basically more pivotal for the 
sub-net than its intra-cellular abundance.  
A similar situation is found for the kinase JNK1. Contrary studies are mentioned in the 
literature so that a definite assumption is difficult to formulate. Considering its function 
within the signal transduction pathway downstream dystrophin, decreased levels of JNK1 are 
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expected in (Dys-) myoblasts that would predominate the activation pathway of NFATc and 
an increase of the expression of NFATc target genes UTRNA, MYF5, and p21. That is 
confirmed by the observation of a reduction of UTRN expression as soon as dystrophin 
expression appears in the adult skeletal muscle (Perkins and Davies, 2003; Miura and Jasmin, 
2006). Nevertheless, one study reported the activation of JNK1 in association with elevated 
dystrophic pathology in mdx mice (Kolodziejczyk et al., 2001). Contrary to this, skeletal 
muscle of physically exercised mdx mice showed aberrantly up-regulation of the 
phosphorylated form of JNK2, but not JNK1 (Nakamura et al., 2005). Additionally, 
considering this sub-net an elevation of JNK1 may decrease expression of UTRNA, MYF5, 
and p21. The expression level of JNK1 was not altered in classic DMD patients what does not 
conform to expectation. A normal expression value was hypothesised for the mild DMD 
patient. Even so, the mRNA expression of JNK1 was significantly decreased in the mild 
phenotypic DMD patient (P<0.05) as expected for classic (Dys-) patients. However, it does 
not supply information about the activity of JNK1 within the patients, which is currently not 
determined in human DMD patients. Additionally, JNK1 is known to be involved in other 
signalling pathways such as the regeneration of neuronal processes, cell survival, and 
proliferation (Bode and Dong, 2007).  
The same results are found for the target protein NFATc. But the transcription factor NFATc 
can be phosphorylated by several other kinases than JNK1, such as the kinase CSNK1A1, 
which was up-regulated in the mild DMD patient compared to the classic DMD brother. 
Similar to c-Jun and JNK1, the phosphorylation state is likely to be more important than the 
expression level.  
A completely different situation is shown for CSNK1A1. An increase in CSNK1A1 
expression was previously found in the mild DMD patient compared to the elder brother, and 
it was assumed that CSNK1A1 may be responsible for the mild phenotype. For that reason, an 
increased expression was also expected for the mild phenotype compared to the other  
5 classic DMD patients. But the expression of CSNK1A1 in classic DMD patients are 
significantly increased compared to controls (P<0.01). By contrast in the mild DMD patient 
the value is significantly decreased (P<0.05) in comparison to classic DMD patients. The 
expression results of the DMD patient with the mild clinical course are similar to the normal 
(Dys+) situation and are consistent with the hypothesis. However, the mRNA expression level 
does not necessarily correlate with the protein level or its phosphorylation status, which are 
not determined in human myoblasts. 
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To summarise, the kinase CSNK1A1 is a very interesting candidate for further studies 
because of its association with DMD pathology. However, what needs to be examined is 
whether an increase in CSNK1A1 expression exacerbates DMD pathology and its decrease 
induces a mild phenotype. With reference to the data of the intra-familial comparison, it can 
be assumed that this is not the case. But this relation between the 2 siblings is in contrast to 
the comparison with 5 DMD patients. Their CSNK1A1 expression level is significantly 
increased contrary to the mild DMD patient. This discrepancy is to be examined and forms 
the basis for further investigations. 
 
 
5.1.3  Experimental modulation of CSNK1A1 expression 
 
For all applications, an increase of proliferation should ideally be accompanied by with an 
unchanged or elevated UTRN expression. In this context, the deactivator CSNK1A1 of the 
transcription factor NFATc, is studied and its impact on proliferation and transcription of 
NFATc target genes, e.g. UTRNA, MYF5, and p21, using SkMCs in cell culture. 
The siRNA technique allows a specific interference in the CSNK1A1 expression in cell 
culture, but not in its activity. The mRNA expression level of CSNK1A1 persisted at normal 
level in (Dys+) SkMCs. It seems reasonable to assume that (Dys+) myoblasts are able to 
diminish siRNA consequences efficiently. This supposition is supported by the fact that the 
CSNK1A1 expression was reduced in (Dys-) SkMCs (from 100% down to 8-45%). An 
efficient counter-regulation might be absent in (Dys-) myoblasts. The expression levels of 
UTRNA, MYF5, and p21 remained unchanged. The expression level of NFATc was not 
determined since siRNA against CSNK1A1 may change the phosphorylation state of NFATc 
but not its expression level. In summary, down-regulation or inhibition of CSNK1A1 did not 
show the expected effects.  
Up-regulation experiments using cDNA plasmid vectors were also performed since the DMD 
patient with the mild phenotype showed enhanced mRNA expression of CSNK1A1 compared 
to the brother with a typical clinical course of DMD. Considering the signal transduction 
pathway, an up-regulation of CSNK1A1 leads to an enhanced accumulation of cytosolic 
NFATc which consequently reduces the expression of NFATc target genes and increases 
proliferation. The effect of CSNK1A1 up-regulation (1,5-82fold) was dependent on the DMD 
patient so that the results did not produce a consistent pattern. The proliferation of SkMCs 
was reduced in all DMD patients, which is inconsistent with the expectation. Except for  
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2 DMD patients, the expression levels of UTRNA, MYF5, and p21 were enhanced or 
remained unchanged.  
Taken together, up- and down-regulation of CSNK1A1 in (Dys-) SkMCs succeeded. The 
results show that neither down- nor up-regulation of CSNK1A1 could influence the NFATc 
target genes as expected and modelled in the signal transduction pathway. The inconsistency 
in the results may be due to the following factors. It is possible that the skeletal myoblasts in 
culture react differently to treatments compared to cells in their original tissue. The muscle 
tissue of DMD patients and controls were taken at different ages and consequently at different 
stages of the disease and muscle development. All the factors mentioned can have an 
important impact on the effect of any treatment and can lead to individual variations. 
Furthermore CSNK1A1 is primarily involved in other signalling pathways as described 
above, which do not affect the parameters determined. In the literature, JNK1 and glycogen 
synthase kinase-3 (GSK3) are also mentioned as kinases for NFATc (Beals et al., 1997; Dong 
et al., 1998), but none of these is stated as the primary kinase of NFATc. Otherwise, NFATc 
might not be the most important transcription factor for UTRNA, MYF5, and p21. For 
example, the transcription factor NFATc is particularly known to regulate the production of 
interleukins in T-cells, eg. IL-4, which activates and increases the immune response of  
T-lymphocytes (Yoshida et al., 1998). However, in mdx mice it was shown that the 
expression of UTRNA is regulable via the NFATc pathway (St-Pierre et al., 2004), but no 
experiments concerning the phosphorylation by CSNK1A1 have so far been performed. The 
antagonist of NFATc phosphorylation is its de-phosphorylation by calcineurin, which is stated 
as the primary phosphatase of NFATc in the literature (Crabtree and Olson, 2002), and is part 
of the second sub-net of the signal transduction pathway. With regard to the hypothesis and 
the results obtained a clear conclusion cannot be drawn.  
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5.2 Subnet connecting de-phosphorylation of NFATc via RAP2B-
triggered calcineurin activation 
 
5.2.1  Petri net analyses of the RAP2B-NFATc sub-net 
 
This sub-net connects the RAP2B-mediated calcium release that activates calcineurin and 
contains the following main components: RAP2B, calcineurin, NFATc, UTRNA, MYF5, and 
p21.  
Among other proteins, RAP2B mediates calcium release from the ER via PLCe and IP3 
pathway. A significant role of IP3Rs in spontaneous calcium release was observed in 
dystrophin-deficient cells (Balghi et al., 2006). Abnormal calcium homeostasis is observed in 
DMD muscle (Constantin et al., 2006). Transfection of BMD mini-dystrophin in a 
dystrophin-deficient mouse cell-line reduced IP3R-mediated calcium release activity, and 
provides evidence for regulation of an IP3 pathway by mini-dystrophin (Balghi et al., 2006). 
Via IP3R, calcium is released into the cytosol. The inflowing calcium is primarily captured by 
either troponin C or calmodulin which activates both proteins.  
Important intra-cellular functions of calcium include muscle contraction and motility. In 1996, 
Anderson et al. studied binding of active calmodulin to the carboxy-terminal domain of 
dystrophin (Anderson et al., 1996). The presence of calmodulin increases, via further 
enzymes such as the protein kinase II, the rate of phosphorylation of dystrophin that was 
shown for several isoforms of dystrophin (Madhavan and Jarrett, 1994; Calderilla-Barbosa et 
al., 2006). However, a negative feedback to the calmodulin pathway through the lack of 
dystrophin is not to be expected. It is known that calmodulin activates kinases which can 
phosphorylate dystrophin, e.g. protein kinase II (Madhavan and Jarrett, 1999). This process is 
upstream dystrophin. This calcium binding protein has several interaction partners, e.g. 
kinases and phosphatases, which in turn interact with various target proteins (Ishida and 
Vogel, 2006). For this study it was proposed that the loss of dystrophin should not have an 
effect on calmodulin or its activity in that way and consequently on the processes considered 
in this network. Due to clarity, modelling of this calmodulin-dystrophin interaction has been 
omitted. However, the inhibition of active calmodulin signalling impairs the dystrophic 
pathology as demonstrated in mdx mice (Chakkalakal et al., 2006).  
Calmodulin combined with calcium activates the phosphatase calcineurin, formerly known as 
serine/threonine protein phosphatase 2B. Calcineurin activation is in particular required in 
slow muscle fibres. The activation of calcineurin can also be triggered through the proteolytic 
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cleavage of calcineurin by calpain, which is also regulated by calcium fluxes (Crabtree and 
Olson, 2002; Wu et al., 2007). Several chemical substances, e.g. CsA, are known to intervene 
in the activation processes of calcineurin. Calcineurin-mediated de-phosphorylation of 
NFATc unmasks a nuclear localisation sequence that allows the migration of NFATc into the 
nucleus and coupling to various other transcription factors, e.g. MEF2, AP-1 (Fos/Jun), 
GATA, Sp1, SP3, and HDAC (Im and Rao, 2004).  
Target genes vary depending on cell type. In skeletal muscle, NFATc aims at several genes 
that especially encode slower, more oxidative muscle proteins and other proteins involved in 
muscle regeneration and differentiation, e.g. MYF5, p21, UTRNA (Michel et al., 2007). In 
turn, inhibition of calcineurin/NFATc signalling is shown to block muscle fibre hypertrophy 
(Dunn et al., 2002), induces slow-to-fast phenotype transformations (Serrano et al., 2001), 
and suppresses UTRNA expression (Chakkalakal et al., 2003). This is consistent with a study 
of Chakkalakal et al., which determined increased UTRNA expression in slower muscle fibres 
compared to fast muscle fibres (Chakkalakal et al., 2003).  
Taking into account this sub-net and the subtraction library results, the following hypothesis 
was established, and describes the opposed signalling pathway of NFATc activity as drawn 
for dystrophin downstream sub-net:  
 
The level of cytosolic calcium is increased in DMD patients and this leads to an elevated 
activity of the phosphatase calcineurin. The augmented de-phosphorylation of NFATc by 
calcineurin produces an enhanced expression of NFATc target genes, e.g. UTRNA, MYF5, 
and p21. The elevation of MYF5 and p21 expression negatively influences the DMD disease 
through decrease of myoblast proliferation. The increase in UTRNA expression is suggested 
to ameliorate the dystrophic pathology, but is inefficient in the absence of proliferation and 
the lack of myoblasts. Consequently, a therapy strategy should focus on the elevation of 
myoblast proliferation. The expression of UTRNA ought to be at least at unaltered levels. 
Considering the signal transduction pathway modelled this postulation should not be 
achievable. 
 
Using Mauritius map and invariant analyses, the RAP2B-calcineurin pathway turned out to be 
the part most relevant for the net behaviour. A knockout in that sub-net would lead to a 
malfunction of 78% of the whole Petri net model. In the literature, this hypothetical effect is 
demonstrated by several knockout animal models. For example, the homozygous calreticulin 
knockout mouse is lethal at the embryonic stage because of failing in heart development 
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(Mesaeli et al., 1999). A mutation in PLCe leading to malfunction of the protein is implicated 
with the nephrotic syndrome in humans (Hinkes et al., 2006). The inhibition of calcineurin by 
CsA and FK506 causes profound bone loss in animal models suggesting a role of calcineurin 
in skeletal remodelling (Sun et al., 2005). Therefore, calcineurin, the phosphatase of the key 
component NFATc, is assumed to have an essential impact on NFATc-mediated transcription, 
as for example on the increase of p21 transcription as one of its favourite target genes. The 
latter can enhance the decrease of myoblast proliferation.  
 
 
5.2.2  RNA expression studies of selected components of the RAP2B 
downstream cascade 
 
Using the subtraction library, the mRNA expression level of RAP2B was increased in the 
mild DMD patient compared to the classic DMD brother. A comparison of the mild DMD 
patient with 5 other classic DMD patients and 5 normal controls is used to verify this result 
and again further components of the pathway were analysed. 
In (Dys-) patients, RAP2B expression is expected to be higher than in (Dys+) controls to 
regulate calcium fluxes. An increase in RAP2B expression is proposed to cause high cytosolic 
calcium concentrations. In DMD patients the calcium balance between the cytosol and ER has 
shifted to the cytosol. This is consistent with increased expression levels of RAP2B in classic 
DMD patients. By contrast, the mild phenotypic DMD patient shows normal RAP2B 
expression data. Therefore, it can be concluded that the elder brother patient may not be 
representative of classic DMD patients, as confirmed by the results of CSNK1A1 mRNA 
analysis (see section 5.1.2). A high cytosolic calcium concentration as found in the classic 
DMD patients may lead to an elevated requirement of calcineurin. However, the expression 
levels of all DMD patients are comparable to normal controls. In addition, the increased 
calcium concentration produces calcineurin activity and does not necessarily induce 
calcineurin expression.  
The same is also applicable to NFATc. Elevated calcineurin activity is proposed to cause an 
enhanced expression of NFATc. In comparison to normal controls, the mRNA values of 
NFATc were unchanged in classic DMD patients, but the mild DMD patient shows 
significantly decreased values (P<0.05). However, the phosphorylation state of NFATc is 
decisive. Calcineurin-mediated de-phosphorylation of cytosolic NFATc leads to increased 
nuclear translocation of NFATc and augmented transcription of NFATc target genes UTRNA, 
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MYF5, and p21. On the basis of the known calcium homeostasis in DMD patients, elevated 
NFATc activity is to be expected even though the mRNA values of NFATc remain 
unchanged. Consequently, the expression level of UTRNA, MYF5, and p21 are expected to 
be increased in DMD patients. Interestingly, the lowest levels of the p21 and MYF5 
expression are determined in the patient with the mild phenotype.  
Furthermore, the DMD patient with the mild phenotype also shows the lowest UTRNA data, 
which indicates a reduced significance of UTRNA in muscle regeneration (Weir et al., 2004). 
Nevertheless, a high expression level of UTRNA is generally assumed in the literature. From 
that point of view it seems useful to modify NFATc activity as suggested by Chakkalakal et 
al. (Chakkalakal et al., 2003) as a therapy strategy for up-regulation of UTRNA, the 
homologous protein of dystrophin. But 3 aspects have additionally to be taken into account 
for such a strategy. The UTRNA mRNA level is already increased in all DMD patients. In 
these patients no positive correlation exists between the phenotype and the UTRNA value that 
supports the results of this study. Data from mdx mice suggest an approximately 4fold rise in 
UTRNA protein levels (Weir et al., 2004). For mdx/CnA* (mdx mice expressing enhanced 
muscle calcineurin activity) a 2fold increase is described, which already attenuates dystrophic 
pathology (Chakkalakal et al., 2004). This phenomenon in mice is obviously different from 
humans.  
In addition, not only UTRNA but also p21 and MYF5 have NFATc as a transcription factor. 
Almost the same pattern is found for Sp1, which was discussed as a potential transcription 
factor to increase UTRNA expression via okadaic acid (Rodova et al., 2004), but neglects  
6 Sp1 sites in the p21 gene (Lu et al., 2000). Consequently, an increase in NFATc expression 
or activity could imply an up-regulation of p21 and MYF5. Both are already elevated in the 
majority of DMD patients and reduce proliferation and muscle regeneration. This effect is not 
conducive to delaying the progression of muscular dystrophy. Concerning a strategy 
downstream of dystrophin to slow down the muscle dystrophy process, a regulated reduction 
of p21 (Endesfelder et al., 2003; Endesfelder et al., 2005) and MYF5 is beneficial in 
combination with unaltered or elevated UTRNA expression levels. As a result, both myoblast 
proliferation and the dystrophin homologous protein are enhanced at the same time. In 
consideration of the Petri net this strategy does not seem feasible. But, contrary experimental 
results in DMD patients, e.g. the failed modulation of NFATc target genes by artificially 
modified CSNK1A1 expression, indicate a more complex signal transduction pathway than 
drawn in the Petri net.  
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Consequently, it is not impossible that the favoured reduction of p21 and MYF5 can be 
combined with an elevation or unchange of UTRNA expression through regulation of 
NFATc. To answer this question, attention should be given to chemical substances already 
used in medical applications which influence the calcineurin/NFATc signalling pathway. 
 
 
5.2.3  Modulation of calcineurin activity using pharmacological 
interventions 
 
Chemical calcineurin inhibitors include CsA, FK506 (tacrolimus), and okadaic acid. Okadaic 
acid inhibits calcineurin to a lesser extent than the protein phosphatases 1 and 2A. However, 
this toxin is proposed to induce UTRN expression (Rodova et al., 2004), and it is that it 
influences the calcineurin/NFAT signalling. The precise adjustment of the okadaic acid 
concentration for each DMD patient and control SkMCs resulted in an increase of cell 
proliferation in some SkMCs cultures. However, this concentration is very close to its high 
toxic concentration. Okadaic acid is non-applicable in medical treatment. CsA and FK506 
have similar modes of action. But, FK506 has more severe side effects, and is suspected of 
causing various types of cancer. Consequently, FK506 and okadaic acid were not considered 
in the study. 
The calcineurin inhibitor CsA is controversially reported in studies using mdx mice and in 
human medical applications. Stupka et al. suggest that the active calcium dependent 
calcineurin pathway is responsible for the benign phenotype of mdx mice compared to DMD 
patients, and definitely negates a positive effect of CsA in mdx mice (Stupka et al., 2004). By 
contrast, another study in mdx mice demonstrated improved muscle function after 
administration of CsA for 4-8 weeks and exercise on treadmill without changes in the calcium 
homeostasis (De et al., 2005). Even so, the mode of action of CsA and calcineurin are not yet 
fully understood and may be different in the human dystrophic pathology.  
To our knowledge, this study is the first to conduct a treatment of CsA in SkMCs of DMD 
patients and controls. As modelled in the signal transduction pathway, the inhibition of 
calcineurin leads to a reduced expression of NFATc target genes, UTRNA, MYF5, and p21. 
That is expected to improve cell proliferation. In this study the proliferation rate is elevated in 
SkMCs (>10-47%), and tends to be more increased in (Dys-) SkMCs.  
Improved cell proliferation can be initiated in (Dys-) SkMCs by down-regulation of the 
expression level of p21 as demonstrated in this group (Endesfelder et al., 2005). The 
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expression levels of UTRNA, MYF5, and p21 showed neither an up-regulation nor a  
down-regulation compared to DMSO-treated SkMCs. The expression data of UTRNA, which 
remained unchanged, are in line with earlier observations (De et al., 2005). Consequently, 
CsA-governed proliferation uses a different signalling pathway that may not involve a 
reduction of p21 expression. Therefore various proteins/pathways can be considered, e.g. the 
cyclin-dependent kinases, the regulation of synthesis of S-phase genes including RB protein 
and E2F, and the transcription factor p53 that regulates proteins of the cell cycle and 
apoptosis. 
The glucocorticoid deflazacort is thought to activate calcineurin/NFAT signalling, and, 
among other pharmacological approaches, can slow down the progression of DMD (Biggar et 
al., 2006; Angelini, 2007). Another glucocorticoid used in DMD therapy is prednison, but 
deflazacort produces fewer side effects than prednison, and was therefore preferred in this 
work. Although a therapeutic effect is visible, the molecular basis of the pharmacological 
effect is not well understood. Investigations in mdx mice indicated an activation of the 
calcineurin phosphatase associated with an up-regulation of the NFATc target gene UTRN 
using deflazacort (St-Pierre et al., 2004). A very recent study reports an ameliorated 
preservation of the spin-spin relaxation time in some muscle types in DMD patients treated 
with deflazacort (Mavrogeni et al., 2009). 
In this study for the glucocorticoid deflazacort, an increase in cell proliferation was 
investigated for (Dys+) SkMCs and (Dys-) SkMCs (>13-50%). But, no alteration in mRNA 
expression of UTRNA, MYF5, and p21 was determined which in this case excludes p21 as a 
potential mediator of the raised cell proliferation. Since this study shows improved cell 
proliferation for deflazacort and CsA, the question arises whether the positive impacts of both 
pharmacological applications can be added up by using a combination of both substances. 
But, as described in the literature, the modes of action of both are in fact proposed to function 
in the opposite direction. However, not only deflazacort but also CsA were already suggested 
and used as drugs in DMD therapy, even though with different results (Sharma et al., 1993; 
St-Pierre et al., 2004; Stupka et al., 2004). Additionally, the German Society for Muscle 
Diseased Persons presently performs a clinical trial using a combination of prednison and 
CsA (Korinthenberg, 2008). 
Consequently, a combination of deflazacort and CsA was tested. In this study, the 
combination of CsA and deflazacort reduces or impaires the elevated proliferation of the 
SkMCs as separately shown for CsA or deflazacort. But the combination of deflazacort and 
CsA produces a significant elevation of UTRNA mRNA levels (P<0.05) and increased 
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protein expression compared to either drug alone. Because of the unchanged mRNA 
expression level of UTRNA after treatment with deflazacort or CsA, it can be assumed that 
NFATc might not be the activator of the UTRNA expression. Several other transcription 
factors, e.g. Sp1, GABP alpha/beta, and the artificial 4-zinc-finger protein, Bagly, as well as 
the myogenic Akt signalling are also feasible (Gyrd-Hansen et al., 2002; Onori et al., 2007; 
Peter et al., 2009). The 3- to 7fold increase in UTRNA mRNA expression is followed by an 
elevated protein level (1.6-2.3fold) in human SkMCs without decreasing cell proliferation. 
Such an increase in UTRNA expression is consistent with the results recently reported using 
an artificial transcription factor called Vp16-Jazz (Mattei et al., 2007; Desantis et al., 2009).  
 
Taken together neither de-phosphorylation nor phosphorylation of NFATc have an influence 
on the expression level of the target genes UTRNA, MYF5, and p21. Therefore, NFATc may 
not be crucial as a transcription factor with an important impact on the expression levels of 
these genes and on p21 regulated proliferation (St-Pierre et al., 2004). This part of the 
hypothesis was not supported by the results. As seen in previous experiments, the expression 
of NFATc also remained unchanged. Nevertheless, an increase in proliferation is determined 
for CsA and deflazacort for the majority of the SkMCs tested. Other modes of action which 
may lead to enhanced cell proliferation should be discussed for deflazacort and CsA as well as 
other NFATc target genes.  
(1) Some chemical substances, such as glucocorticoids, are assumed to be able to integrate 
into the DNA (von Knebel et al., 1991), either to influence the histone code or to simulate or 
initiate transcription factor functions. That could be a potential explanation for deflazacort but 
seems to be unlikely for CsA. (2) The inhibition of calcineurin and the subsequent cytosolic 
localisation of NFATc may involve more complex biochemical consequences than those 
modelled in the Petri net and stated in the literature. (3) The age and/or stage of a DMD 
patient might also have an influence on the effect of pharmacological interventions. 
But, contrary to expectations as proposed in the hypothesis, it is possible to influence target 
genes of NFATc at different levels. Increased UTRNA expression values are found using a 
combined application of CsA and deflazacort and this does not lead to an elevation of  
p21 expression followed by a diminished proliferation. 
The question arises whether this increase in UTRNA expression in cell culture suffices to 
improve dystrophic pathology or to slow down the progression of DMD patients. It therefore 
remains to be seen whether the data of the clinical trial of the drug combination produce 
results as promising as the one explored in this study.  
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5.3 Future directions 
 
Future directions include investigations in systems biology and molecular biology with the 
two fields collaborating closely. 
In systems biology, it is intended to refine the Petri net model, but also to extend the modelled 
pathway which particularly includes transcription factors, further NFATc target genes and cell 
cycle proteins. This extension will lead to a very complex model that is difficult to overview 
if modelled at one hierarchical level. Therefore, a hierarchical Petri net with 2 or more levels 
must be considered in which, for example, the transcriptional level can be modelled into one 
hierarchical level. The discovery of other transcription factors and connecting pathways will 
also make it possible for analyses, such as Mauritius maps, to identify other points of 
application for chemical substances and modification of gene expression and thereby therapy 
strategies downstream dystrophin. 
Consequently, in molecular biology, it is necessary to discover specific transcription factors 
or artificial molecules. Both make it easier to enhance or to silence expression of each of the 
relevant genes separately. In the context of detected molecules, which specifically interact 
with DNA binding domains, the search for NFATc inhibitors using in vitro selection 
technology (SELEX) on combinatorial RNA libraries with random nucleotide sequences 
should be mentioned (Bae et al., 2002; Cho et al., 2004). Alternatively, attempts to increase 
selectivity of gene expression by transcription factors, gene substitution and silencing for 
example via RNA-interference could be performed in parallel. Several factors come into 
consideration. Dogra et al. report increased activation of a number of about 30 nuclear 
transcription factors in mdx mice that are involved in numerous cell signalling pathways 
(Dogra et al., 2008). The CARP protein is one transcription factor that is increased in the mdx 
model (Laure et al., 2009). That can be applied for modelling and animation of a hierarchical 
Petri net representing the DMD pathology and the normal situation.  
A very important further development would be an increase in the number of DMD patients at 
different ages of biopsy and control SkMCs to corroborate the statistical significance of the 
data. Using human primary myoblasts, an increase as well as a knockdown of further several 
proteins of the net is intended to validate the network itself and its analyses results. The 
subsequent examinations at mRNA and protein level complement the modelling of expression 
regulation. However, the analyses used are very specific to one gene or protein. Modulation of 
proteins or gene expression has rather a complex impact on several proteins and subsequent 
pathways. For this application antibody microarray analysis may be used in future 
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experiments, in particular to compare treated and untreated SkMCs. This is useful for 
studying the role of pharmacological interventions in (Dys+) SkMCs compared with  
(Dys-) SkMCs. Clontech offers a comprehensive antibody microarray which can detect 
approximately 500 proteins covering protein kinases, cell cycle, neurobiology, cancer, and 
apoptosis. Many proteins of the Petri net model are included in this array (Andersson et al., 
2005; Chaga, 2008). Furthermore, not only the protein abundance but also activity tests of 
proteins, in particular concerning de- and phosphorylation, are of special interest since many 
protein interactions of the Petri net model are based on these protein modifications. For this 
application, conventional ELISA tests and Western blots can be considered as well as protein 
interaction assays using chip technology. Wide scale protein expression and activity analyses 
mediate the understanding of the molecular basis of DMD and its effective pharmacological 
and gene modifying interventions. 
The iterative process of theoretical modelling and molecular biological experiments will give 
more insight into the biological pathways and consequently can advances the understanding 
of the pathogenesis of various diseases.  
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6 Summary 
 
Duchenne muscular dystrophy (DMD) is one of the most frequently inherited neuromuscular 
diseases in children. It is caused by the absence of dystrophin (Dys-), what influences several 
downstream signal transduction pathways. To date no successful therapy is available. Currently, 
strategies are being considered which involve dystrophin downstream processes to make up for 
the lack of dystrophin. Analysing 2 siblings with an intra-familially different course of DMD 
using a cDNA subtraction library, 5 genes were determined to be up-regulated in the brother with 
the mild phenotype that might be responsible for a compensatory effect (Sifringer et al., 2004).  
In this thesis, extensive data base searches associated 2 of these genes, ras related protein 2B 
(RAP2B) and casein kinase 1 A1 (CSNK1A1), to signal transduction pathways downstream 
dystrophin with de-/phosphorylation of the transcription factor nuclear factor of activated  
T-cells (NFATc) as intersection point. The established network can be sub-divided into to  
sub-nets. The first sub-net, the RAP2B downstream pathway, activates NFATc by its  
de-phosphorylation via the phosphatase calcineurin. The second sub-net, the dystrophin 
downstream cascade, represents the de-activation pathway of NFATc by its phosphorylation 
through CSNK1A1 and the c-Jun N-terminal kinase 1 (JNK1). It first represents the complex 
processes of DMD pathology in a Petri network which is a tool of systems biology for modelling 
of discrete distributed systems at different abstraction levels that can be applied to gene regulatory 
processes. Theoretical knockout analyses of the Petri net model using Mauritius maps and 
invariants identified de-/activation of NFATc as the most relevant part of the network. 
For further investigations, in addition to RAP2B and CSNK1A1 7 candidate genes were selected 
from the de- and the phosphorylation part of NFATc: calcineurin, JNK1, jun oncogene (c-Jun), 
myogenic factor 5 (MYF5), the cyclin-dependent kinase inhibitor 1A (p21), NFATc, and utrophin 
A (UTRNA). UTRNA is homologue to dystrophin. MYF5 and p21 regulate differentiation and 
proliferation. All 3 are positively regulated target genes of the transcriptions factor NFATc. The 
transcription factor c-Jun negatively regulates p21 expression. The mRNA expression levels of 
these genes were studied in 5 classic DMD patients, the mild DMD patient, and 5 normal controls 
using Real-Time PCR. In most cases no significant differences were detectable. But contrary to 
the results of the subtraction library, which are restricted to 2 patients, the mild DMD patient 
represents a significantly decreased CSNK1A1 mRNA level in comparison with the classic DMD 
patients (P<0.05). The same results were found for NFATc and JNK1 (P<0.05) in comparison to 
(Dys+) individuals. Moreover, the lowest levels of the p21 and MYF5 expression were also 
determined in the phenotypically mild patient. The UTRNA gene is expressed at nearly normal 
level compared to classic DMD patients with increased values of up to 14fold. These results give 
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a preference to an increase of proliferation to slow down the muscle dystrophy process that should 
ideally coincide with an unchanged or elevated UTRNA expression for appropriate therapeutic 
concepts, which currently concentrate mainly on UTRNA. 
It was to be tested whether the p21 regulated myoblast proliferation and the increase in UTRNA 
protein level can be enhanced at the same time even if both proteins have NFATc as transcription 
factor. The contradictory effect of CSNK1A1 in DMD patients and the most interesting position 
of calcineurin within the network as antagonist of CSNK1A1 led to further investigations 
concerning the modulation of both proteins and their effects on proliferation and gene expression 
of NFATc target genes in human skeletal muscle cells (SkMCs) in culture. Considering the 
network model, an increase of CSNK1A1 expression is proposed to reduce the expression of 
UTRNA, MYF5, and p21 followed by elevated SkMCs proliferation. The gene expression of 
CSNK1A1 was successfully altered by plasmid cDNA vector and siRNA transfection. But no 
clear effect was found on proliferation and gene expression level of UTRNA, MYF5, and p21. 
Calcineurin was modulated by deflazacort and cyclosporin A (CsA). The separate use of 
deflazacort and CsA led to an increased proliferation of SkMCs without affecting the expression 
of MYF5, and p21 at mRNA level. The combined application as suggested in a clinical study 
showed slightly elevated proliferation results. The UTRNA mRNA and protein expression was 
not changed by CsA. But enhanced values were observed when using deflazacort. This effect was 
increased by the concurrent application of both substances. At the mRNA level an increase of 
about 3- to 7fold was observed and of about 2fold at protein level. The effect on UTRNA 
expression seems to be restricted to SkMCs of DMD patients. 
To summarise, neither de-phosphorylation nor phosphorylation of NFATc has a clear influence on 
the expression level of the target genes UTRNA, MYF5, and p21. This suggests that NFATc may 
not be the important transcription factor for the target genes and consequently on p21 regulated 
cell proliferation. But an elevation of proliferation was observed for (Dys-) SkMCs by application 
of deflazacort and/or CsA which indicates other target points than NFATc. In contrast to the 
expectations from the Petri net the proliferation was elevated without a concurrent decrease of 
UTRNA expression, which gives positive impetus for appropriate therapy strategies but shows 
that the Petri net will have to be extended. 
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7 Zusammenfassung 
 
Die Muskeldystrophie Duchenne ist eine der am häufigsten vererbbaren neuromuskulären 
Erkrankungen im Kindesalter. Es wird ausgelöst durch das Fehlen des Proteins Dystrophin 
(Dys-), welches in eine Vielzahl von Signaltransduktionswegen involviert ist. Derzeit steht 
keine erfolgreiche Therapie zur Verfügung. Gegenwärtig werden Strategien in Betracht 
gezogen, welche Dystrophin nachgeschaltete Prozesse einbeziehen, um den Verlust von 
Dystrophin zu kompensieren. Durch die Transcriptomanalyse eines Geschwisterpaares mit 
einem intra-familiär unterschiedlichen Verlauf der DMD wurden fünf Gene mittels einer 
cDNA Subtraktionsbank identifiziert, die in dem Bruder mit dem milden DMD-Phänotyp 
hochreguliert sind und damit für einen kompensatorischen Effekt verantwortlich sein könnten 
(Sifringer et al., 2004). 
Mit Hilfe von umfangreichen Datenbankrecherchen konnten zwei dieser Gene, das Ras 
Related Protein 2B (RAP2B) und die Casein Kinase 1 AI (CSNK1A1), in Zusammenhang zu 
Dystrophin nachgeschalteten Signaltransduktionswegen gestellt werden, deren Knotenpunkt 
die De-/Phosphorylierung des Transkriptionsfaktors Nuclear Factor of Activated T-cells 
(NFATc) darstellt. Das dabei etablierte Netzwerk kann in zwei Teilnetze unterteilt werden. 
Das erste Teilnetz, der RAP2B nachgeschaltete Signalweg, stellt die Aktivierung von NFATc 
durch dessen De-Phosphorylierung über die Phosphatase Calcineurin dar. Das zweite 
Teilnetz, die Dystrophin nachgeschaltete Reaktionskaskade, beinhaltet den  
De-Aktivierungsweg von NFATc durch Phosphorylierung mittels CSNK1A1 und der c-Jun 
terminalen Kinase 1 (JNK1). Beide veranschaulichen erstmalig die komplexen Prozesse der 
DMD-Pathogenese in einem Petri-Netz. Ein Petri-Netz ist ein mathematisches Modell der 
Systembiologie zur Modellierung von diskreten Systemen auf unterschiedlichen 
Abstraktionsebenen und findet bei genregulatorischen Prozessen Anwendung. Theoretische 
Knockout-Analysen des Petri-Netzes mit Hilfen von Mauritius-maps und  
Invariant-Untersuchungen ergaben, dass die De-/Aktivierung von NFATc das bedeutendste 
Element des Netzwerkes ist.   
Für weitere Studien wurden, zusätzlich zu RAP2B und CSNK1A1, sieben weitere 
Kandidatengene aus dem De- und dem Phosphorylierungs-Netz von NFATc ausgewählt: 
Calcineurin, JNK1, Jun Oncogene (c-Jun), Myogenic Factor 5 (MYF5), Cyclin-Dependent 
Kinase Inhibitor (p21), NFATc und Utrophin A (UTRNA). Utrophin ist homolog zu 
Dystrophin. MYF5 und p21 regulieren die Differenzierung bzw. Proliferation von 
Muskelzellen. Alle drei sind positiv regulierte Zielgene von NFATc. Der Transkriptionsfaktor 
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c-Jun hingegen beeinflusst die p21-Expression negativ. Das mRNA-Expression-Niveau von 
diesen Genen wurde in fünf klassischen DMD Patienten, dem milden DMD Patienten und 
fünf Normalkontrollen mittels Real-Time PCR untersucht. In den meisten Fällen konnten 
keine signifikanten Unterschiede detektiert werden. Aber im Gegensatz zu den Ergebnissen 
der Subtraktionsbank, welche auf zwei Patienten beschränkt sind, zeigte der milde DMD 
Patient ein signifikant verringertes CSNK1A1-mRNA-Niveau im Vergleich zu den klassichen 
DMD Patienten (P<0,05). Ähnliche Ergebnisse ergaben sich für NFATc und JNK1 (P<0,05) 
im Vergleich zu Normalkontrollen. Desweiteren wurden für p21 und MYF5 im phänotypisch 
milden DMD Patienten das geringste Expressionsniveau bestimmt. Das  
UTRNA-mRNA-Niveau befand sich auf nahezu normalem Niveau im Vergleich zu DMD 
Patienten mit einer bis zu 14fachen Erhöhung. Diese Ergebnisse führten zur Entwicklung 
einer Therapiestrategie, die eine Proliferationserhöhung, um den dystrophen Prozess zu 
verlangsamen, mit einem gleichzeitig unveränderten oder gesteigerten UTRNA-Niveau 
vereint. Derzeitig konzentrieren sich derartige Therapiestrategien lediglich auf die Erhöhung 
von UTRNA.  
Es folgten Untersuchungen, ob die p21 regulierte Myoblasten-Proliferation und das UTRNA 
Protein-Niveau verstärkt werden können, obwohl beide NFATc als Transkriptionsfaktor 
besitzen. Die gegensätzliche Wirkung von CSNK1A1 in DMD Patienten und die 
bemerkenswerte Rolle von Calcineurin innerhalb des Netzwerkes als CSNK1A1-Antagonist 
führten zu weiteren Untersuchungen. Diese beinhalteten die Modulation von beiden Proteinen 
und die Studie von deren Auswirkungen auf Proliferation und Genexpression von NFATc 
Zielgenen in humanen Skelettmuskelzellen (SkMCs) in Kultur. Unter Beachtung des 
Netzwerkmodells sollte eine Erhöhung der CSNK1A1 Expression das Niveau von UTRNA, 
MYF5 und p21 reduzieren, gefolgt von einer gesteigerten Proliferation der SkMCs. Die 
Genexpression von CSNK1A1 wurde durch die Transfektion von Plasmid-cDNA-Vektoren 
und siRNA erfolgreich verändert. Dennoch konnte kein eindeutiger Effekt auf Proliferation 
und Expression von UTRNA, MYF5 und p21 festgestellt werden. Calcineurin wurde durch 
Deflazacort und Cyclosporin A (CsA) beeinflusst. Die separate Verwendung von Deflazacort 
und CsA führte zu einem Anstieg der Proliferation ohne Einfluss auf die mRNA-Expression 
von MYF5 und p21 zu nehmen. Die Kombination von beiden, ähnlich praktiziert in einer 
klinischen Studie, ergab leicht erhöhte Proliferationswerte. Die Expression von UTRNA auf 
mRNA- und Protein-Ebene blieb durch CsA unverändert. Eine leichte Steigerung hingegen 
konnte durch Deflazacort festgestellt werden. Diese Wirkung wurde durch die Kombination 
noch verstärkt. Das mRNA-Niveau erhöhte sich auf das drei- bis siebenfache, während die 
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Proteinexpression eine Verdopplung aufzeigte. Dieser Effekt scheint sich auf DMD Patienten 
zu beschränken. 
Zusammengefasst, weder die De- noch die Phosphorylierung von NFATc hat einen 
eindeutigen Einfluss auf das Expressionsniveau der Zielgene UTRNA, MYF5 und p21. Dies 
lässt vermuten, dass NFATc nicht der ausschlaggebende Transkriptionsfaktor für diese 
Zielgene ist und folglich auch nicht die p21 regulierte Zellproliferation beeinflusst. Dennoch 
konnte eine Erhöhung der Proliferation durch Deflazacort und/oder CsA induziert werden, 
was auf die Existenz weiterer Zielgene von NFATc oder auf andere Angriffspunkte von 
beiden Substanzen schließen lässt. Entgegen den Erwartungen aus dem Petri-Netz ist eine 
Steigerung der Proliferation ohne gleichzeitig die UTRNA Expression zu senken möglich. 
Diese Ergebnisse geben Anlass zur Entwicklung einer entsprechenden Therapiestrategie, 
zeigen aber auch die Notwendigkeit der Erweiterung des Petri-Netzes. 
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9  Appendices 
 
9.1 Glossary 
 
Boolean 
networks 
A network that consists of Boolean variables the state of which is defined by other network 
variables. 
Boolean is a computational logic that sets data value to true or false (usually 1 and 0, 
respectively). 
Tanimoto 
coefficient 
A normalised simple distance measure, in this case based on the Parikh vector is used as 
distance measure. Vectors ti and tj describing two t-invariants is defined for Parikh vector 
and support as: 
 s(ti, tj) = sij = | (ti) tj)| 
                       |(ti) (tj)|  
where (ti) and (tj) denote vectors of the t-invariants. The pair-wise similarity sij expressed by 
this coefficient is transformed into a distance dij by dij = 1 − sij . 
Firing rule A transition t 0 T can fire in a marking, m, if t is enabled in m. 
After firing of t, a successive marking, m’, is reached with m’ := m + Δt. 
The minimum number of tokens are defined on the pre-places by the marking  
t -(p) := W (p, t ), if (p, t) 0 F and t - (p ) := 0, if (p, t ) ⌠ F, and the number of tokens, which 
are added to each post-place by t+ := W (t, p ), if (t, p ) 0 F and t+ (p ) := 0, if (t, p ) ⌠ F.  
Δt := t - – t + gives the change of marking in the considered place. 
Incidence 
matrix 
A (k × l)- matrix, c, with k as number of places and l as number of transitions. Every matrix 
element ci,j corresponds to the token change on place pi by firing of transition tj. 
Liveness of 
Petri nets 
A Petri net is live if every transition within the net is live, and is dead if all transitions are 
dead in the initial marking. A dead transition is not in any firing sequence. 
Petri net N = (P, T, F, W, m0), with m an arbitrary marking in N, and t 0 T an arbitrary 
transition. 
• A transition t is live in the marking, m in N, if for every marking, m’ 0 RN (m), 
a further marking m” 0 RN (m’) with 
 m' → m'' 
  
 exists. 
• A transition t is dead in the marking, m in N, if for every marking,  
m’ 0 RN (m), holds: t– ⇐m’. 
• A marking, m, is called live in N, if all transitions, t 0 T, are live in m. 
• A marking, m, is called dead in N, if all transitions, t 0 T, are dead in m. 
• A transition t is called live (dead) in N, if t is live (dead) in m0. 
• A Petri net, N, is called live (dead), if m0 is live (dead) in N. 
• A Petri net, N, is called deadlock-free, if there is no reachable marking, where all 
transitions, t 0 T in N, are dead. 
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Mauritius 
maps 
Petri net N = (P, T, F, W, m0);  X is denoted as the set of all n T-invariants x. A finite binary 
tree, T = (V, E), is called Mauritius map, if 
• the set V is a finite set of transitions belonging to a t-invariant, x. The root vertex is located 
in the lower left corner. 
• the set E = (H, R) is a finite set of edges between vertices, indicating dependencies of  
t-invariants. 
• the set H represents horizontal edges, which connect vertices belonging to the same t-
invariant. 
• the set R represents vertical edges, which connect vertices of the left subtree with vertices 
of the right upper subtree belonging to the same t-invariant. 
MCT-sets X is denoted as the set of all n T-invariants x. Two transitions ti and tj belong to the same 
MCT-set, if and only if they participate in exactly the same T-invariants:  
∀i, j 0 prot, ti and tj correspond to the same MCT-set, if and only if  
∀x 0 X, ti 0 supp(x), tj 0 supp(x). 
This dependency relation leads to maximal common sets of transitions. A transition 
set A ⊆ T is called an MCT-set, if and only if 
∀x 0 X : A ⊆ supp(x) ω A 1 supp(x) = ∅ . 
Minimal 
invariant 
An invariant u is called minimal if its support supp (u) does not contain the support of any 
other invariant supp (z),  
i.e. ∫ invariant z : supp (z) δ supp (u),  
and the largest common divisor of all non-zero entries of u is equal to one. In the following 
we refer to minimal invariants writing invariants for short. Trivial t-invariants consist of two 
transitions describing the forward or backward reaction of a reversible reaction. 
ODE Ordinary Differential Equation. 
P-invariant Vector definition y ≥ 0, y 0 Nk0 that verifies CT · y = 0.  
It stands for a set of places, over which the weighted sum of tokens is always constant. For a 
P-invariant y and any markings m1, m2 0 Nk0 that are reachable by the firing of transitions, it 
holds y · m1 = y · m2. 
Petri nets Bipartite directed labbled-graphs consisting of two types of nodes: places and transitions 
with (P, T, F, W, m0), if it holds: 
• P and T are two sets with P ∩ T = ∅, P ⊥ T ≠ ∅ 
The elements of the sets P and T are called places and transitions, 
respectively. 
• F is a two digit relation with F ⊆ (P x T) ⊥ (T x P). 
The elements of F are called arcs. F is called the flux relation of N. 
• W : F → N , is the weight of the arcs. 
• m0 : P → N0, is the initial marking of N. 
The directions of the edges define for each transition a set of pre-places and a set of 
post-places, denoted as •t := ch and 
t • := {p | p 0 P ϖ (t, p ) 0 F }, respectively. Accordingly, there are for each place a 
set of pre-transitions and a set of post-transitions, denoted as 
•p := {t | t 0 T ϖ (t, p ) 0 F } and p • := {t | t 0 T ϖ (p, t ) 0 F }, respectively.  
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Places Passive system elements; e.g. chemical compounds, proteins complexes, genes.  
P = {p1, . . . , pl} 
Reachability 
graph 
Petri net N = (P, T, F, W, m0): A graph is called a reachability graph of 
N, if: 
• The set RN  represents the vertices of the graph. 
• (m, m’) denotes an edge of the graph, if a transition t exists with 
 m' → m'' 
  
. 
Support of a 
vector 
The set of non-zero elements of a vector is called the support of the vector u, written as supp 
(u).  
t-invariant Describes the system behaviour of the network. Vector definition based on the incidence 
matrix: vector x ≥ 0, x 0 Nl0 with the equation C · x = 0. 
Tokens Represent a number of molecules or chemical compounds 
Transitions Active system elements; e.g. chemical reactions. T = {t1, . . . , tl} 
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